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Abstract
All papillomaviruses have a non-coding region of approximately 500-1000 bp called 
the upstream regulatory region (URR) or long control region (LCR). The LCR is the 
transcriptional control unit of the virus. Mucosal epitheliotropic papillomaviruses, for 
example, BPV-4 and HPV-16 and -1 8 , have a similar LCR organisation: a promoter 
region, an epithelial specific enhancer, and a highly conserved distribution of DNA  
binding sites for the viral E2 protein. When compared with the HPV-16 LCR, the 
BPV-4 LCR has a higher transcriptional response to activation by E2 in its target cell 
type. E2 up-regulates transcription from the BPV-4 LCR preferentially in primary 
bovine palate keratinocytes (PalK) when compared with fibroblasts (PalF) (Morgan 
et al., 1998). The BPV-4 LCR and primary bovine cell system presents a model to 
study the mechanisms of E2 mediated transcriptional regulation of mucosal 
epitheliotropic papillomaviruses and the cell type specificity of this regulation.
Insertion of multiple E2 sites upstream from the LCR promoter demonstrates that the 
enhanced epithelial response to E2 is not due to the epithelial specific enhancer in the 
BPV-4 LCR, but is a property of the BPV-4 promoter region which responds better to 
several transcriptional activators in PalK cells. This is a promoter specific effect as 
the tk promoter shows no such epithelial preference to upstream activators. E2 
responsive chimaeric promoter constructs suggest that the BPV-4 promoter region 
upstream of the TATA box determines the cell type selective response of the BPV-4 
promoter. Deletion analysis identifies two novel repressor elements, PRE-1 and PRE- 
2, that are at least in part responsible for mediating the enhanced epithelial response 
of this promoter. These elements function in cis to repress the basal activity of the
XVIII
SV40 promoter. PRE-2 binds a specific protein complex in both PalK and PalF cells. 
The active DNA binding protein in this complex is a major species of approximately 
50 kDa. PRE-2 mutants that do not compete for binding in band shift assays do not 
repress transcription when multimerised upstream of the SV40 promoter. Also, non­
binding mutations introduced into the BPV-4 promoter show that the PRE-2 binding 
factor represses the transcriptional response of the BPV-4 promoter to E2. The PRE- 
2 binding protein seems to represent a novel transcriptional repressor and regulator of 
papillomavirus transcription.
The E2 amino terminal transactivation domain is essential for regulating transcription 
and replication of the viral genome. Far western blot analysis shows that the HPV-16 
E2 amino terminus is able to interact with different cellular factors in keratinocytes 
and fibroblasts. The isolation of cDNAs encoding proteins interacting with this 
region of E2 in HeLa cells (an immortalised keratinocyte cell line) is described. One 
of the cDNAs encodes the full length L31 ribosomal protein. L31 specifically 
interacts with the HPV-16 E2 transactivation domain in vitro . Also, an in vitro 
interaction is demonstrated between E2 and a truncated version of a protein 
previously shown to bind the cytoplasmic domain of integrin p4. These E2 interacting 
factors may represent potential regulators of transcription, replication or cellular 
growth control.
1Chapter 1 -  Introduction
1.1. Papillomaviruses
1.1.1. Human papillomavirus life cycle
Papillomaviruses are a family of small double stranded DNA viruses that infect a 
wide range of animals inducing benign proliferative lesions, or warts. 
Papillomaviruses exhibit both host species and tissue specificity. Over 90 types of 
human papillomaviruses (HPVs) have been identified, based on different degrees of 
sequence homology. HPVs are strictly epitheliotropic and can be divided into two 
subsets depending on the tropism for the target cell type, infecting either the 
cutaneous epithelium of the skin or mucosal epithelium at specific body locations 
(Chan et al., 1995). Productive infection by HPV is absolutely dependent upon the 
differentiation of the host cell (for reviews see (Howley, 1996; Stubenrauch and 
Laimins, 1999)). HPVs are believed to infect proliferating undifferentiated 
keratinocytes in the basal layers of the stratified epithelium. Following infection, the 
HPV genomes are established as autonomous replicating nuclear plamids, copy 
number is amplified to approximately 50-100 copies per cell and a low level of HPV 
early gene expression occurs. As infected cells migrate upwards from the basal layer 
and undergo differentiation productive viral DNA replication and expression of the 
viral late genes is induced resulting in the assembly and release of progeny virion. In 
normal epithelia, differentiating suprabasal cells exit the cell cycle after leaving the 
basal layer. However, papillomaviruses require a proliferating host cell to replicate 
their genomes. One major consequence of papillomavirus infection is therefore a 
blockage of cell cycle exit and induction of S-phase, allowing HPV genomes to be
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replicated to high levels in the intermediate layers of the epithelium. Early gene 
transcription increases concomitantly with the onset of vegetative viral DNA  
replication, while transcripts encoding the late genes are restricted to the terminally 
differentiated layers of the epithelium where virions are being assembled and 
released (Durst et al., 1992).
1.1.2. HPVs are causative agents of human cancers
Papillomavirus infection usually results in self-limiting, productive proliferative 
lesions which spontaneously regress. However, a subset of the mucosal 
epitheliotropic HPVs, termed high risk, are causally involved in the pathogenesis of 
various anogenital cancers (zur Hausen, 1989). Over 90% of human cervical cancers 
contain viral sequences from HPV-16 and -1 8 , often integrated into the host genome 
(zur Hausen, 1991). Despite the identification of these HPV types as causative agents 
of human cancers, this is not part of the normal viral life cycle as poorly 
differentiated cancer cells are not permissive for production of viral progeny. Primary 
HPV-16 and -1 8  lesions are common and frequently inconspicuous. Cells infected by 
high risk HPV types may acquire a transformed phenotype, over a prolonged period 
of time, due to additional genetic and epigenetic events and develop into malignant 
tumours. Low risk mucosal epitheliotropic HPVs, for example, HPV-6 and -11  
induce pronounced, benign proliferative warts known as genital warts or 
condylomata acuminata and very rarely associate with malignancies (Gissmann, 
1992). Cutaneous HPVs can also be classified as high risk or low risk depending on 
the association with skin cancers in vivo. Infection by high risk cutaneous HPVs, for 
example HPV-5 and -8 , is associated with the development of squamous cell 
carcinoma, particularly in immunosuppressed patients. Patients with
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epidermodysplasis verruciformis (EV), a rare hereditary lifelong disease, are 
susceptible to persistent infection by HPV types -5  and -8 , and have a high risk of 
developing skin cancer (Pfister, 1992). Low risk cutaneous HPVs, such as HPV-1 
and -2 , induce warts on the skin which show limited growth and normally regress. 
HPV types -1 6  and -18 were officially declared a human carcinogen by the World 
Health Organisation in 1995 (IARC/WHO, 1995).
1.1.3. Animal model systems
The differentiation dependence of the HPV life cycle, the ethics of studies in humans 
and the lack of suitable in vitro culture systems has hindered the study of the 
complete virus life cycle. Animal model systems have proved an invaluable tool to 
study the interaction of a papillomavirus with its natural host. The two most 
extensively studied animal papillomaviruses are the cottontail rabbit (CRPV) and 
bovine (BPV) papillomaviruses. CRPV induces papillomas in domestic rabbit skin 
that are histologically similar to cutaneous human papillomas, while the natural 
history of CRPV induced disease parallels that of high risk HPV infection (Kreider 
and Bartlett, 1981; Wettstein, 1987). The CRPV system has been a valuable model to 
study the molecular basis for papillomavirus latency and how reactivation of latent 
infections occurs at the molecular level (Amelia et al., 1994). There are two groups 
of BPVs (Jarrett et al., 1984): subgroup A  comprises BPV-1, -2 and -5  and subgroup 
B contains BPV-3, -4 and -6 . The viruses of subgroup A  induce fibropapillomas, 
with both a fibroblastic and epithelial component, as infection leads to an initial 
transformation of the sub-epithelial fibroblasts followed by papillomatosis. The 
subgroup B viruses are epitheliotropic, showing a similar tissue tropism to the HPVs, 
inducing epithelial papillomas with no dermal involvement.
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1.1.4. Papillomavirus genomic organisation
Bovine papillomavirus-1 (BPV-1) is perhaps the most extensively studied 
papillomavirus and has long been the paradigm of all papillomaviruses. The ease 
with which BPV-1 could be isolated from warts and its ability to transform cells in 
culture led to the sequencing of the complete BPV-1 genome and the assignment of 
functions to the individual open reading frames (ORFs) (Law et al., 1981). The BPV- 
1 genome is a closed circle of approximately 7.8 kb that exhibits an organisation 
similar to all papillomaviruses (Iftner, 1990). It can be divided into three regions: 
regions encoding the early, E1-E8, and late, LI and L2 gene products, separated by a 
non-coding region of approximately 1000 bp called the long control region (LCR) 
(Fig. 1.1.). All the ORFs are present on the same DNA strand, and only this strand is 
expressed as a mRNA (for a review see (Baker, 1990)). A  polyadenylation site is 
present at the end of each coding region. The early region encodes the proteins 
essential for transcription and replication of the viral genome and the viral 
transforming proteins, while the late region encodes the proteins necessary for viral 
DNA encapsidation. Although the early genes are expressed in all layers of the 
epithelium, expression of the late genes is restricted to the terminally differentiated 
keratinocytes, in the upper layers of the epithelium. Numerous polycistronic BPV-1 
transcripts, which show a complex pattern of splicing between the ORFs, have been 
identified (Baker, 1990). In BPV-1 transcripts from the early region are initiated from 
multiple promoters and are polyadenylated at the early polyadenylation site. 
However, transcripts encoding the E6, E7, E l and E2 ORFs of the high risk HPV 
types originate at the early promoter located upstream of the E6 ORF. This promoter 
is designated p l05  in HPV-18 and p97 in HPV-16 and -31  (Stubenrauch and
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Laimins, 1999). BPV-1 late mRNAs are transcribed from a single late promoter (PL), 
located within the E7 ORF, and are polyadenylated at the late polyadenylation site 
(Baker and Howley, 1987). A  differentiation dependent late promoter has also been 
identified for HPV-16 (p846) and HPV-31 (p742). Expression of the late region 
mRNAs therefore requires a differentiation dependent shift in polyadenylation site 
usage and activation of the late promoter (Barksdale and Baker, 1993).
1.1.5. Papillomavirus protein function
The gene products of the major papillomavirus ORFs have been well characterised 
for BPV-1 and many HPVs. The E l protein is essential for viral DNA replication. 
The involvement of E l in replication was originally predicted by sequence 
similarities to SV40 large T antigen (Tag) (Clertant and Seif, 1984). 
Papillomaviruses utilise a number of cellular factors to replicate the viral genome. 
These include DNA polymerase a-primase (Bonne-Andrea et al., 1995b; Park et al.,
1994) and 8 which synthesise the viral DNA, replication protein A  (RPA), a single­
stranded DNA binding protein which stabilises the open duplex region of the DNA at 
the replication fork, proliferating cell nuclear antigen (PCNA), replication factor C 
(RFC) and topoisomerases I and II (Kuo et al., 1994; Melendy et al., 1995). E l is a 
68-72 kDa nuclear phosphoprotein with ATPase and helicase activities (Sun et al., 
1990; Yang et al., 1993). E l specifically binds an 18 bp inverted repeat (E1BS) in 
the viral origin of replication located in the 3 ’ region of the LCR (Holt et al., 1994). 
Functional origins of replication have been defined for BPV-1 and several HPVs 
including types -1 6  and -1 8  (for a review see (Ustav and Ustav, 1998)). The E1BS is 
flanked by an A/T rich region and two E2 DNA binding sites. Initial binding of E l 
leads to a structural distortion of the origin, DNA unwinding and the formation of a
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hexameric E l complex with ATPase and DNA helicase activities (Gillette et al., 
1994; Sedman and Stenlund, 1998).
Efficient viral DNA replication requires the formation of a specific complex between 
E l and the viral E2 protein, targeting E l to the origin of replication (Sedman and 
Stenlund, 1995). In vitro replication of BPV-1 DNA has suggested that the BPV-1 E2 
protein is not required for elongation and is released from the origin after the initial 
binding step (Bonne-Andrea et al., 1995a). Although biochemical analysis of HPV 
E l proteins has been much more limiting than that of BPV-1 E l, the HPV-11 and -  
16 E l and E2 proteins have also been shown to associate (Bream et al., 1993; Storey 
et al., 1995). The E1-E2 interaction has been mapped to both the N-terminal and C- 
terminal regions of both BPV-1 and HPV E l and E2 proteins suggesting several 
functional interactions. The minimal DNA binding domain in the amino terminus of 
BPV-1 E l binds the E1BS in an E2 dependent manner. Only the E2 DNA binding 
domain interacts with this E l fragment suggesting that the DNA binding domains of 
E l and E2 cooperate in the process of binding DNA (Chen and Stenlund, 1998). The 
C-terminal helicase domain of HPV-16 E l binds the E2 transactivation domain and 
the DNA polymerase a-primase p68 subunit in a mutually exclusive manner 
(Masterson et al., 1998). The HPV E l proteins can also interact with histone HI 
(Swindle and Engler, 1998) and hSNF5, a component of the SWI/SNF ATP 
dependent chromatin remodelling complex (Lee et al., 1999). E l is also a tight- 
binding substrate of cyclin E-cyclin dependent kinase-2 (Cdk-2) in vitro, a key cell 
cycle regulator of S-phase. Phosphorylation of E l by cyclin E/Cdk complexes is 
required for efficient viral DNA replication in vitro and in vivo. This interaction may
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be a crucial determinant of cell-cycle regulation of papillomavirus DNA replication 
(Ma et al., 1999).
The E2 protein is the major regulator of viral transcription, is essential for the 
initiation of viral DNA replication and has a number of pleiotropic effects within the 
cell. The function of E2 will be described in detail later. No function has been 
assigned to the E3 ORF. Only a few papillomavirus types possess it.
The role of the E4 protein in the viral life cycle is still subject to speculation. E4, first 
identified in HPV-1 induced warts, is highly divergent between papillomavirus types. 
E4 is expressed as a 10 kDa polypeptide fused to the five amino-terminal residues of 
E l (E1AE4) (Doorbar et al., 1988). In HPV-11 and -31  the mRNA encoding E1AE4 
is the most abundant viral RNA transcript in the intermediate layers of the epithelium 
(Desaintes and Demeret, 1996). Although this transcript is initiated from the 
differentiation dependent late promoter E1AE4 is not a component of the virus 
particle. E1AE4 is also not needed for transformation in vitro. The HPV-16 E1AE4 
protein, when expressed in human epithelial cells, associates with the intermediate 
filament network. This results in the total collapse of the keratin cytoskeleton 
suggesting a possible involvement in virus release by disturbing the integrity o f the 
infected cells (Doorbar et al., 1991).
The product of the E5 ORF is the major transforming protein of BPV-1 (Schiller et 
al., 1986). BPV-1 E5 is a 44 amino acid, disulphide linked, homodimeric 
transmembrane protein, localised largely in the membranes of the endoplasmic 
reticulum and Golgi apparatus (Schlegel and Wade-Glass, 1987). BPV-1 E5 can 
transform established mouse fibroblasts in the absence of other viral gene products,
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and has been shown to induce cellular DNA synthesis (Leptak et al., 1991). BPV-1 
E5 exhibits a short region of sequence homology with platelet derived growth factor 
(PDGF). BPV-1 E5 directly binds the PDGF receptor, inducing ligand independent 
oligomerisation and stimulation of signal transduction in the absence of mitogens. 
Amino acids in the transmembrane and juxtamembrane domains of the PDGF 
receptor, not the ligand binding domain, are required for the interaction with E5 
(Meyer et al., 1994). BPV-1 E5 also indirectly activates the epidermal growth factor 
(EGF) and colony stimulating factor-1 (CSF-1) receptors (Martin et al., 1989). BPV- 
1 E5 can bind the 16 kDa protein of the ductin family of proteolipids, a major 
structural component of gap junctions and a subunit of the vacuolar H+-ATPase 
(Finbow et al., 1991). It is proposed that the interaction with ductin indirectly 
potentiates mitogenic signalling by inhibiting the vacuolar ATPase, a proton pump 
responsible for the acidification of cytoplasmic organelles, inhibiting receptor down 
regulation. However, mutations in the E5 transmembrane domain, which retain the 
ability to interact with ductin, are not transforming (Sparkowski et al., 1996). HPV- 
16 E5, although not as powerful a tranforming agent as BPV-1 E5, can transform 
mouse keratinocytes, stimulate the transforming activity of the EGF receptor, bind 16 
kDa ductin and down regulate the function of cellular gap junctions (Oelze et al.,
1995).
In high risk mucosal HPV types, the blockage of cell cycle exit and induction of S- 
phase in differentiated suprabasal cells is mediated by the products of the E6 and E7 
ORFs (Cheng et al., 1995). E6 and E7 are the major transforming proteins of these 
papillomaviruses. Co-expression of high risk HPV E6 and E7 can immortalise 
primary human genital epithelial cells (Vousden, 1991). The low risk HPV E6 and
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E7 proteins, expressed from the same strong promoters, function very inefficiently in 
cell transformation and immortalisation assays, reflecting biochemical differences in 
the activities of these viral gene products (Storey et al., 1988). The HPV E6 gene 
product is an approximately 18 kDa protein that contains two zinc binding CXXC 
motifs (Barbosa et al., 1989). A  series of alternatively spliced transcripts lacking the 
E6 C-terminus also exist, but the encoded proteins are rapidly turned over and are 
hardly detectable in vivo (Schneider-Gadicke and Schwartz, 1986). High risk HPV 
E6 proteins function, at least in part, by binding and specifically stimulating the ATP 
dependent degradation of the p53 tumour suppressor protein (Scheffner et al., 1990; 
Werness et al., 1990). The N-terminus of E6 simultaneously interacts with E6AP, a 
cellular ubiquitin ligase, and the core region of p53 targeting p53 for ubiquitin 
dependent proteolysis (Huibregtse et al., 1991). E6AP does not interact with p53 in 
the absence of E6. E6 proteins from low risk genital HPVs, cutaneous HPVs and 
animal papillomaviruses either do not, or only weakly associate with E6AP or p53, 
and do not affect p53 stability (Elbel et al., 1997). The binding affinity of different 
E6 proteins for the p53 core region correlates with their efficiency to stimulate p53 
degradation. Although, the C-terminal domain of E6 from both high and low risk 
HPV types is able to bind the p53 C-terminus, it is only the interaction of E6 with the 
p53 core region that induces degradation (Li and Coffino, 1996). The E6 protein may 
also use additional pathways to disrupt p53 mediated growth suppression. HPV-16 
E6 can block p53 binding to its DNA recognition site, probably through the 
interaction with the C-terminal domain of p53 (Lechner and Laimins, 1994), and can 
downregulate p53 activity by targeting the transcriptional coactivator p300/CBP 
(Zimmermann et al., 1999). p53 independent functions of E6 may also contribute to 
growth regulation. High risk HPV E6 proteins can bind the focal adhesion protein
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paxillin (Tong and Howley, 1997), the pro-apoptotic protein bak (Thomas and Banks, 
1999), the c-myc oncoprotein (Gross-Mesilaty et ah, 1998), the putative human 
tumour suppressor protein disc large (hDCG) (Kiyono et al., 1997) and can stimulate 
telomerase activity during keratinocyte immortalisation (Kiyono et al., 1998).
The product of the E7 ORF from high risk HPV types is an approximately 17 kDa 
protein present in both the nucleus and cytoplasm of infected cells (for a review see 
(Zwerschke and Jansen-Durr, 2000)). The E7 amino terminus shows structural and 
functional homologies to a portion of conserved region 1 (CR1) and the entire CR2 
domain of the adenovirus E la  and SV40 large Tag oncoproteins (Vousden, 1991). 
The CR2 domain contains a consensus casein kinase II (CKII) phosphorylation motif 
and a LXCXE retinoblastoma protein (pRb) family binding site. pRb and the related 
proteins, p l0 7  and p l30 , can mediate the association of E7 with cyclin A/cdk-2 and 
cyclin E/cdk-2 complexes (Davies et al., 1993; Dyson et al., 1992; Dyson et al., 
1989). The E7 carboxy terminus contains two zinc binding CXXC motifs that 
function as a dimerisation domain (McIntyre et al., 1993). Mutations in the CXXC or 
LXCXE motifs drastically reduce or abolish the transforming activity of E7. HPV-16 
E7 preferentially binds the hypophosphorylated, tumour suppressor form of pRb 
releasing transcriptionally active E2F family members. The E2F transcription factor 
family regulates expression of many genes responsible for progression into S-phase, 
for example, cyclin E, cyclin A  and b-myb (Weinberg, 1995). E7 proteins from low  
risk HPV types bind pRb with a reduced affinity compared to high risk HPV types 
correlating with transforming capacity (Munger and Phelps, 1993). However, the 
ability of E7 to interact with pRb family members is not the only determinant of 
oncogenic potential. The C-terminus of HPV-16 E7 can interact with and block the
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activities of the p27Kipl and p21WAF1 cyclin dependent kinase inhibitors (Jones et al., 
1997; Zerfass-Thome et al., 1996). These inhibitors negatively regulate cell cycle 
progression and play a role in inhibiting cellular proliferation during epithelial cell 
differentiation. E7 can regulate gene expression through interacting with E2F 
unrelated transcription factors. HPV-16 E7 interacts with the Jun component of the 
AP-1 transcription factor through one of its CXXC motifs (Antinore et al., 1996). 
This interaction activates transcription of AP-1 responsive genes suggesting that E7 
can promote Go/Gi progression under conditions where external proliferative signals 
are reduced or absent. HPV-16 E7 has also been shown to interact with TATA box 
binding protein (TBP), the affinity of which is increased by CKII phosphorylation 
(Massimi et al., 1997). The interaction of E7 with TBP may mediate transcriptional 
repression or activation at certain promoters to promote cell cycle progression. The 
first cytoplasmic target of E7 has recently been identified. HPV-16 E7 interacts with 
enzyme type M2 pyruvate kinase (M2-PK) increasing the rate of glycolysis, 
suggesting that E7 can directly alter the carbohydrate metabolism of the host cell to 
allow sustained proliferation (Zwerschke et al., 1999).
The function of the putative BPV-1 E8 has not yet been established.
The products of the L I and L2 ORFs are only expressed in the terminally 
differentiated layers of the epithelium late in the virus life cycle. LI is the major 
capsid protein and L2 is the minor capsid protein of the virion. These two proteins 
encapsidate a histone associated, closed circular, double stranded DNA  
minichromosome. X-ray crystallography shows that the icosahedral outer shell of the
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virion contains 72 pentamers of LI (Chen et al., 2000). L2, a largely internal protein, 
is present at roughly 1/30 the abundance of LI (Kirnbauer et al., 1993).
1.1.6. Bovine papillomavirus type 4 (BPV-4)
BPV-4 is a mucosal epitheliotropic papillomavirus that infects the upper alimentary 
canal of cattle causing benign papillomas with a high risk of progressing to 
carcinoma in cattle feeding on bracken fern (Campo et al., 1980; Campo et al., 1994). 
The BPV-4 genome is a double stranded closed circle of 7265 nucleotides. BPV-4 
has a genetic organisation similar to all other papillomaviruses: regions encoding the 
early and late gene products separated by the non-coding LCR (Fig. 1.2.). Numerous 
BPV-4 transcripts, initiated from two major promoters, have been identified: the 
early promoter (PE), maps to the TATA box at nucleotide 283 (Jackson and Campo, 
1995) and the late promoter (PL) maps between nucleotides 777 and 902 (Stamps and 
Campo, 1988). The BPV-4 E l, E2 and E7 proteins show a high degree of sequence 
homology to the equivalent proteins in other papillomaviruses. BPV-4 also encodes a 
polypeptide analogous to the E1AE4 fusion protein described for HPV-1. The BPV-4 
E8 ORF, located at the 5 ’ end of the early region, encodes a protein homologous to 
the E5 protein of BPV-1. Although BPV-4 E8 and BPV-1 E5 have different genomic 
locations BPV-4 E8 has recently been renamed E5 because of the many functional 
similarities between these proteins (see below) (Morgan and Campo, In press). The 
L3 and L4 ORFs do have translation start codons but their function, if any, is not 
known (Campo et al., 1996). The main difference between the BPV-4 genome to that 
of most papillomaviruses is the absence of the E6 ORF, which is also deleted in the 
related epitheliotropic papillomaviruses, BPV-3 and -6 .
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The ability of BPV-4 to transform cells in culture provides an excellent model for the 
identification of genetic and epigenetic events which contribute to the multiple steps 
of tumourigenic progression. Although BPV-4 DNA alone can transform established 
NIH3T3 mouse fibroblasts (Campo and Spandidos, 1983), BPV-4 requires the 
cooperation of active ras to morphologically transform primary bovine fibroblasts 
(PalF) derived from a foetal palate (Jaggar et al., 1990). The transformed cells have 
an extended life span and are capable of anchorage independent growth but are not 
immortal or tumourigenic in nude mice. This indicates that viral infection represents 
only one event during malignant progression and that additional events are needed 
for the development to carcinoma. E7, expressed in all layers of papillomas at all 
stages of development, and E8, expressed only in the basal and suprabasal layers of 
papillomas, are the major transforming proteins of BPV-4 (Anderson et al., 1997). In 
cooperation with ras, BPV-4 E7 induces morphological transformation of PalF cells 
in the absence of all other viral genes (Pennie et al., 1993). BPV-4 E7 contains the 
two zinc binding CXXC motifs and the pRb family binding domain, but does not 
possess the CKII phosphorylation site conserved in the E7 proteins of high risk HPV 
types. BPV-4 E8 encodes a 42 amino acid hydrophobic peptide that is localised to 
cellular membranes. BPV-4 E8 alone does not cooperate with an active ras gene to 
confer any growth advantage to PalF cells. However, BPV-4 E8 contributes to 
cellular transformation by conferring an anchorage independent growth phenotype on 
PalF cells co-transfected with E7 and ras (Pennie et al., 1993). Also, NIH3T3 cells 
expressing E8 alone are capable of anchorage independent growth and escape growth 
arrest after serum withdrawal. Like BPV-1 E5, BPV-4 E8 interacts with ductin and 
induces down regulation of gap junctional intercellular communication in PalF cells 
(Faccini et al., 1996). Also, E8 upregulates expression of cyclin A increasing the
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activity of the cyclin A/cdk-2 complex, and deregulates expression of the cell cycle 
inhibitor p27Kn>, contributing to transformation (O'Brien and Campo, 1998).
Experimental reproduction of the progression of papillomas to carcinomas in cattle 
has identified the immunosuppressants and mutagens present in bracken fern as 
cofactors necessary for the development of BPV-4 associated alimentary canal cancer 
(Campo et al., 1994). Immunosuppressed cattle are subjected to life long 
papillomatosis. The persistant papillomas are at a high risk of progressing to cancer 
as they are continually exposed to the mutagens present in the fern (for a review see 
(Jackson et al., 1996)). Also, the in vitro transformation system has demonstrated that 
the flavinoid quercetin, one of the most potent mutagens found in bracken, can 
synergise with BPV-4 E7 to confer a fully malignant phenotype to PalF cells 
(Cairney and Campo, 1995; Pennie and Campo, 1992). Quercetin induces mutations 
in DNA through the generation of single stranded breaks (Fazal et al., 1990), can act 
as an initiator of tumour progresion (Sakai et al., 1990) and disrupts normal cell 
signalling pathways by interfering with kinases and phosphatases (Van Wart-Hood et 
al., 1989). Quercetin also induces growth arrest of PalF cells in both the G1 and 
G2/M phases of the cell cycle and can upregulate the transcriptional activity of the 
BPV-4 LCR (Connolly et al., 1998). Papillomas induced by BPV-4 can therefore 
progress to carcinoma even though BPV-4 does not have an E6 ORF or encode E6- 
like functions. If disruption of p53 function is important in BPV-4 cell 
transformation, it may occur by alteration of the cellular gene. Indeed, the in vitro 
bovine cell transformation model has revealed a correlation between transcriptionally 
inactivating p53 mutations and tumourigenicity. In PalF cells, p53 protein is elevated 
and transcriptionally activated in response to quercetin. However, in tumourigenic
Chapter 1-Introduction 15
cells although p53 protein levels increase in response to quercetin, p53 is 
transcriptionally inactive. Sequencing of the bovine p53 gene in tumourigenic cell 
lines shows a glycine to valine substitution in conserved region V in the p53 DNA  
binding domain (Beniston, 1999).
1.2. Control of papillomavirus transcription
HPV-16, -18 and BPV-4 are mucosal epitheliotropic papillomaviruses. This may 
reflect a restricted distribution of an epithelial cell receptor for the virus or the 
cellular factors necessary for viral DNA replication or gene expression may be 
limited to the mucosal epithelium. However, the receptor utilised by 
papillomaviruses for the initial step of infection appears to be ubiquitously expressed 
as both artificial virions and virus-like particles can bind to a variety of cell lines 
(Muller et al., 1995; Sibbet et al., 2000). Also, HPV genomes can replicate in various 
undifferentiated cell lines regardless of their natural permissiveness to infection 
(Desaintes and Demeret, 1996). As viral gene expression is limited to the host cell 
type, the tropism for the mucosal epithelium and the differentiation dependence of 
the viral life cycle might be dictated at the transcriptional level. The level of 
transcription of the viral genome is also a major determinant of the transformation 
potential of the virus. Enhanced transcription of both HPV-16 and BPV-4 has been 
shown to lead to increased transformation efficiency in vitro (Jaggar et al., 1990; 
Lees et al., 1990). Most human cervical tumours contain physical integration of the 
viral DNA into the host genome. Integration is a terminal event for the virus resulting 
in disruption of the E l and E2 ORFs (zur Hausen, 1991). However, specific 
transcripts originating from the E6 and E7 ORFs, expressed under aberrant control of 
an intact LCR, are consistently found in HPV associated tumours (Schwartz et al.,
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1985) and are required for maintenance of the transformed phenotype (zur Hausen, 
1991). Infection by high risk HPV types is frequently detected in women with 
cervical intraepithelial neoplasia (CIN), benign cervical lesions that are the 
progenitors of cervical carcinomas (Nelson et al., 1984). O N  is graded from I to III 
depending on the extent to which epithelial differentiation has been disrupted. 
Integration of viral DNA has been proposed as an activation mechanism for 
progression from advanced pre-invasive lesions to cervical cancers. Viral copy 
number is negatively correlated with the clinical stage of the tumour and directly 
associated with the degree of histological differentiation (Berumen et al., 1994). 
Integration leads to the loss of papillomavirus control of E6 and E7 expression, due 
to disruption of the E2 gene, resulting in a selective growth advantage of cells (Jeon 
et al., 1995).
1.2.1. The papillomavirus E2 protein
The E2 ORF, essential for the viral life cycle, encodes a 42-48 kDa protein 
(depending on the papillomavirus) consisting of three modular domains: a conserved 
amino terminal transactivation domain, a central flexible hinge region and a 
conserved carboxy terminal DNA binding and dimerisation domain (Fig. 1.3.). The 
E2 protein binds to the 12 bp palindromic DNA sequence -ACCGNNNNCGGT- as a 
dimer (for reviews see (Ham et al., 1991b; McBride et al., 1991)). The BPV-1 
genome contains 17 E2 DNA binding sites (Li et al., 1989) while the mucosal 
epitheliotropic HPVs have 4 (McBride et al., 1991). Genetic analysis of BPV-1 first 
demonstrated that the E2 protein is a transcriptional activator. However, BPV-1 also 
encodes two truncated versions o f E2 which act as transcriptional repressors by 
antagonising the function of the full length protein (Lambert et al., 1987; Lambert et
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al., 1989). A  31 kDa E2 polypeptide translated from an internal methionine lacking a 
region of the amino terminus and a 28 kDa E8-E2 fusion, generated by alternate 
splicing, containing 11 amino acids of E8 linked to the E2 carboxy terminus, have 
also been described. HPV types encode an E2 protein homologous to the BPV-1 
transactivator. The E2 protein can activate transcription from heterologous promoters 
in a variety of mammalian cell lines and in yeast (Cripe et al., 1987; Morrissey et al., 
1989; Romanczuk et al., 1990; Thierry and Yaniv, 1987). This indicates that the 
interactions of E2 with the transcription machinery may be conserved. One E2 site 
inserted upstream from a heterologous promoter only activates transcription weakly, 
whereas two constitute a strong inducible enhancer suggesting that a complex o f two 
E2 dimers is the functional form of E2 (Gauthier et al., 1991). Indeed, one E2 dimer 
cannot cooperate with cellular factors such as AP-1 to activate transcription whereas 
two E2 dimers can. Also, the strong cooperative activation between E2 sites can 
occur over a large distance suggesting that the interaction between E2 dimers and 
cellular factors necessary for activation may be facilitated by DNA looping, bringing 
E2 molecules close to the promoter (Thierry et al., 1990).
The carboxy terminal region of E2, consisting of approximately 90 amino acids, is 
necessary and sufficient for dimerisation and sequence specific DNA binding 
(Prakash et al., 1992). This domain does not contain any known eukaryotic DNA  
binding motifs, for example, the zinc finger or leucine zipper. The crystal structure of 
the E2 carboxy terminus bound to its DNA target reveals a novel antiparallel p-barrel 
structure responsible for dimerisation. Also, two a-helices from each E2 C-terminal 
molecule in the dimer interact with the major groove of the DNA. The E2 carboxy 
terminus dimer induces a substantial bend (42-44°) in the DNA (Hegde et al., 1992).
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The C-terminal domain contacts the guanosines on either strand of the consensus 
motif, which are on the same face on the DNA. An internal A-T rich core increases 
the affinity of the interaction between E2 and the DNA (Sanders and Maitland,
1994). Direct protein-protein interactions between the E2 C-terminus and both viral 
and cellular proteins have been demonstrated. The E2 C-terminus can bind the viral 
E l protein (Chen and Stenlund, 1998) and the cellular p53 tumour suppressor protein 
(Massimi et al., 1999). Also, the E2 C-terminus has been shown to bind two 
components of the cellular basal transcription machinery, TBP and TFIIB (Rank and 
Lambert, 1995). However, the significance of these interactions have yet to be 
determined as the E2 transactivation domain is able to function independently of the 
C-terminus to activate transcription when tethered to the heterologous GALA or 
LexA DNA binding domains (McBride et al., 1989b).
The non-conserved internal linker region of the E2 protein is not required for DNA  
binding or transcriptional activation. This region varies in length between different 
papillomaviruses and is rich in proline residues suggesting that it acts as a flexible 
hinge. Also, the hinge region contains the two major phosphorylation sites of the 
BPV-1 E2 protein (McBride et al., 1989a). E l binds preferentially to the 
underphosphorylated form of E2 suggesting that phosphorylation at these sites may 
regulate stable replication of the viral genome (Lehman et al., 1997). In addition, the 
hinge region of HPV-11 E2 has been shown to contain the determinants for nuclear 
localisation and nuclear matrix association (Zou et al., 2000).
The amino terminal transactivation domain of E2, consisting of approximately 200 
amino acids, is highly conserved among papillomavirus types and is essential for
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transcription and replication of the viral genome (for a review see (Desaintes and 
Demeret, 1996)). This region mediates protein-protein interactions with cellular 
factors involved in transcription, replication and growth control and binds E l, the 
papillomavirus replication factor, targeting it to the origin of replication. X-ray 
crystallography reveals that the HPV-16 E2 amino terminus can form a dimer in 
solution and consists of two domains (Antson et al., 2000). Domain 1, residues 1-92, 
is composed of three long, antiparallel a-helices rich in acidic amino acids. Domain 
2, residues 110-201, has an antiparallel P sheet structure. It is proposed that the 
amino terminal domains from distantly bound E2 dimers interact with each other to 
stabilise the formation of DNA loops. There are 17 amino acids in the E2 
transactivation domain that are identical between paillomavirus E2 proteins, 
indicating that they may be crucial for protein structure and viral function (Brokaw et 
al., 1996). Many conserved amino acids are clustered at the dimer interface, 
reflecting the functional importance of amino terminal dimer formation, or are 
exposed to the solvent indicating a role mediating important protein-protein 
interactions. Targeted mutational analysis of these amino acids, introducing alanine 
substitutions to minimise structural disruption, has demonstrated that the ability of 
E2 to regulate transcription and replication can be separated (Brokaw et al., 1996; 
Ferguson and Botchan, 1996; Sakai et al., 1996). Mutation at amino acid 73 (I73A) 
results in an E2 protein that fails to activate transcription but still supports viral DNA  
replication. Also, E2 with a mutation at position 39 (E39A) retains wild type 
transcriptional activity but fails to interact with E l and is defective in transient 
replication assays. There is a good correlation between the ability of mutant E2 
proteins to bind E l and to support replication, demonstating the functional 
importance of the E1-E2 interaction for efficient viral DNA replication in vivo.
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However, two mutant E2 proteins (R37A and D122A) have been identified that 
retain E l and DNA binding but are unable to stimulate replication. This suggests that 
E2 also plays an additional role in viral DNA replication. Indeed, E2 has been shown 
to alleviate nucleosome mediated repression of BPV-1 DNA replication suggesting a 
role in chromatin modification (Li and Botchan, 1994).
E2 regulates viral gene expression through contacting components of the cellular 
transcription machinery. However, the cellular factors involved in E2 mediated 
transcriptional regulation and the mechanism by which E2 modulates viral gene 
expression remains relatively unclear. The E2 transactivation domain has been shown 
to functionally interact with the cellular transcription factors TFIIB, Spl and AMF-1 
(activation domain modulating factor 1) (Breiding et al., 1997; Li et al., 1991; Yao et 
al., 1998). The interaction between E2 and TFIIB, an essential component of the 
RNA polymerase II transcription machinery, has been mapped to residues 74-134 
while the AMF-1 interaction is mediated by E2 amino acids 134-216. AMF-1 binds 
p300/CBP and enhances its interaction with E2 (Peng et al., 2000). A  direct 
interaction between E2 and p300/CBP has also been demonstrated (Lee et al., 2000). 
p300/CBP is a multi-functional transcriptional co-activator involved in mediating 
protein-protein interactions between activator proteins and the basal machinery 
(Nakajima et al., 1997). p300/CBP also possesses intrinsic histone acetyltransferase 
(HAT) activity and has been implicated in chromatin remodelling (Bannister and 
Kouzarides, 1996).
E2 requires the co-operation of at least one additional DNA binding proximal 
promoter factor, such as Sp l, or other factors that interact with papillomavirus
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promoters, such as AP-1, Oct-1, NF-l/CTF, or USF for the activation of a minimal tk 
TATA box promoter (Ham et al., 1991a; Ushikai et al., 1994). The inability of E2 to 
activate a minimal tk TATA box promoter can also be overcome by TBP 
overexpression suggesting that recruitment of TFIID, a multisubunit complex 
composed of TBP and TBP-associated factors (TAFs), is normally a rate limiting 
step for activation by E2 (Ham et al., 1994). E2 and TBP bind co-operatively to DNA  
through a direct interaction mediated by the carboxy terminal domain o f E2. E2 does 
not affect the on rate of association but reduces the off rate increasing the amount of 
TBP bound to the TATA box (Steger et al., 1995). An E2 mutant lacking the 
transactivation domain but containing the C-terminal TBP binding domain does not 
activate promoters containing a TATA box and Spl site. This suggests that the E2 
transactivation domain affects another step in the assembly of the pre-initiation 
complex after TBP has bound the DNA.
As well as regulating viral gene expression and being required for viral DNA  
replication E2 possesses other functions essential for the viral life cycle. Long term 
episomal maintenance of viral genomes requires expression of the E l and E2 
proteins (Piirsoo et al., 1996). Within replicating cells E2 and BPV-1 genomes are 
found associated with mitotic chromosomes (Skiadopoulos and McBride, 1998). It is 
proposed that E2 links the genomes to mitotic chromosomes to ensure viral genomes 
are segregated to daughter cells in approximately equal numbers. This interaction is 
mediated by the E2 amino terminus (Bastien and McBride, 2000). Recently, it has 
been shown that phosphorylation o f BPV-1 E2, at sites located in the hinge region, 
can also modulate viral genome copy number by regulating E2 protein levels 
(Penrose and McBride, 2000). Furthermore, BPV-1 E2 is directed to promonocytic
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leukaemia protein (PML) oncogenic domains (PODs) by the papillomavirus L2 
protein (Day et al., 1998) and BPV-1 has also been shown to facilitate the packaging 
of plasmid DNA into pseudovirions (Zhao et al., 2000).
E2 can also disrupt cellular growth control in certain HPV transformed and HPV 
negative cell lines. The exact mechanism of how E2 induces apoptosis and cell cycle 
arrest remains unclear and may differ between papillomavirus E2 molecules despite 
the many similarities. Overexpression of BPV-1 E2 or HPV-18 E2 proteins in HeLa 
cells leads to growth arrest in the G1 phase of the cell cycle and p53 dependent 
induction of apoptosis (Dowhanick et al., 1995; Hwang et al., 1996). HeLa cells 
contain integrated copies of the HPV-18 genome that have a disrupted E2 gene but 
actively express E6 and E7. Re-introduction of E2 causes a decrease in E6 and E7 
expression, reactivation of p53 and the p21 cyclin dependent kinase inhibitor, 
accumulation of hypo-phosphorylated pRb and decreased E2F expression. The 
growth suppressive effect of E2 is at least in part mediated by transcriptional 
repression of the p i05 promoter and depends on a specific function of the E2 
transactivation domain, not shared by other acidic transactivators such as VP16 
(Goodwin et al., 1998). However, a truncated E2 protein lacking the amino terminus 
also represses E6 and E7 expression in HeLa cells, but fails to induce apoptosis. 
HPV-16 E2 can also inhibit cell cycle progression in HPV negative cells (Webster et 
al., 2000) and BPV-1 and HPV-18 E2 proteins have been shown to upregulate p53 
mediated transcriptional activation in transformed cell lines (Desaintes et al., 1997). 
Therefore, E2 can induce apoptosis through mechanisms that are unrelated to its 
inhibitory effect on viral oncogene expression. BPV-1 E2 has also been shown to 
induce G1 arrest through p53 independent mechanisms. BPV-1 E2 inhibits
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proliferation of HT-3 cells, a p53 negative cervical carcinoma cell line containing 
integrated HPV-30 DNA (Naeger et al., 1999). Overexpression of E2 leads to 
repression of E6 and E7 expression, a reduction in cdk-2 activity and an 
accumulation of hypo-phosphorylated pRb. E2 does not induce p21 but represses 
expression of cyclin A, which regulates cdk-2 activity, and cdc25 phosphatases 
which activate cdk-2. Overexpression of HPV E2 proteins has also been shown to 
cause a growth arrest in the G2/M phase of the cell cycle in both yeast and 
mammalian cells (Fournier et al., 1999; Frattini et al., 1997).
1.2.2. Organisation of the papillomavirus LCR
All papillomaviruses have a non-coding region of 500-1000 bp called the LCR. The 
LCR is the transcriptional control unit of the virus regulating expression of the viral 
transforming proteins and of the proteins essential for the viral life cycle. Mucosal 
epitheliotropic papillomaviruses, for example, BPV-4 and HPV-16 and -18 , have a 
similar LCR organisation (Fig. 1.4.): a promoter region, an epithelial specific 
enhancer and an identical distribution of DNA binding sites for the virally encoded 
E2 protein (Morgan et al., 1998). Immediately upstream from the TATA box are two 
E2 DNA binding sites separated from each other and the TATA box by 3 or 4 bp. 
Two additional upstream sites flank the enhancer region: one beside the E l DNA  
binding site involved in the regulation of viral DNA replication and one a further 
300-400 bp upstream. The conservation of the organisation of E2 DNA binding sites, 
which is not observed in the cutaneous HPV LCRs, strongly suggests that the 
mechanism E2 uses to regulate transcription from mucosal epitheliotropic LCRs is 
conserved.
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1.2.3. Transcriptional regulation of the LCR by E2
Transient transfections using various cell lines and E2 expression systems have 
demonstrated that HPV-16 and -1 8  E2 proteins can both activate and repress 
transcription from their respective LCRs (Bernard et al., 1989; Bouvard et al., 1994). 
The precise position of the E2 DNA binding site determines whether E2 functions as 
an activator or repressor. Mutational analysis has demonstrated that binding of E2 to 
the promoter distal sites enhances transcription while repression is mediated through 
the TATA proximal E2 DNA binding site (Romanczuk et al., 1990). In vitro 
transcription studies have shown that E2 regulates transcription from the HPV-18 
LCR in a dose dependent manner (Steger and Corbach, 1997). Low levels of E2 
stimulate the LCR promoter, whereas increasing amounts result in promoter 
repression. E2 therefore autoregulates its own expression levels. Binding assays have 
demonstrated that E2 binds E2 BS4, the most distal site to the promoter, with the 
highest affinity. The TATA box proximal site, E2 BS1, has the lowest affinity for E2 
suggesting that this site only becomes occupied at high levels of E2 (Steger and 
Corbach, 1997). It is hypothesised that repression of the HPV-16 and -1 8  LCR 
promoters by E2 is mediated by E2 interacting with BS1 and disrupting assembly of 
the basal transcription machinery, resulting in a down-regulation of transcription 
initiation (Steger et al., 1995). Disruption of the E2 ORF by integration of the viral 
genome into the host chromosome would relieve repression of LCR promoter 
activity by high levels of E2. The overall effect of the E2 protein on LCR promoter 
activity is therefore dependent on the relative affinity of E2 for each binding site, the 
number and arrangement of the binding sites and the level of expression of E2 within 
the cell.
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When compared to the HPV-16 LCR, the BPV-4 LCR has a higher transcriptional 
activity in its target cell type, primary bovine palate keratinocytes (PalK). Also, PalK 
and primary bovine palate fibroblasts (PalF) are easily maintained and transfected in 
tissue culture. Low to intermediate levels of HPV-16 and BPV-4 E2 upregulate 
transcription efficiently from the BPV-4 LCR in PalK cells but do so only poorly in 
PalF (Morgan et al., 1998). The BPV-4 LCR and primary bovine cell system 
therefore presents a model to study the mechanisms of E2 mediated transcriptional 
regulation of mucosal epitheliotropic papillomaviruses and the cell type specificity of 
this regulation.
1.2.4. Epithelial specific regulation of papillomavirus transcription by 
cellular factors
DNAse I footprinting has demonstrated that the BPV-4 LCR (Fig. 1.4.) contains 
numerous binding sites for potential cellular transcription factors while deletion 
analysis of the BPV-4 LCR has identified several positive and negative E2 
independent control elements that regulate transcription from the heterologous tk 
promoter in established mouse fibroblasts (Jackson and Campo, 1991). Each of the 
three positive regulatory elements seems to be paired with a negative control element 
which modulates its activity. However, cellular factors upregulate transcription from 
the BPV-4 LCR preferentially in epithelial cells (Morgan et al., 1999). An epithelial 
specific enhancer of approximately 200 bp in the central portion of the LCR, that 
fails to activate transcription from the SV40 promoter in fibroblasts, accounts for 
99% of the transcriptional activity of the LCR. Two main regions, Sitel and Site 2, 
contribute to enhancer activity. The cellular factors binding to the BPV-4 enhancer 
still require characterisation. However, the BPV-4, HPV-16 and -1 8  enhancers are of
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a similar size and position, located in the central portion of the LCR. A  400 bp 
enhancer in the HPV-16 LCR, and a 200 bp enhancer region in the HPV-18 LCR, 
critical for efficient transcription from these promoters, have been identified (for a 
review see (Hoppe-Seyler and Butz, 1994)). These constitutive enhancers are 
epithelial specific as they fail to activate transcription from heterologous promoters 
in non-epithelial cell types. Tissue specific gene expression can be determined by 
factors present exclusively in the target cell type, for example, the basic helix-loop- 
helix (bHLH) transcription factor MyoD in striated muscle (Weintraub et al., 1991) 
and the POU domain protein Pit-l/GHF-1 in the anterior pituitary (Bodner et al., 
1988). However, no one factor has been identified, present exclusively in epithelial 
cells, that determines the epithelial specific nature of the papillomavirus enhancer 
elements. It has been proposed that epithelial specificity is brought about by the co­
operative interactions of ubiquitously expressed transcription factors. The mechanism 
of this activation may involve synergism or antagonism between DNA bound factors 
that are differentially expressed, or modified in a cell type dependent manner. 
Epithelial specificity might also be established by non-DNA bound co-factors that are 
expressed in a cell type specific manner or interact only with a particular state of a 
DNA bound factor. Binding sites for the ubiquitously expressed cellular transcription 
factors AP-1, NF-1, Oct-1, PEF-1, TEF-1 and the glucocorticoid receptor are 
commonly found in papillomavirus enhancer regions, though at different locations 
and in varying numbers.
Activator protein-1 (AP-1) factors play an important role in the activation of HPV 
transcription. The HPV-16 LCR contains three AP-1 binding sites within the 
enhancer region while the HPV-18 LCR contains two AP-1 recognition elements,
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one within the enhancer and the other located in the proximal promoter region 
(Chong et al., 1991; Thierry et al., 1992). Mutational inactivation of these AP-1 sites 
within the context of the complete LCR severely reduces promoter activity. AP-1 
factors, encoded by the jun and fos proto-oncogenes, consist of either jun-jun 
homodimers or jun-fos heterodimers. Both jun and fos constitute multi-gene families: 
three jun family members, c-jun, junB, and junD, and four fos family members, c-fos, 
fosB, fral, and fra2, have been identified. AP-1 proteins can confer a high degree of 
transcriptional variability to a gene as different jun and fos family members have 
similar DNA binding specificities but different tissue distributions and activation 
potentials. Also, subtle sequence variations from the consensus API binding motif 
are preferentially recognised by specific subsets of AP-1 proteins. Both jun and fos 
family members have been shown to be differentially expressed during epithelial 
differentiation (Wilkinson et al., 1989). In nuclear extracts prepared from human 
keratinocytes, junB, expressed predominantly in the terminally differentiated layers 
of the epidermis during mouse organogenesis, is the major jun component 
recognising the HPV-18 AP-1 elements (Thierry et al., 1992). However, AP-1 factors 
are necessary but not sufficient for activation of HPV-16 and -1 8  transcription in 
keratinocytes as LCR transcriptional activity could not be detected in jun/fos co­
transfected fibroblasts suggesting that additional factors must be involved in 
determining epithelial specificity. Consistent with this, a putative keratinocyte 
specific transcription factor, KRF-1, has been shown to interact with AP-1 to activate 
HPV-18 gene expression in squamous epithelial cells (Mack and Laimins, 1991). 
However, KRF-1 binding sites are not present in the HPV-16 LCR and KRF-1 does 
not appear to contribute to cell type specific activation of other genital HPV types.
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Nuclear factor 1 (NF1) proteins are a family of transcription factors encoded by four 
genes, NF1-A, -B, -C and -X , whose diversity is further increased by differential 
RNA splicing (Apt et al., 1993). NF1 proteins bind their consensus motif as dimers. 
The amino terminal DNA binding and dimerisation domains of all NF1 proteins are 
highly conserved but the carboxy terminal, proline rich transactivation domains are 
heterogeneous. Seven NF1 sites within the HPV-16 LCR and three sites within the 
HPV-18 enhancer have been identified (Gloss et al., 1989). Most of these sites only 
contain half the consensus binding motif and bind NF1 with low affinity. Mutational 
analysis of the HPV-16 LCR has demonstrated that NF1 and AP-1 can functionally 
co-operate to regulate papillomavirus transcription (Chong et al., 1990). Epithelial 
cells contain proteins derived from the NF1-C gene (NF1/CTF), but in fibroblasts 
where the viral enhancer is inactive, high levels of NF1 from the NF1-X gene is 
expressed (Apt et al., 1994). Overexpression of NF1-X in epithelial cells 
downregulates the activity of the HPV-16 enhancer, demonstrating a crucial role for 
the NF1 binding sites in the epithelial specific function of the viral enhancer.
POU domain proteins, for example, the ubiquitous Oct-1, are characterised by a 150- 
160 amino acid stretch containing highly conserved amino (POU specific) and 
carboxy (POU homeodomain) terminal regions separated by a variable linker (for a 
review see (Wegner et al., 1993)). The POU specific and the POU homoedomains 
form a high affinity, sequence specific DNA binding domain. Although POU domain 
proteins generally have weak, intrinsic, amino terminal transactivation domains, the 
POU domain provides an interface for functionally important interactions with other 
proteins, for example, Oct-1 binds to a related octomer motif in the HSV early 
promoter recruiting the multi-subunit host cell factor HCF/C1 and the virally
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encoded VP16 acidic transactivator (O'Hare et al., 1988). The resultant complex 
allows a strong activation of transcription of HSV immediate early genes. Also, the 
interaction of POU domains with cell type specific co-activators might be an 
important determinant of cell type specific gene expression, for example, a B-cell 
specific coactivator, OCA-B, potentiates Oct-1 mediated activation of the 
immunoglobulin heavy chain promoter (Luo et al., 1992). The enhancer in the HPV- 
16 LCR contains a degenerate octomer binding site overlapping a binding site for a 
novel 110 kDa protein, PEF-1 (papillomavirus enhancer binding factor 1). PEF-1 
binding to this element upregulates, while Oct-1 binding downregulates enhancer 
activity (Sibbet et al., 1995). However, Oct-1 has also been shown to activate the 
HPV-16 enhancer via a synergistic interaction with NF-1 (O'Connor and Bernard,
1995). Two degenerate octomer binding sites are present in the HPV-18 enhancer. 
Overexpression of Oct-1 represses HPV-18 transcription (Hoppe-Seyler and Butz, 
1994). A  DNA binding defective Oct-1 mutant with a triple amino acid substitution 
in the homeodomain indicates that repression does not require direct DNA binding by 
Oct-1 but involves protein-protein interactions. However, the HPV octomer elements 
can activate transcription when inserted upstream of a heterologous promoter (Morris 
et al., 1993). Epoc-l/skn-la, a POU domain protein expressed almost exclusively in 
the skin, binds and activates the HPV-16 and -1 8  promoters (Yukawa et al., 1996). 
Epoc-l/skn-la transcripts show a similar differentiation dependent distribution of 
expression as HPV transcripts during the viral life cycle.
Binding sites for the transcriptional enhancer factor (TEF) proteins 1 and 2, 
previously shown to bind and co-operatively activate the SV40 enhancer, have been 
identified in the HPV-16 enhancer (Chong et al., 1991; Ishiji et al., 1992).
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Squelching experiments have indicated that transcriptional activation by TEF-1 
requires a limiting, cell specific co-activator. Mutational analysis suggests that TEF-1 
is a major determinant of HPV-16 enhancer activity.
Several additional factors have been shown to contribute to enhancer activity. The 
HPV-16 and -1 8  enhancer is responsive to certain steroid hormones through binding 
sites for the glucocorticoid and progesterone receptors (Chan et al., 1989). The HPV- 
16 LCR contains three different glucocorticoid responsive elements (GREs) while 
one is present in the HPV-18 LCR. HPV-16 and -1 8  transcriptional activity is also 
suppressed by overexpression of wild type p53 (Chan et al., 1989). Deletion analysis 
has mapped the p53 responsive domain to the epithelial specific enhancer. The HPV- 
16 and -1 8  enhancers also contain CpG dinucleotide repeats and are downregulated 
by site specific methylation (List et al., 1994). In vivo footprinting has suggested that 
these enhancer regions are more densely occupied than previously thought and 
suggest that additional novel factors contribute to HPV enhancer activity (Bednarek 
et al., 1998). The activity of many of the factors that interact with papillomavirus 
enhancers can also be regulated by post translational mechanisms, for example, 
phosphorylation and glycosylation, allowing the integration of information carried by 
different signal transduction pathways.
Deletion of the LCR region upstream from the constitutive enhancer has no 
significant effect on transcriptional activity. This region contains the late 
polyadenylation site and is presumed to be involved in regulating the stability of late 
mRNAs. The 3 ’ promoter region of mucosal epitheliotropic LCRs contains the origin 
of DNA replication, a TATA box and three binding sites for virally encoded E2.
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Binding sites for the cellular factors Spl, YY-1 and C/EBP are also commonly found 
in HPV promoters.
In HPV gene expression Spl binds to a single GC rich box within the proximal 
promoter (Hoppe-Seyler and Butz, 1992). Spl bound to this site mediates promoter 
activation by the epithelial specific enhancer. Also, Spl can functionally interact with 
the viral E2 protein (Li et al., 1991). Sp l is one of at least four ubiquitously 
expressed transcription factors derived from a multigene family. All these factors 
contain a highly conserved zinc finger DNA binding domain and a glutamine rich 
activation domain. Spl is a transcriptional activator while Sp3 acts as a repressor, 
probably due to competition with Spl for the same binding sites (Hagen et al., 1994). 
In various epithelial and fibroblast cell lines high levels of Spl compared to Sp3 are 
consistently found where the HPV-16 promoter is active and low levels are found 
where it is inactive (Apt et al., 1996).
Yin-yang 1 (YY1) is a zinc finger protein that functions either as a transcriptional 
repressor, activator or initiator binding protein, depending on the sequence context. 
YY1, bound to sites in the HPV-16 and -1 8  proximal promoter region, mediates 
transcriptional repression (Bauknecht et al., 1992). These sites are often found 
mutated in primary tumours or metastases containing non-integrated HPV-16 
episomes suggesting an important role for YY1 mediated negative regulation of HPV 
gene expression (May et al., 1994). CCAAT/enhancer binding protein (C/EBP) 
factors, a family of conserved, leucine zipper (bZip) DNA binding proteins, have also 
been implicated as both positive and negative regulators of HPV gene expression 
(Bauknecht and Shi, 1998). C/EBP factors are linked to cellular differentiation and
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proliferation control in a variety of tissues including adipose and skin (Muller et al., 
1999), suggesting a role in differentiation dependent regulation of HPV transcription.
The overall LCR sequence homology between BPV-4 and HPV-16 and -1 8  LCRs is 
low. BPV-4 therefore uses distinct cellular factors from the HP Vs to achieve 
epithelial specificity, for example, there is no BPV-4 promoter proximal Spl site and 
no AP-1 sites in the BPV-4 LCR (Morgan et al., 1999). However, C/EBP family 
members have been implicated as negative regulators of BPV-4 transcription 
(McCaffery and Jackson, 1994) and there are several putative NF1 sites in the BPV-4 
LCR and octomer like sequences in the BPV-4 enhancer region. The BPV-4 LCR 
and primary bovine cell system therefore presents another opportunity to study the 
mechanisms mucosal epitheliotropic papillomaviruses use to achieve epithelial 
specific transcriptional regulation.
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THE BPV-1 GENOME
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Fig. 1.1. Organisation of the BPV-1 genome. The BPV-1 genome is a closed circle 
of approximately 7.9 kb that exhibits an organisation similar to most 
papillomaviruses. The open reading frames (ORFs) are shown as boxes. E represents 
early and L late ORFs.
THE BPV-4 GENOME
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Fig. 1.2. Representation of the BPV-4 genome. The BPV-4 genome (approximately 
7.2 kb) is smaller than that of BPV-1. The main difference of the BPV-4 genome to 
that of most papillomavirus is the absence of the E6 ORF.
34
The papillomavirus E2 protein
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Fig. 1.3. Diagrammatic representation of the papillomavirus E2 protein. The E2
protein consists of three modular domains: a conserved amino terminal domain, a 
central flexible hinge and a conserved carboxy terminal domain. The function of each 
domain is shown and the interactions with viral and cellular factors are indicated. 
The amino acid numbers refer to HPV-16 E2.
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Fig. 1.4. Organisation of the BPV-4 LCR from nucleotide 6710 to 331. Four 
binding sites for the viral E2 protein are shown as circles. This organisation of E2 
DNA binding sites is identical in the HPV-16 and -1 8  LCRs. Binding sites for 
potential transcription factors as identified by footprinting studies are shown (boxes 
1-13). Nuclear factors interacting with the LCR are indicated. Sequence elements are 
also shown: I indicates the putative initiator element, T the TATA box, C the CAAT 
box and N indicates NF-1 like elements. The BPV-4 LCR contains three positive 
control elements each of which seems to be paired with a negative element. CE boxes 
represent positive control elements and NR boxes represent negative regulatory 
elements. QR indicates the quercetin repsonsive element. The epithelial specific 
enhancer is also shown. This is of a similar size and position to the enhancer in the 
HPV-16 and -1 8  LCRs. The two main regions contributing to enhancer activity, Sites 
1 and 2, are depicted.
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Chapter 2 -  Materials and Methods
2.1. Materials
2.1.1. Antibodies 
Amersham International pic
Anti-mouse IgG horseradish peroxidase linked whole antibody (raised in sheep)
TVG261, a monoclonal antibody directed against amino acids 2-17 in the amino 
terminus of HPV-16 E2, was a kind gift from Dr. M. Hibma, ICRF Tumour Virus 
Group, University of Cambridge.
2.1.2. Bacteriology
Beatson Institute Central Services
L-broth
Becton Dickinson Labware
Falcon 1059 polypropylene tubes 
Falcon 2059 polypropylene tubes
Beta laboratories
Yeast extract
Bibby Sterilin Ltd
90mm and 150mm bacteriological petri dishes 
Clontech
E.Coli BM25.8 cells 
E.Coli XLl-Blue
Difco Laboratories
Bacto-Agar
Bactotryptone
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Fisons Scientific Equipment
Glycerol
Gibco BRL Europe Life Technologies Ltd
E. Coli DH 5a competent cells
Nunc
Sterile disposable inoculating loops
Sigma Chemical Co. Ltd
Ampicillin
Betaine
Carbenicillin
Chloroamphenicol
Isopropyl-thio-P-D-galactosidase (IPTG)
Lysozyme
Maltose
Sorbitol
Tetracycline
2.1.3. Cell lines
PalK cells are primary bovine palate keratinocytes derived from foetal biopsies.
PalF cells are primary bovine palate fibroblasts derived from foetal biopsies.
Swiss 3T3 cells are an immortalised mouse fibroblast cell line.
HeLa cells are an HPV-18 positive keratinocyte cell line derived from an invasive 
cervical carcinoma (ECACC Ref. No. 8609201).
2.1.4. Chemicals and Reagents
Amersham International pic
Enhanced Chemiluminescence (ECL) Western detection agent
BDH Analar Laboratory Supplies
Ammonium persulfate (APS)
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D-glucose
Boehringer Mannhein Ltd
Caesium chloride
Calbiochem
Guanidine hydrochloride
Fisons Scientific Equipment
Acetic acid 
Ammonium acetate 
Butan-2-ol 
Chloroform
di-sodium hydrogen orthophosphate (anhydrous) 
Dimethyl sulfoxide (DMSO)
Ethylene diamine tetra acetate (EDTA) disodium salt 
EGTA
Lithium chloride 
Hydrochloric acid 
Magnesium acetate 
Magnesium chloride 
Magnesium sulphate 
Methanol
Potassium chloride 
Potassium hydroxide 
Propan-2-ol 
Sodium acetate 
Sodium chloride
Sodium dihydrogen orthophosphate 
Sodium dodecyl sulphate (SDS)
Sodium pyrophosphate
Gibco BRL Europe Life Technologies Ltd
Agarose (ultrapure electrophoresis grade)
Glycine
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Tris base
James Burrough Ltd
Ethanol
Pharmacia Biotech Ltd
ATP
Poly (dl-dC)
Promega
Nuclease free H2O 
RNasin Ribonuclease Inhibitor
Severn Biotech Ltd
30% (w/v) acrylamide: 0.8% (w/v) bis-acrylamide 
40% (w/v) acrylamide: 2.1% (w/v) bis-acrylamide
Sigma Chemical Co. Ltd
p -mercaptoethanol 
Bicinchonoinic Acid (BCA) solution 
Bovine Serum Albumen (BSA)
Bromophenol Blue 
Coomassie Brilliant Blue R
Copper (II) sulphate (pentahydrate 4% (w/v) solution) 
Dithiothreitol (DTT)
Ethidium bromide 
Ficoll (type 400)
Glutathione (reduced)
HEPES
Leupeptin
Nonidet P-40 (NP-40)
Phenol:Chloroform:Isoamyl Alcohol (25:24:1 (v/v)) 
PMSF
Ponceau S solution
TEMED (N,N,N’,N* -tetraethylethylenediamine)
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Tween-20 (Polyoxyethylene sorbitan nonolaurate)
2.1.5. Enzymes and Kits
Gibco BRL Europe Life Technologies Ltd
All restriction enzymes and reaction buffers were obtained from Gibco BRL.
NBL Gene Sciences
Alkaline phosphatase 
T4 DNA ligase 
T4 polynucleotide kinase
Perkin Elmer Corporation
GeneAmp PCR Core Kit
Promega Ltd
Luciferase Assay System
Pfu polymerase
Reporter Lysis 5x Buffer
TNT T7/T3 Coupled Reticulate Lysate System
TNT T7 Quick Coupled Transcription kit
Quiagen Ltd
QLAprep Spin plasmid miniprep kit 
QLAquick gel extraction kit
Sigma Chemical Co. Ltd
Protein Kinase A, catalytic subunit
2.1.6. Miscellaneous
Amersham International pic
Hybond-C extra
Alpha Laboratories Ltd
Microcentrifuge tubes
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Pastettes
Cadisch and Sons
70 pm filter nylon gauze
Canberra Packard Ltd
Superpolyethylene scintillation vials
Costar Corporation
96 well plates
Cruachem Ltd
Cruachem oligonucleotide purification (COP) cartridges
Decon Laboratories Ltd
Decon 75
Du Pont (UK) Ltd 
Polyallomer ultracentrifuge tubes
Gelman Sciences Ltd
Sterile 0.2 pm acrodisc filters
Premier Beverages
Marvel (dried skimmed milk)
Satorius AG
Collodion Bags
Sigma Chemical Co. Ltd
Kodak X-OMAT AR X-ray film 
GST beads
Technical Photo Systems
Fuji RX medical X-ray film
Whatman International Ltd
Whatman 3MM filter paper
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2.1.7. Molecular Weight Markers
Amersham International pic
Rainbow™ coloured protein molecular weight markers
Gibco BRL Europe Life Technologies Ltd
X DNA/ Hindlll digested 100 bp ladder
2.1.8. Phage Libraries
Clontech
^Triplex human HeLa 5 ’ STRETCH PLUS cDNA library
2.1.9. Plasmids
pGL3 is a luciferase reporter vector obtained commercially from Promega.
pGL3 PRO, also available commercially from Promega, contains the SV40 promoter 
driving expression of the luciferase gene.
pGL3 CONT contains the SV40 enhancer-promoter driving expression of the 
luciferase gene. This reporter plasmid is commercially available from Promega.
pLCR contains the wild type BPV-4 LCR from nucleotide 6710-331 cloned into the 
BamHI site of the pOluc luciferase plasmid. pLCR was a gift from Dr Maria Jackson 
(Beatson Institute).
pLCR-E2(3)mtl contains the BPV-4 LCR from nucleotide 6710-331 and has the 
TATA box proximal E2 BS1 mutated to prevent E2 binding. This plasmid was a gift 
from Dr Maria Jackson (Beatson Institute).
pLCR-E2(d/3) contains the full length BPV-4 LCR with both the TATA box 
proximal E2 DNA binding sites mutated. Again, a gift from Dr Maria Jackson 
(Beatson Institute).
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pBluescript SKII, available commercially from Stratagene, contains the T3 and T7 
promoters for in vitro transcription and translation.
pCMV and pCG are mammalian expression vectors.
pCMV HPV-16 E2 expresses the wild type HPV-16 E2 protein under control of the 
cytomeglovirus promoter. A  kind gift from Dr Lawrence Banks (International Centre 
for Genetic Engineering and Biotechnology, Italy).
pCG BPV-1 E2 expresses wild type BPV-1 E2 under control of the cytomeglovirus 
promoter. This plasmid was a gift from Dr Mart Ustav (Estonian Biocentre).
pCG VP16-E2 expresses a chimaeric protein which has the VP 16 transactivation 
domain fused to the BPV-1 E2 DNA binding domain under control of the 
cytomeglovirus promoter. This plasmid was a gift from Dr Mart Ustav (Estonian 
Biocentre).
pVP16-LexA expresses the VP16 transactivation domain and the LexA DNA  
binding domain as a fusion protein. This vector was a gift from Dr Chris 
Batholomew (Glasgow Caledonian University).
phTBP expresses human TBP from the cytomeglovirus promoter. phTBP was a kind 
gift from Dr Moshe Yaniv (Unite des Virus Oncogenes, Paris).
ptkluc contains the tk promoter from HSV-1 cloned into the pGL2 luciferase vector.
pGEX-2TK contains a GST domain and the recognition sequence for the catalytic 
subunit of protein kinase A. This plasmid is commercially available from Pharmacia 
Biotech.
pGADT7 contains the GAL4 activation domain, the T7 promoter and an HA epitope 
tag. pGADT7 is available commercially from Clontech.
pGADGH is also available commercially from Clontech. This yeast expression 
vector generates a hybrid protein containing the GAL4 activation domain.
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2.1.10. Radiochemicals
Amersham International pic
Redivue [y 32P] dATP 
Redivue [35S] methionine
2.1.11. Tissue Culture
Beatson Institute Central Services
Sterile distilled water 
Sterile glycerol
Sterile phosphate buffered saline (PBS)
Sterile phosphate buffered saline + EDTA (PE)
Becton Dickinson Labware
18 gauge sterile syringe needles 
60, 90 and 140 mm tissue culture dishes 
Falcon 2097 polypropylene tubes 
Falcon 2098 polypropylene tubes 
Serological plastic pipettes 
Sterile Plastipak syringes
Bibby Sterilin Ltd
Sterile plastic bijoux and universal containers
Costar Corporation
Disposable cell scrapers
Gibco BRL Europe Life Technologies Ltd
Special Liquid medium
lOx Dulbecco’s Modified Eagles Medium
lOx Nutrient Mixture F-10 (HAM)
2.5% Trypsin
200 mM L-glutamine
7.5% sodium bicarbonate
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100 mM sodium pyruvate
Globepharm
Foetal calf serum
Harlan Sera-Lab Ltd
Foetal calf serum
Nunc
Cryotubes
T25, T75 and T175 cm2 tissue culture flasks
Sigma Chemical Co. Ltd
Adenine
Cholera enterotoxin 
Epidermal growth factor (EGF) 
Hydrocortisone 
Insulin
Polybrene (Hexadimethrine bromide)
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2 .2 . M eth o d s
2.2.1. Tissue culture
All cell culture work was performed using strict aseptic techniques inside a laminar 
flow hood (Class II Microbiological Safety Cabinets, Medical Air technology Ltd., 
Manchester, UK). Cells were incubated at 37°C in a dry atmosphere containing 5% 
(v/v) CO2 (Heraeus, Essex, UK).
2.2.1.1. Swiss 3T3 Feeder cells
Swiss 3T3 feeders were grown in Special Liquid Medium containing 10% (v/v) 
foetal calf serum and 2mM glutamine. Ceils were seeded at approximately 106 
cells/T175 tissue culture flask and grown until confluency. Confluent cells were 
washed twice with PBS (phosphate buffered saline) and trypsinised using a solution 
of 0.25% (w/v) trypsin in PE buffer (PBS containing ImM EDTA). Flasks were 
incubated at 37°C until the cells detached, the cells were resuspended in growth 
medium, transferred to a sterile universal tube and pelleted by centrifugation at 1 0 0 0  
rpm for 5 min at room temperature. The cell pellet was resuspended in fresh growth 
medium and the concentration determined using a haemocytometer. Swiss 3T3 cells 
were either passaged 1 in 1 0  or lethally irradiated with 60 grays of y-irradiation using 
a 60Cobalt source prior to use as feeders. Feeder cells, incapable of further cell 
division, were plated out at a density of approximately 2 x l0 6 cells/T175 tissue 
culture flask before the addition of keratinocytes.
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2.2.1.2. PalK cells
PalK cells, prepared from bovine foetal biopsies as described for human cervical 
keratinocytes (Cuthill et al., 1993), were routinely cultured on irradiated Swiss 3T3 
feeders in Special Liquid Medium supplemented with 10% (v/v) foetal calf serum, 
2mM glutamine, 2% (w/v) lOx Nutrient Mixture F-10, 0.31% (w/v) sodium 
bicarbonate, 10 ng/ml cholera enterotoxin, 10 ng/ml EGF, 0.5 ^ig/ml hydrocortisone, 
5 fxg/ml insulin and 180 pM adenine. PalK cells were grown to approximately 80- 
90% confluency and then passaged (split 1 in 4) or seeded into the appropiate tissue 
culture dish. The feeder cells were removed from the PalK cells by incubating with 5 
ml PE at 37°C prior to trypsinisation as they are less firmly attached to the tissue 
culture flask compared to the keratinocytes.
2.2.1.3. PalF cells
PalF cells, prepared as described (Jaggar et al., 1990) from the same foetal biopsy 
used to prepare the PalK cells, were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% foetal calf serum, 2 mM glutamine, 1 
mM sodium pyruvate and 0.375% sodium bicarbonate. PalF cells were grown until 
just subconfluent and then passaged 1 in 2  or seeded into the appropiate tissue culture 
dish.
2.2.1.4. Transient transfection of PalK cells
PalK cells were transfected using the polybrene-DMSO technique. 5 x l0 5 cells were 
seeded on a 60 mm tissue culture dish without feeders. 18 hours later the medium 
was replaced with 2  ml growth medium containing 1 0  pg/ml polybrene and the
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plasmid DNA. After 5-6 hours the DNA-polybrene containing medium was removed 
and 5 ml of Special Liquid Medium containing 35% DMSO was added to the cells 
for 3 min. Following this incubation the cells were washed twice with PBS and then 
re-fed with 5 ml fresh growth medium. The cells were harvested 42-48 hours later.
2.2.1.5. Transient transfection of PalF cells
PalF cells were transiently transfected using a standard calcium phosphate 
precipitation technique. Cells were plated out at 2 x l0 5/60 mm tissue culture dish. 
The following day a calcium phosphate precipitate containing the DNA was added to 
the cells. This was carried out as follows for each 60 mm cell monolayer: 250 pi of a 
solution containing the plasmid DNA in 250 mM CaCL was added dropwise with 
gentle mixing to 250 pi of 2x HEPES buffered saline (280 mM NaCl, 10 mM KC1, 
1.5 mM Na2HP0 4 .2 H2 0 , 50 mM HEPES). The mixture was left for 30 min to allow 
a fine precipitate to form and added directly into the medium above the cell 
monolayer. 16-18 hours later the cells were washed twice with PBS and refed with 
fresh growth medium. The cells were harvested 24-32 hours later.
2.2.1.6. Luciferase assay
PalK and PalF cells were lysed directly on the tissue culture plates. The medium was 
removed and the cells washed twice with PBS. 300 pi of Reporter Lysis Buffer 
(Promega) was added to the plate and left for 10 minutes. The cell lysate was then 
scraped from the dish and placed in a 1.5 ml centrifuge tube. The lysate was cleared 
by centrifuging the sample for 1 0  min and removing the supernatant to a fresh tube. 
An aliquot of the supernatant was then assayed for luciferase activity using the 
Luciferase Assay System (Promega) with a BioOrbit 1251 (80 pi supernatant) or a
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Tropix TR717 Microplate luminometer (10 pi). To standardize for cell number, the 
protein concentration was determined using the BC A/Q 1SO4 assay (Section 2.2.3.5.). 
pGL3CONT (which contains the SV40 promoter and enhancer driving expression of 
the luciferase gene) was transfected in parallel to confirm efficient transfection. This 
construct demonstrates high levels of transcriptional activity in both keratinocytes 
and fibroblasts. All transfections were repeated at least three times in duplicate.
2.2.1.7. Nuclear extract preparation
PalK and PalF nuclear extracts were prepared as follows. Approximately 1x10 cells 
were washed twice with 5 ml ice-cold PBS, removed from the tissue culture dish by 
scraping and transferred to a sterile universal container. The cells were pelleted by 
centrifugation at 2000 rpm for 5 min, re-suspended in 1.5 ml ice-cold PBS and 
transferred to a clean eppendorf tube. The cells were pelleted again by spinning in a 
microfuge at 14 000 rpm for 2 min at 4°C and re-suspended in 400 pi hypotonic lysis 
buffer (10 mM HEPES/KOH pH. 7.9, 1.5 mM MgCl2, 10 mM KC1, 0.5 mM DTT 
and 0.2 mM PMSF). Samples were incubated on ice for 10 min, vortexed for 10 sec, 
pelleted and the supernatant was removed. The pellet was re-suspended in 50 pi high 
salt buffer (20 mM HEPES/KOH pH. 7.9, 25% (v/v) glycerol, 420 mM NaCl. 1.5 
mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT and 0.2 mM PMSF) and incubated on ice 
for 20 min. The cellular debris was removed by centrifugation (14000 rpm, 15 min, 
4°C). The supernatant was removed, frozen on dry ice and stored at -7 0  °C until use.
2.2.1.8. Whole cell extract preparation
PalK, PalF and HeLa whole cell extracts were prepared in the same manner. 
Transiently tranfected cells were washed twice with ice-cold PBS. Cells were lysed
Chapter 2-Materials and Methods 52
on ice in 50 pi SDS-PAGE lysis buffer ( lOOmM Tris HC1 pH6.8, 2% SDS, 20% 
glycerol), removed from the tissue culture dish and transferred to a clean eppendorf 
tube. The cells were sonicated ( 2x 10 sec) and clarified by centrifugation (14 000 
rpm, 10 min, 4°C). The supernatant was removed, frozen on dry ice and stored at -  
70°C until use. The protein concentration was determined by absorbance 
measurement at 280nm using a Beckman DU 650 spectrophotometer. An OD280 
reading of 1 corresponds to approximately 1 pg/pl protein.
2.2.2. Molecular biology
2.2.2.1. Oligonuceotide synthesis
Oligonucleotides were synthesised on an Applied Biosystems Model 381A DNA  
synthesiser using the manufacturers protocols and Cruachem reagents by Beatson 
Institute technical services staff. The oligonucleotides were synthesised with or 
without trityl group protection. “Trityl o f f ’ oligonucleotides, obtained as a pellet, 
were dissolved in 1ml sterile distilled water. “Trityl on” oligonucleotides, obtained in 
ammonia and routinely used as primers for PCR amplification, were deprotected after 
synthesis by incubation in a 55°C water bath overnight. The oligonucleotides were 
detritylated using a Cruachem oligonucleotide purification (COP) cartridge according 
to the manufacturers instructions. The final oligonucleotide was eluted from the COP 
cartridge in 1-2 ml acetonitrile, precipitated using ethanol and sodium acetate 
(Section 2.2.2.5.) and resuspended in 0.5-1 ml sterile distilled water. The final 
concentration of oligonucleotide was determined by absorbance measurement at 260 
nm and 280 nm using a Beckman DU 650 spectrophotometer. An OD260 reading of 1 
corresponds approximately to 33 fxg/ml single stranded DNA or 50 pg/ml double
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stranded DNA. The OD260/OD280 ratio provided an estimate of the DNA sample 
purity.
2.2.2.2. Agarose gel electrophoresis
Agarose gel electrophoresis was performed using horizontal gel cast apparatus 
(Promega). 1% agarose gels were routinely used unless otherwise stated. The 
appropiate amount of ultrapure electrophoretic grade agarose was dissolved in 0.5x 
TBE buffer (5x TBE: 40mM Tris base, 16 mM acetic acid, 1 mM EDTA, pH 8.0) by 
heating the solution in a glass conical flask in a microwave. The gel cast apparatus 
with a comb containing the appropiate number and size of teeth to form the sample 
wells was assembled and the gel was poured. The solidified gel was placed in the gel 
tank and submerged in 0.5x TBE buffer containing 0.5 pg/ml ethidium bromide. 
Samples containing lx  loading buffer (lOx loading buffer: 0.45% (w/v) bromophenol 
blue, 1% (w/v) SDS, 100 mM EDTA, 2.5% (w/v) Ficoll 400) were loaded into 
individual wells. An appropiate sized DNA ladder was loaded into the first and/or 
last well in the gel and the DNA was separated by running at 70-100 constant voltage 
until the dye front was 1-4 cm from the end of the gel. Separated DNA was 
visualised by illumination on a short wave (312 nm) UV light box and photographed 
using an Appligene Imager.
2.2.2.3. Polyacrylamide gel electrophoresis
In general, 6 or 8% polyacrylamide gels were set up. This was carried out by adding 
the appropiate volume of 40% (w/v) acrylamide: 2:1% (w/v) bisacrylamide solution 
to 0.5x TBE buffer. Polymerisation of the gel was catalysed by the addition of 0.07% 
APS and 0.08% TEMED. The solution was mixed thoroughly and poured between
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two glasss plates (1 or 2 mm) clamped together in the gel forming apparatus (ATTO). 
A comb to make the sample wells was placed in the top of the gel immediately after 
pouring. The gel was then left to polymerise in the vertical position. After the gel had 
set, the spacer was removed and the gel, formed between the two glass plates, was 
placed vertically into the electrophoresis tank (ATTO). The tank was filled with 0.5x 
TBE buffer, the comb was removed and each well was washed out with 0.5x TBE 
using a syringe. Polyacrylamide gel electrophoresis (PAGE) was carried out at 100- 
150 constant voltage.
2.2.2.4. Restriction Enzyme Digests
Restriction digests were performed using the appropiate enzymes and reaction 
buffers according to the manufacturers instructions. Typically, 5-10 units of 
restriction enzyme/pg DNA was used. In general, small quantities of plasmid DNA  
(<5 pg) were digested in a 30 pi reaction volume for 2-3 hrs at 37°C whereas PCR 
fragments were digested overnight at 37°C.
2.2.2.5. DNA purification
DNA samples were purified by phenol chloroform extraction after each manipulation 
to remove contaminants such as residual enzyme activities. An equal volume of 
phenol:chloroform:isoamyl alcohol (24:24:1 v/v/v) was added to the DNA solution. 
The aqueous DNA and organic phases were mixed by vortexing and separated by 
centrifugation in a microfuge (14 000 rpm, 5 min, room temp). The upper aqueous 
phase was carefully removed making sure none of the interphase was taken and 
transferred to a clean eppendorf tube. DNA samples were then precipitated using 
organic solvents to remove contaminants such as salt. Double stranded DNA was
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precipitated by adding 1/10 volume of 3M sodium acetate and 2.5 volumes ethanol. 
The sample was mixed and left at -20°C  for 1 hour to facilitate precipitation. The 
DNA was pelleted in a microfuge (14 000 rpm, 20 min, 4°C), washed with 70% 
ethanol to remove any traces of salt and pelleted again. After the ethanol was 
removed, the purified DNA was air dried and resuspended in the appropiate volume 
of sterile distilled water. PCR fragments were routinely precipitated by the addition 
of 4/5 volume 10M ammonium acetate and 2.5 volumes ethanol. The DNA was 
pelleted and washed as described above and the process was repeated. Single 
stranded oligonucleotides were precipitated by the addition of 1 /1 0  volume lithium 
chloride and 3 volumes of ethanol. The samples were left on dry ice for 20 min, 
pelleted by centrifugation in a microfuge (14 000 rpm, 30 min, 4°C) and washed with 
70% ethanol as before. Alternatively or in combination with organic solvent 
precipitation, DNA fragments to be used in cloning were purified by agarose gel 
electophoresis and DNA extraction using a QIAquick gel extraction kit according to 
the manufacturer’s instructions.
2.2.2.6. DNA ligation
Plasmid DNA and the DNA fragment to be inserted into the vector were separately 
digested using the appropiate restriction enzymes (Section 2.2.2.4). The 5 ’ phosphate 
residues of linearised vector DNA were dephosphorylated to prevent vector 
religation. 1 pi (1  unit) of alkaline phosphatase was added at the end of a restriction 
digest reaction. The reaction mixture was incubated for 30 min at 37°C followed by a 
second incubation at 70°C for 10 min to stop all enzyme activity. The plasmid DNA  
and DNA fragment were then purified as detailed above (Section 2.2.2.5.). The DNA  
fragment was ligated into the cut vector using 1 pi (4 units) of T4 DNA ligase in lx
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ligase buffer in a 20 pi reaction volume. This was carried out according to the 
manufacturer’s instruction. An excess of DNA fragment compared to vector was 
used for ligation reactions. Reactions were routinely incubated overnight at 11°C.
2.2.2.7. Transformation of Competent Bacterial Cells
E. Coli DH 5a competent cells were used for the propagation of plasmid DNA unless 
stated otherwise. Stocks of competent cells were stored at -70°C  until use when they 
were thawed on ice. 1 pi of purified ligation reaction or 1-2 ng plasmid DNA was 
added to a chilled polypropylene tube (Falcon 2059). 20 pi of competent cells were 
then aliquoted into each tube and left on ice for 30 min. Cells were heat shocked at 
42°C for 1 min and then returned to ice for 5 min. 100 pi sterile SOC medium (25 
bactotryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KC1, 10 mM MgCk, 10 
mM MgSC>4, 20 mM glucose) was added to each sample and the tubes were 
incubated at 37°C for 1 hour with shaking. The transformation mixes were spread on 
L-agar plates containing the appropiate antibiotic, plates were inverted and incubated 
overnight at 37°C to allow colony formation.
2.2.2.8. Small Scale Preparation of Plasmid DNA (Miniprep)
Small amounts of plasmid DNA were obtained from transformed bacterial colonies 
to allow the identification of positive transformants. A  single bacterial colony was 
used to inoculate 3 ml of L-Broth (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 
1% (w/v) NaCl) containing antibiotic (100 pg/ml ampicillin unless stated otherwise) 
and was grown overnight at 37°C with shaking. 1.5 ml of bacterial culture was 
pelleted by cenrifugation in a microfuge (14 000 rpm, 1 min). Plasmid DNA was
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prepared from the colony using the QIAprep Spin plasmid miniprep kit according to 
the manufacturer’s instructions.
2.2.2.9. Large Scale Preparation of Plasmid DNA (Maxiprep)
1 ml of a 3 ml overnight bacterial culture was used to inoculate 500 ml of L-broth 
containing the appropiate antibiotic in a 2 litre glass conical flask. The culture was 
incubated overnight at 37°C with shaking. Bacterial cells were pelleted by 
centrifugation (8000g, 10 min, 4°C) using a Sorvall rotor. The bacterial pellet was 
resuspended in 10 ml TGE (50 mM glucose, 25 mM Tris-Cl (pH 8.0), 10 mM 
EDTA) containing 5 mg/ml lysozyme and allowed to stand at room temperature for 5 
minutes. 20 ml of freshly prepared alkaline SDS (0.2M NaOH, 1% SDS) was added, 
the contents were mixed and the solution was incubated on ice for 10 minutes. 15 ml 
of an ice cold 5M potassium acetate solution was added and the contents were mixed 
by inverting the tube sharply several times. The solution was incubated on ice for 10 
min and then centrifuged at 8000g for 20 min at 4°C. The bacterial debris forms a 
tight pellet on the bottom of the tube. The supernatant was filtered through nylon 
gauze and 0.6 volumes of isopropanol added. The solution was mixed and left to 
stand at room temperature for 15 minutes. Nucleic acid was pelleted by 
centrifugation as before, the supernatant was removed and the pellet was allowed to 
air dry. The pellet was resuspended in 9 ml distilled H20 , lOg of caesium chloride 
was added and allowed to dissolve. 0.5 ml 10 mg/ml ethidium bromide was added 
and the solution was transferred to a 10 ml polyallomer ultracentrifuge tube. Samples 
were balanced carefully with CsCl solution, each tube was sealed and placed in a 
T1270 Sorvall rotor. A  protective cap was placed over the top of each tube and the
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plasmid DNA was banded by centrifuging at 55000 rpm for 24 hours at 20°C in a 
Sorvall OTD Combi 80 ultracentrifuge.
The tube was carefully removed from the centrifuge rotor and placed securely in a 
clamp on a retort stand. An 18 gauge needle was first inserted into the top of the tube 
to act as a air inlet and then a second needle attached to a 2  ml syringe was inserted 
into the side of the ultracentrifuge tube just below the plasmid band. The plasmid 
DNA was removed using the syringe and transferred to a clean ultracentrifuge tube. 
A  second round of centrifugation was carried out as before. The plasmid DNA was 
removed again and transferred to a 5 ml bijoux tube. Eithidium bromide in the 
solution was extracted by adding an equal volume of water saturated butanol. The 
solution was mixed causing the ethidium bromide to separate with the organic phase. 
This was removed and discarded and the process repeated until the lower aqueous 
phase became colourless. CsCl was removed by transferring the plasmid DNA  
solution into a dialysis tube (Collodion Bag), placing the tube in a large beaker filled 
with water and dialysing overnight with stirring at 4°C. The plasmid DNA was 
precipitated using sodium acetate and ethanol as described in Section 2.2.2.5.
2.2.2.10. Polymerase Chain Reaction (PCR)
Unless stated otherwise, PCR reactions containing 1 ng of DNA template, 20 pmol of 
each primer, 200 pM each dNTP, 1 pi (2.5 units) Pfu polymerase in a total volume of 
50 pi containing lx  Pfu reaction buffer were set up in 0.5 ml sterile eppendorf tubes. 
A  negative control containing no template and a positive control were always 
included with each set of PCR reactions. One drop of paraffin oil was added to the 
top of the each reaction mixture to prevent evaporation. PCR amplification was
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carried out using a Perkin Elmer Cetus type 480 DNA thermal cycler. Unless 
otherwise stated, samples were heated to 94°C for 1 min (denaturing step), 50°C for 1 
min (annealing step) and 72°C for 1 min (elongation step). This cycle of denaturing, 
annealing and elongation was repeated 25 times. 5 pi each PCR reaction was 
analysed by agarose gel electophoresis and the PCR products were purified using the 
techniques described in Section 2.2.2.5.
To generate the BPV-4 promoter constructs the corresponding BPV-4 promoter 
regions were PCR amplified as Bglll-Hindlll fragments. Primer sequences are 
shown in Table 2.1. with the restriction sites in bold. The PCR fragments were 
cloned into the pGL3 luciferase vector.
Primer Nucleotide sequence
5 ’ PV pro 5 ’ acgtagatctggtcgaaactctcacgct 3 ’
5 ’ 80bpTATA 5 ’ acgtagatctaggtaagtgttgtacctaac 3 ’
5 ’ 80bp mtl 5 ’ acgtagatctaggtccttgttgtacctaac 3 ’
5 ’ 6 6 bp TATA 5 ’ acgtagatctcctaacaactgtttacctag 3 ’
5 ’ 41bp TATA 5 ’ acgtagatctatatcagttgcaaaccattc 3 ’
5 ’ 19bp TATA 5 ’ acgtagatcttcgtaaagaatcgaatgcat 3 ’
5 ’ 3bp TATA 5 ’ acgtagatctgcatatataaggagagcagt 3 ’
3 ’ PV pro 5 ’ tgccaagcttcaccaaatccgcactgctctc 3 ’
Table 2.1. Primers for PCR amplification of the BPV-4 promoter
Oligonucleotides used to PCR amplify L31 and EIF3 are shown in Table 2.2. L31 
was PCR amplified as a EcoRI-XhoI fragment from pTriplEx-L31 and inserted into 
pGADT7. EIF3 was PCR cloned as a Xmal-Xhol fragment from pGADGH-EIF3 into 
pGADT7.
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Primer Nucleotide Sequence
5 ’L31 5 ’ acgtgaattcatggctcccgcaaagaaggt 3 ’
3 ’TriplExAmp 5 ’ atacgactcactatagggcgaattggcc 3 ’
5 ’GAL4AD 5 ’ ctattcgatgaagataccccaccaaaccc 3 ’
3 ’GAL4AD 5 ’ agatggtgcacgatgcacag 3 ’
Table 2.2. Oligonucleotides to PCR amplify L31 and EIF3
2.2.2.11. Splicing by overlap extension PCR
Splicing by overlap extension PCR can be used to join two halves of the same gene 
with a sequence change incorporated in the middle (site directed mutagenesis) or to 
join two completely unrelated sequences. The first round of PCR was set up as 
described (Section 2.2.2.10.). Primers were designed so that the products of the two 
primary PCR reactions contained 20 bp overlapping complementary ends. By using 
the primers annealing at the non-overlapping ends a second PCR reaction was carried 
out using the products of the first reaction as a template. It should be noted that it is 
necessary to purify the primary PCR products before the second step. This resulted 
in the primary products priming on each other and extending to yield a hybrid 
product. The 5 ’lcr-tkTATA and 3 ’lcrTATA primers were used in conjunction with 
the 5 ’RV3 and 3 ’GL3 external primers to generate the lcr/tk hybrid promoter. The 5 ’ 
RV3, 3 ’GL3, 5 ’tk-lcrTATA and 3 ’tkTATA primers were used to generate the tk/lcr 
hybrid. These promoters were cloned into pGL3 as Bglll-Hindlll fragments. The 
I73A mutant E2 transactivation domain was constructed using 5 ’E2AD and 3 ’E2AD 
with the 5T73A and 3T73A internal primers and inserted into pGEX2TK as a 
BamHI-EcoRI fragment. Primer sequences are shown in Table 2.3.
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Primer Nucleotide Sequence
5 ’ RV3 5 ’ ctagcaaaataggctgtccc 3 ’
3 ’ GL3 5 ’ ctttatgtttttggcgtcttcca 3 ’
5 ’ lcr-tkTATA 5 ’ tcaatcgtaaagaatcgaatgcatattaaggtgacgcgtg 3 ’
3 ’ lcrTATA 5 ’ attcgattctttacgattgaatggtttgcaactg 3 ’
5 ’ tk-lcrTATA 5 ’ cgcggtccgaggtccacttcgcatatataaggagagcagt 3 ’
3 ’ tkTATA 5 ’ gaagtggacctcggaccgcgccgccccgactgca 3 ’
5 ’ E2AD 5 ’ tgcaggatccgagactctttgccaacgt 3 ’
3 ’ E2AD 5 ’ tgcagaattccggcgacggctttggtatgggtcgcggcggg 3 ’
5 ’ I73A 5 ’ cattacaagcagctgaactgcaactaacgttagaaacaat 3 ’
3 ’ 173A 5 ’ cagttcagctgcttgtaatgctttattctttgatacagcc 3 ’
Table 2.3. Primer sequences used for splicing by overlap extension PCR
2.2.2.12. Direct PCR screening of Bacterial Colonies
Transformed bacterial colonies were directly PCR screened to determine if the 
plasmid DNA contained an insert of the correct size. Commercially available primers 
complementary to the appropiate region in the plasmid were used for PCR screening. 
A  reaction mix using reagents from a Perkin Elmer GeneAmp PCR kit was set up in 
bulk. Each 20 pi reaction volume contained 2 pi lOx Taq buffer, 2 pi MgC^ solution 
(2.5 mM final conc.), 0.4 pi each dNTP (200 mM), 1 pi each primer (10 pmol), 0.2 
pi Taq polymerase and 11.2 pi sterile distilled water. The bulk reaction mix was 
aliquoted into 0.5 ml sterile eppendorf tubes. The edge of the colony to be screened 
was picked using a sterile yellow pipette tip. The pipette tip was then swirled in the 
reaction mix. Each reaction mix was covered with a single drop of paraffin to prevent 
evaporation. Samples were first heated to 95°C for 5 min in the PCR machine to help 
lyse the bacteria. Samples were then heated to 95°C for 30 sec, 55°C for 30 sec and 
72°C for 30 sec. After this cycle was repeated 25 times the temperature was held at
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72°C for 10 min. 5 pi of each PCR product was analysed by agarose gel 
electrophoresis.
2.2.2.13. Generation of Concatenated Oligonucleotides
Concatenated oligonucleotides to be used in cloning were generated as follows. The 
oligonucleotdes containing potential transcription factor binding motifs were 
synthesised without the trityl moiety (Table 2.4.). The single stranded 
oligonucleotides were separated by polyacrylamide gel electrophoresis, excised, 
eluted overnight in a minimal volume of elution buffer (0.1% SDS, 0.5M NH4OAC, 
lOmM MgOAc) and purified by LiCl and EtOH precipitation (Section 2.2.2.5.). 
Equimolar amounts of complementary oligonucleotides were annealed together by 
heating to 95°C and then allowing to cool slowly to room temperature. This 
generated a double stranded oligonucleotide containing the appropiate binding motif 
with Bam Hl/Bglll compatible ends. The oligonucleotides were end- labelled with T4 
kinase according to the manufacturer’s instructions, ligated together and restriction 
digested with BamHl/Bglll. This ensured that only concatamers of binding sites 
facing in the same orientation were generated, as ligation in the wrong orientation 
reconstituted a restriction site. The oligonucleotides were separated on a 6 % 
polyacrylamide gel, the bands corresponding to the correct number of binding sites 
were excised, eluted overnight in minimal volume of elution buffer and purified by 
phenol chloroform extraction and ethanol precipitation. E2 and LexA binding sites 
were inserted into the Bglll site upstream of the BPV-4 promoter region in the pGL3 
luciferase vector. E2 sites were also inserted into the Bglll site upstream of the pGL3 
tk and hybrid promoter constructs. Binding sites for PRE-1, PRE-2 and PRE-2mtl
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were cloned into the Bglll site upstream of the SV40 promoter in the pGL3 PRO 
luciferase vector.
Primer Nucleotide sequence
E2 upper strand 5 ’ gatccaccgaaaacggtcgggaccgaaaacggta 3 ’
E2 lower strand 5 ’ gatctaccgttttcggtccgaccgttttcggtg 3 ’
LexA upper strand 5 ’ gatccttgctatataaaaccagtggttatatgtacagtaa 3 ’
LexA lower strand 5 ’ gatcttactgtacatataaccactggttttatatacagcag 3 ’
PRE-1 upper strand 5 ’ gatcccaatcgtaaagaatcgaatgca 3 ’
PRE-1 lower strand 5 ’ gatcttgcattcgattctttacgattgg 3 ’
PRE-2 upper strand 5 ’ gatccgctaggtaagtgttgtaccta 3 ’
PRE-2 lower strand 5 ’ gatctaggtacaacacttacctagcg 3 ’
PRE-2mtl upper strand 5 ’ gatccgctaggtccttgttgtaccta 3 ’
PRE-2mtl lower strand 5 ’ gatctaggtacaacaaggacctagcg 3 ’
Table 2.4. Oligonucleotides for the generation of transcription factor binding sites
2.2.2.14. DNA sequencing
The fidelity of all plasmid constructions was verified using an Applied Biosystems 
373A automated sequencer. The region to be sequenced was initially PCR amplifying 
using commercially available primers complementary to the appropiate region of the 
vector DNA. For example, RV3 and GL3 primers (Promega) were routinely used to 
sequence constructs in pGL3. PCR reactions containing 0.5 pg plasmid DNA, 3.2 
pmol primer and 8  pi Big Dye Terminator Reaction premix were made up to 20 pi 
with RQ grade H2O. 250 pi thin walled eppendorf tubes were used for all sequencing 
PCR reactions. Samples were heated to 95°C for 30 sec, 50°C for 30 sec and 60°C for 
4 min. This cycle was repeated 25 times. PCR products were precipitated using 
sodium acetate and ethanol as shown in Section 2.2.2.5. and dried under vacuum
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using a speedivac. Sequencing gel electrophoresis was performed by members of the 
Beatson Institute technical services staff.
2.2.2.15. End Labelling Double Stranded Oligonucleotides
Single stranded oligonucleotides to be used in band shift assays (Section 2.2.2.16.) 
were synthesised “trityl o f f ’ as described in Section 2.2.2.1. Oligonucleotides were 
separated by polyacrylamide gel electrophoresis, precipitated, and annealed together 
as shown in Section 2.2.2.13. The double stranded oligonucleotide was 32P labelled 
with T4 polynucleotide kinase. Kinase reactions contained 3 pi ds oligonucleotide 
(lpm ol/ pi), 2 pi [y 32P] ATP, 2 pi 1 Ox T4 kinase buffer and 1 pi T4 kinase in a total 
volume of 20 pi. Reactions were incubated at 37°C for 30 min. The 32P labelled 
oligonucleotide was separated on a 8% polyacrylamide gel. No loading buffer was 
added to the sample. To monitor the progress of the gel loading dye was added to the 
first and last wells. When the dye front was approximately 2/3 down the gel the 
position of the oligonucleotide was determined by exposing the gel, covered with 
cling film, to X-ray film for approximately 45 sec. The labelled probe was excised 
from the gel using a sterile scalpel and eluted overnight at 37°C in distilled water. 
The specific activity of a P labelled probe was determined using a scintillation 
counter.
2.2.2.16. Band Shift Assays
Nuclear extracts were prepared from cells in culture as described in Section 2.1.7. 
Band shift assays were carried out as follows. 10-15 pg nuclear extract (or 5 pi in 
vitro translated HPV-16 E2) was added to 3 pg poly(dl-dC) in a final volume of 30
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\i\ binding buffer. For E2 band shifts the binding buffer was 10 mM Tris-Cl (pH 7.0), 
100 mM KC1, 1 mM MgCl2, ImM DTT, ImM EDTA and 5% glycerol. For PRE-2 
band shifts the binding buffer contained 20 mM HEPES pH 7.9, 4% ficoll, 2 mM 
MgCl2, 40 mM KC1, 0.1 mM EGTA and 0.5 mM DTT. After 15 min pre-incubation 
at room temperature, approximately 5 fmol of 32P labelled probe was added. The 
binding reaction was incubated for a further 15 min at room temperature and then 
electrophoresed on a 6 % polyacrylamide gel (100 volts, room temperature). All 
polyarylamide gels used in band shift assays were pre-run for 1 hr prior to use to 
equilibrate the gel. Competition band shifts were performed under the same 
conditions except that a 100- or 500-fold excess non-radioactive self oligonucleotide 
or AP-1 oligonucleotide was added were indicated. After electrophoresis, the gel was 
transferred onto Whatman 3MM filter paper and dried using a Biorad 583 gel drier 
(80°C for 2 hours). The dried gel was placed in a lead, light tight cassette with 
intensifying screens and exposed to X-ray film at -70°C overnight.
2.2.2.17. Phage Based Expression Cloning
E. Coli XLl-Blue cells were infected with a XTiplexEx HeLa cDNA library and 
plated out according to the manufacturer’s instructions. The library was initially 
titered to give an estimate of the number of independent clones. XLl-Blue cells were 
streaked out onto an LB-agar plate containing 10 mM MgSC>4 and 15 pig/ml 
tetracycline (LB/MgSCVtet). An isolated XLl-Blue colony was used to inoculate 50 
ml of L-broth containing 10 mM MgSC>4 and 0.2% maltose. Mg2+ and maltose are 
required for optimal adsorption of phage onto bacteria. The integrity of the X phage 
particles requires the Mg2+ and maltose induces expression of the phage receptor. 
The culture was incubated overnight at 37°C with shaking. The cells were pelleted by
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centrifugation (3 000 rpm, 5 min), the supernatant poured off and the pellet 
resuspended in 25 ml (1/2 volume) 10 mM MgSC>4. Serial dilutions of the phage 
library was made in lx  lambda dilution buffer (0.1 M NaCl, 10 mM MgSO4.7 H2 0 , 35 
mM Tris-HCl pH 7.5). 10 pi X lysate was added to 90 pi dilution buffer. 10 pi of this 
dilution was diluted 1 in 10 again. This process was repeated two more times. 10 pi 
each dilution was added to 400 pi XLl-Blue overnight culture and allowed to adsorb 
at 37°C for 15 min. 2 ml melted LB/MgSC>4 top agar (100 ml I^broth, 1 ml 1M 
MgSC>4, 0.72 g agar) was added, the samples were mixed quickly by inverting and 
immediately poured onto 90 mm LB/MgSCVtet plates pre-warmed to 37°C. The 
plates were swirled to allow an even distribution of the top agar, cooled at room 
temperature for 1 0  min to allow the top agar to set, inverted and incubated overnight 
at 37°C to allow plaques to develop. The following morning plaques were counted 
and the phage titer calculated (pfu/ml: plaque forming units/ml).
lx lO 6 independent clones were initially screened. As XTriplEx expresses each cDNA  
in all three open reading frames 2-3 times this amount of phage plaques were plated 
out. 50 150 mm plates at 5 x l0 4 plaques/plate were set up. This was carried out as 
described above except 500 pi XLl-Blue and 7 ml top agar was used for the larger 
sized plate. Once the plaques had developed each plate was overlayed with a 
nitrocellulose filter that had been pre-soaked in 10 mM IPTG for 15 min and allowed 
to air dry. The plates were then incubated for 6 - 8  hours at 37°C to transfer plaques to 
the nitrocellulose and induce expression of the library encoded proteins. Following 
this, each plate was chilled at 4°C for at least 30 min, the orientation of the filter to 
plate was marked by piercing a 20-G needle dipped in India ink through the filter into 
the agar. The back of the agar plate was also marked. The filters were then removed
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from the plates and washed 3x 10 min in TBS-T (10 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 0.05% Triton X-100). Filters were blocked for at least 2 hours at 4°C in HB 
buffer plus 5% dried milk (Section 2.2.3.8.) and probed with 150 000 cpm/ml 32P 
labelled GST-E2 (see Sections 2 .23 .6 -1 .) in 30 ml binding buffer (Section 2.2.3.8.) 
overnight at 4°C. Labelled probe was removed, the filters were washed 4 times in 
binding buffer, dried and exposed for autoradiography at -70°C  (2 hours and 
overnight). Filters were orientated with the plates, agarose plugs of positive plaques 
were picked using a sterile pasteur pipette and stored in 1 ml lambda dilution buffer 
containing a drop a chloroform (4°C). Positive plaques were purified through two 
more rounds of screening. The secondary screen contained approximately 2000 
pfu/150 mm plate whereas the tertiary screen contained approximately 400 pfu/150 
mm plate.
Plasmid DNA was rescued from the positive plaques by transduction into E. Coli 
BM25.8 cells. These cells express cre-recombinase when grown at 31°C excising the 
plasmid automatically. BM25.8 cells were streaked onto an LB-agar plate containing 
50 pg/ml kanamycin and 150 |ig/ml chloroamphenicol (LB/kan/cam). An isolated 
colony was used to innoculate 10 ml LB/MgSC>4 broth and incubated overnight at 
31°C with shaking. 100 pi 1M MgCl2 (10 mM final cone) was then added to the 
overnight culture. Following this, 200 pi of the overnight culture was mixed with 150 
pi of the eluted positive plaque and incubated at 31°C for 30 min. 400 pi L-broth was 
added and the samples incubated for 1 hour at 31°C with shaking. 100 pi of each 
infected cell suspension was spread out on an LB/carbenicillin plate and grown 
overnight at 31°C to obtain isolated colonies. Colonies were directly PCR screened 
using the 5 ’TriplEx and 3 ’TriplEx primers (Clontech) to determine the size of the
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insert (Section 2.2.2.12.). Positive cDNAs were sequenced (Section 2.2.2.14.) and 
compared with those in databases using basic logic search alignment (BLAST).
2.2.3. Protein Manipulation
2.2.3.I. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
10% SDS-polyacrylamide gels were routinely used to resolve protein samples. The 
resolving gel was made by adding the appropiate volume of 30% (w/v) acrylamide: 
0.8% (w/v) bis-acrylamide to lx  resolving gel buffer (4xRGB: 1.5 M Tris-HCl (pH 
8.8), 0.4% SDS). 0.08% TEMED and 0.1% APS were then added to catalyse 
polymerisation. This solution was poured between 2 glass plates as described in 
Section 2.2.3. The top of the gel was covered with isopropanol and left to polymerise. 
Once the gel had set, the isopropanol was poured off, washed with water and blotted 
dry. A  5% stacking gel was poured on top of the resolving gel, a comb was inserted 
and the gel was left to polymerise. Stacking gels consist of the appropiate volume of 
30% (w/v) acrylamide: 0.8% (w/v) bis-acrylamide in lx  stacking gel buffer (4xSGB: 
0.5 M Tris-HCl (pH 6.8), 0.4% SDS) with 0.08% TEMED and 0.1 % APS to catalyse 
polymerisation.
Protein samples were mixed with an equal volume of 2x SDS gel loading buffer 
(lOOmM Tris-HCl (pH 6.8), 2% (v/v) p-mercaptoethanol, 4% SDS, 0.2% 
bromophenol blue, 20% glycerol), boiled for 5 min and loaded into the individual 
sample wells. 5 pi Rainbow™ protein molecular weight marker (14.3-200 kD) was 
added to the first and last well in the gel. Protein gels were run at approximately 40 
mA constant current in lx  SDS-PAGE running buffer (25mM Tris, 250 mM glycine,
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0.1% (w/v) SDS). After electrophoresis, proteins were either transferred to 
nitrocellulose (Section 2.2.3.2.) or stained for 20 min using a solution containing 
0.25% Coomassie Brilliant Blue dissolved in 45% (v/v) methanol, 45% (v/v) H2O 
and 10% (v/v) glasial acetic acid. To visualise the protein bands the gel was 
destained in the same solution minus the Coomassie Blue.
2.2.3.2. Semi-Dry Electrophoretic Transfer
Separated protein samples were transferred to nitrocellulose by semi-dry 
electrophoretic transfer. After SDS-PAGE, one of the glass plates was removed and 
the stacking gel was cut away. Six sheets of Whatmann 3MM paper and a piece of 
nitrocellulose membrane (Hybond Cextra) were cut to the size of the gel. The 
nitrocellulose membrane was soaked in distilled water and the blotting paper was 
soaked in transfer buffer (48 mM Tris base, 39 mM glycine, 0.037% (v/v) SDS and 
20% methanol). Three layers of absorbent paper were placed on the bottom plate 
(anode) of the blotting apparatus, followed by the nitrocellulose membrane, the gel 
and another three layers of absorbent paper. Any air bubbles were removed and the 
transfer was performed at 180 mA for 1 hour. The fidelity of transfer was checked by 
staining the nitrocellulose with Ponceau S solution.
2.2.3.3. Western Blot Analysis of HPV-16 E2 Expression Levels
PalK and PalF cells were transiently transfected with increasing amounts of pCMV 
HPV-16 E2 expression vector. Equal amounts of whole cell extract were separated 
by 10% SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane 
was incubated in blocking buffer (5% (w/v) dried milk in PBS-T ( 0 . 1% (v/v)
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Tween in PBS)) overnight at 4°C with shaking. The nitrocellulose filter was washed 
3x 5 min in PBS-T and then incubated in 10ml of a 1:50 dilution of the TVG261 
monoclonal antibody in blocking buffer (2 hours, 4°C with shaking). The primary 
antibody solution was removed and the filter was washed 4x 5 min in PBS-T. The 
membrane was then incubated for 1 hour at room temperature in 20ml of a 1:5000 
dilution of anti-mouse IgG HRP linked whole antibody in blocking buffer. The 
secondary antibody solution was removed and the membrane was washed 3x 5 min 
in PBS-T. Excess surface liquid was removed from the membrane and the western 
blot developed by enhanced chemiluminescence (ECL).
2.2.3.4. UV Crosslinking
A  derivative of the PRE-2 oligonucleotide was synthesised with bromodeoxyuridine 
(BrdU) in place of thymine to enhance UV induced protein/DNA crosslinking. The 
single stranded oligonucleotides were purified, annealed and P labelled with T4 
kinase as described in Section 2.2.2.15. Radiolabelled ds BrdU-PRE-2 was used to 
probe PalK and PalF nuclear extracts in a band shift assay (Section 2.2.2.16.). After 
electrophoresis, the gel was UV irradiated (304 nm) for 45 min at 4°C to covalently 
crosslink the protein to the DNA. This was carried out by removing one of the gel 
plates, covering the gel in cling film, placing the gel directly on a transilluminator 
and covering with a bag of ice. The gel was visualised using a phoshor imager and 
the bands corresponding to the retarded complexes excised using a scalpel. The gel 
pieces were soaked in SDS-PAGE sample buffer for 15 min at 37°C and loaded 
directly onto a 10% SDS gel. Following electrophoretic separation, the gel was 
transferred onto Whatmann 3MM filter paper, dried, exposed to film (-70°C) and 
visualised by autoradiography.
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2.2.3.5. BCA/C11SO4 Protein Assay
The protein concentration of a sample was determined using the BCA/G 1SO4 assay. 
Protein reduces alkaline Cu(II) to Cu(I) in a concentration dependent manner. 
Bicinchoninic acid (BCA) forms a purple complex with Cu(I) with an absorbance 
maximum at 562 nm. 10 pi of each protein sample (or dilution) was added to a 96 
well plate. 200 pi of developing solution (5ml BCA and 100 pi Q 1SO4) was added to 
each well and the plate was incubated at 37°C for 30-60 min. The absorbance of each 
sample was measured at 590 nm using a Dynatech MR7000 automatic plate reader. 
The protein concentration was obtained using a standard curve generated from the 
absorbance measurements of a series of BSA solutions of known concentration.
2.2.3.6. Expression and Purification of GST Proteins
Individual bacterial colonies transformed with GST fusion protein expression vectors 
were used to innoculate 10 ml L-broth plus 100 pg/ml ampicillin (LB-amp) and 
grown overnight at 37°C with shaking. 1 ml of overnight culture was used to 
innoculate 50 ml LB-amp containing 0.5 M sorbitol and 2.5 mM betaine. Cultures 
were grown at 37°C with shaking until an absorbance measurement at 600 nm of 0.6- 
0.8 was obtained. Expression was induced by the addition of IPTG (final conc. 0.3 
mM) and the culture was incubated overnight with shaking at room temperature. 
Bacteria were pelleted by centrifugation at 2500 g for 10 min. The pellet was 
resuspended in 5 ml (1/10 volume) of NETN (20 mM Tis-HCl (pH 8.0), 100 mM 
NaCl, 1 mM EDTA, 0.5% Nonidet P-40 (NP40)) containing protease inhibitors (2 
mM PMSF and 5 p,g/ml leupeptin). Samples were sonicated (3x 30 sec), centrifuged 
at 12000 g for 10 min using a Sorvall rotor and the supernatant was removed. Fusion
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proteins were purified on glutathione-Sepharose beads by incubating 1 ml 
supernatant (crude extract) with 50 pi beads for 30 min at room temperature with 
rotation. The beads were pelleted in a microfuge (14000 rpm, 10 sec) and washed 3x 
0.5 ml NETN. The beads were resuspended in 30 pi NETN and purified proteins 
were analysed by 10% SDS-PAGE (Section 2.2.3.1.) before subsequent 
manipulations.
223 .1 . 32P labelling of GST Fusion Protein Probes
Recombinant plasmids allowing the expression of chimaeric proteins containing the 
E2 amino terminal wild type and mutant sequences fused to the GST domain and a 
recognition site for protein kinase A  were constructed using standard molecular 
biology techniques (Section 2.2.2.). Proteins were bacterially expressied and purified 
as shown above (Section 2.2.3.6 .). Following purification the beads were washed 
with 30 pi HMK buffer (20 mM Tris (pH 7.5), 100 mM NaCl, 12 mM MgCl2). 
Proteins were then 32P labelled on the beads in 30 pi HMK buffer containing 1 mM 
DTT and 10 units of the catalytic subunit of protein kinase A  (30 min, 37°C). The 
reaction was stopped by adding 1 ml stop buffer (10 mM sodium phosphate (pH 
8.0), 10 mM sodium pyrophosphate, 10 mM EDTA and 10 mg/ml BSA) and the 
beads were washed 3x in NETN. Labelled probes were eluted from the beads using 
50 pi elution buffer (20 mM glutathione (reduced), Tris pH8.0, 120 mM NaCl). 
Elution was repeated and incorporated radioactivity was quantified using a 
scintillation counter. Aliquots of labelled protein were analysed by 10% SDS-PAGE 
(Section 2.2.3.1.), the gel was transferred onto filter paper, dried, exposed to film for 
2 min and visualised by autoradiography (Section 2.2.2.16.).
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2.2.3.8. Far Western Blot Analysis
PalK, PalF and HeLa whole cell extracts were prepared from cells in culture as 
described in Section 2.2.1.8 . 60 pg each sample was separated by SDS-PAGE and 
transferred to nitrocellulose (Section 2.2.3.1. and 2.2.3.2.). Nitrocellulose filters were 
denatured/renatured in 6  M to 0.187 M guanidine hydrochloride as follows: the 
membrane was submerged in 250 ml 6  M guanidine hyrochloride in HB buffer (25 
mM HEPES pH 7 .7 ,25  mM NaCl, 5 mM MgCl2, 1 mM DTT) for 10 min at 4°C with 
shaking. The solution was removed, replaced with the same buffer and the incubation 
repeated. The solution was removed again, 125 ml was decanted into a measuring 
cylinder and an equal volume of HB buffer (without guanidine hydrochloride) added. 
The membrane was incubated in 250 ml of the 1:2 dilution for 5 min at 4°C with 
shaking. This dilution step was repeated four times. After the final dilution the 
membrane was washed 2x 5 min in HB buffer at 4°C. Membranes were then blocked 
in HB buffer containing 5% dried milk and 0.05% NP-40 followed by 1% milk plus 
0.05% NP-40. Each incubation step was carried out for 2 hours at 4°C with shaking. 
The membranes were then incubated with 200 000 cpm/ml of 32P labelled probes 
(Section 2.2.3.7.). This was performed overnight in 10 ml binding buffer (20 mM 
HEPES pH 7.7, 75 mM KC1, 0.1 mM EDTA, 2.5 mM MgCl2, 0.05% NP-40, 1% 
dried milk, ImM DTT) at 4°C with shaking. Membranes were washed 3x 10 min in 
binding buffer alone, dried and exposed for autoradiography at -70°C  (1-3 days).
2.2.3.9. In vitro Transcription-Translation and GST-PuII Down Assays
HPV-16 E2 was subcloned from pCMV-HPV-16 E2 into the BamHI site of 
pBluescript SKII under control of the T3 promoter using standard molecular biology
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techniques (Section 2.2.2.). HPV-16 E2 was in vitro transcribed-translated using the 
TNT T7/T3 Coupled Reticulate Lysate kit (Promega) as instructed by the 
manufacturer. The efficiency of transcription-translation was checked using a 
luciferase control plasmid and assaying for luciferase activity. In vitro transcribed- 
translated HPV-16 E2 was used for band shift assays (Section 2.2.2.16). In vitro 
transcription-translation of pGADT7 constructs to produce 35S labelled proteins was 
carried out using the TNT T7 Quick Coupled Transcription kit (Promega) according 
to the manufacturer’s instructions. 1 pi each reaction was analysed by 10% SDS- 
PAGE and proteins were fixed in 2.5% methanol and 7.5% glacial acetic acid for 30 
min with shaking. The gel was transferred onto filter paper, dried and exposed for 
autoradiography at -70°C  overnight.
GST pull down assays were performed as follows: pGEX and pGEX-E2AD (cloned 
by Iain Morgan) were used to transform competent bacterial cells. GST fusion 
proteins were expressed and purified as described in Section 2.2.3.6 . The proteins 
immobilised on beads were pre-washed three times in pull down buffer (PDB: 50 
mM Tris pH 7.9, lOOmM NaCl, ImM DTT, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% 
NP-40, 1 mM PMSF). The NaCl concentration in PDB can be changed to assess the 
specificity of binding. 7.5 pi 35S labelled in vitro translated protein was then 
incubated with approximately 1 pg immobilised fusion protein (approximately 1 0  pi 
protein on beads) in a total volume of 200 pi fresh PDB for 30 min at 4°C with 
rotation. The beads were pelleted in a microfuge (14 000 rpm, 10 sec) and washed 
four times in PDB. Bound proteins were separated by 10% SDS-PAGE, fixed, the gel 
was transferred onto filter paper, dried and exposed for autoradiography at -70°C  
overnight.
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Chapter 3 -  Results 
3 .1 . T ran scr ip tion a l a n a ly s is  o f  th e  B PV -4 LCR
All papillomaviruses have a non-coding region of 500-1000 bp called the long 
control region (LCR). The LCR is the transcriptional control unit of the virus and 
contains a number of binding sites for transcription factors including virally encoded 
E2 (for a review see (Ishiji, 2000)). The LCR of mucosal epitheliotropic 
papillomaviruses, for example, HPV-16, -18 and BPV-4, have a similar organisation: 
a promoter region, an enhancer region and a highly conserved distribution of E2 
DNA binding sites (Fig. 3.1.1a). One of the restrictions of these viruses to the 
epithelial cell type is at the transcriptional level. The enhancer of these 
papillomaviruses is epithelial specific as it fails to activate transcription from 
heterologous promoters in non-epithelial cell types (Cripe et al., 1987; Gloss et al., 
1987). The BPV-4, HPV-16 and -18 enhancers are of a similar size and position. 
There are two main regions contributing to the BPV-4 LCR enhancer activity 
(Morgan et al., 1999). One of these sites, Site 2, is 100% conserved in the HPV-16 
LCR. There are four E2 DNA binding sites located in the HPV-16, -18 and BPV-4 
LCRs. Immediately upstream of the TATA box are two E2 DNA binding sites 
separated from each other and the TATA box by 3 or 4 base pairs. Two additional 
sites flank the epithelial specific enhancer: one beside the E l DNA binding site 
involved in the regulation of viral DNA replication and one a further 300-400 bp 
upstream. This conservation of the organisation of E2 DNA binding sites between the 
HPV-16, -18 and BPV-4 LCRs strongly suggests that the mechanism E2 uses to 
regulate transcription from mucosal epitheliotropic LCRs is conserved. This
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organisation of E2 DNA binding sites is lost in the cutaneous HPV and subgroup A  
BPV LCRs.
Studies on E2 transcriptional regulation of the human mucosal epitheliotropic 
papillomaviruses have been hindered by poor access to the natural target cell type 
and by the observation that some of the HPV promoters, including HPV-16, are 
repressed in immortalised epithelial cells. The BPV-4 LCR and primary bovine 
palate keratinocytes (PalK) and palate fibroblasts (PalF) present a model system to 
study the mechanism of E2 transcriptional regulation of mucosal epitheliotropic 
papillomaviruses and the cell type specificity of this regulation. Comparisons are 
made between the results in PalK cells, the natural target cell type for transformation 
by BPV-4, with PalF cells from the same source. Several E2 molecules, including 
BPV-1 E2, BPV-4 E2 and HPV-16 E2, activate transcription efficiently from the 
BPV-4 LCR in PalK cells but do so only poorly in PalF (Morgan et al., 1998). Low 
to intermediate levels of E2 upregulate transcription in keratinocytes, while at high 
levels transcription is down-regulated. Mutation of E2 binding site 1 (BS1), which is 
3 bp upstream from the TATA box, abrogates down-regulation of transcription by 
high levels of E2 (Jackson and Campo, 1995; Morgan et al., 1998). The inability of 
E2 to upregulate transcription in fibroblasts is promoter specific as E2 can activate 
transcription from heterologous promoters in a variety of cell types. A  chimaeric 
molecule that has the VP16 transactivation domain fused to the BPV-1 DNA binding 
domain upregulates transcription from the BPV-4 LCR in a cell type independent 
manner suggesting that the epithelial specific transcriptional regulation of the BPV-4 
LCR is mediated by the E2 transactivation domain (Morgan et al., 1998). However, 
the BPV-4 LCR is approximately 40-fold more active in PalK than in PalF cells in
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the absence of E2 due to the presence of the epithelial specific enhancer (Morgan et 
al., 1999).
3.1.1. Generation of E2 responsive BPV-4 promoter constructs
Epithelial specific transcriptional regulation of the BPV-4 LCR promoter by E2 may 
be mediated at three levels: the E2 protein might function more efficiently in 
epithelial cells, E2 may interact with the epithelial specific enhancer to regulate 
transcription or the LCR promoter may show an enhanced epithelial response to 
transcriptional activators. To determine which of these possibilities are responsible 
for the enhanced epithelial response of the BPV-4 LCR to E2, the epithelial specific 
enhancer was removed and a series of concatamers of increasing numbers of E2 
DNA binding sites were cloned upstream from the BPV-4 promoter in the position of 
E2 BS3 (Fig. 3.1.1b). Reporter constructs were generated by PCR amplifying the 
BPV-4 LCR promoter from nucleotide 184-310 as a Bglll-Hindlll fragment from 
pLCR, pLCR-E2(3)mtl and pLCR-E2(d/3). These plasmids contain the BPV-4 LCR 
from nucleotides 6710 to 331 cloned into the BamHI site of pOluc. pLCR contains 
the wild type BPV-4 LCR sequence while pLCR-E2(3)mtl and pLCR-E2(d/3) 
contain the TATA box proximal E2 DNA binding site mutations preventing E2 
binding (Jackson and Campo, 1995). The BPV-4 promoter fragments were then 
cloned into the pGL3 luciferase vector to generate a series of plasmids with the 
following nomenclature: the PV series represents the wild type LCR promoter 
sequence, the PV1 series has the TATA proximal E2 DNA binding site mutated 
whereas the PV2 series has both the TATA proximal and the adjacent E2 site 
mutated (Fig. 3.1.1b). Increasing numbers of E2 DNA binding sites were then 
inserted upstream from these promoters. Oligonuleotides were designed which when
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annealed together generate a pair of E2 sites separated by 4 base pairs with 
BamHl/Bglll compatible ends. After end-labelling with T4 kinase and ligation, the 
double stranded oligonucleotides were restriction digested with BamHl/Bglll. This 
ensured that only concatamers of E2 binding sites facing in the same orientation were 
obtained as ligation in the wrong orientation reconstituted a restriction site. After 
separation on a 6 % polyacrylamide gel, the bands corresponding to 2, 4, 6  and 8  E2 
sites were excised, purified and cloned into the Bglll site immediately upstream of 
the BPV-4 promoter region. The E2 site sequence corresponding to E2 BS4 in the 
BPV-4 LCR was used to generate these constructs. BPV-1 E2 has previously been 
shown to bind this site with high affinity binding (Sanders and Maitland, 1994). 
Also, BS4 mediates transactivation of the BPV-4 LCR by BPV-1 E2 and forms a 
more stable E2-oligonucleotide complex in vitro than the TATA box proximal E2 
DNA binding sites (Jackson and Campo, 1995). Consistent with this, Fig. 3.1.2. 
demonstrates that in vitro translated HPV-16 E2 specifically binds the synthetic 
double stranded E2 site in a band shift assay. Binding to the -ACCGAAAACGGT- 
sequence was competed by 1 0 0 -fold excess non-radioactive self oligonucleotide but 
not by the related AP-1 oligonucleotide. No binding was detected when in vitro 
translated luciferase protein was used as a non-specific control (Fig. 3.1.2).
3.1.2. E2 upregulates transcription from the BPV-4 promoter 
preferentially in epithelial cells
PalK and PalF cells were co-transfected with the E2 responsive promoter constructs 
and HPV-16 E2, which functions in an identical manner to BPV-4 E2 on the BPV-4 
LCR, to study the mechanism of E2 mediated transcriptional regulation of the BPV-4 
promoter. In contrast to the full length LCR, the BPV-4 promoter constructs have
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similar background transcriptional activity in both PalK and PalF cells. Also, in the 
absence of E2 protein the E2 sites do not enhance transcription and without the BPV- 
4 promoter sequences E2 does not activate transcription indicating there is no cryptic 
promoter in the pGL3 reporter plasmid that is responsive to E2 (data not shown). In 
PalK cells, HPV-16 E2 upregulates transcription from the BPV-4 promoter in an 
additive manner increasing as the number of E2 binding sites increases (Fig 3.1.3). A  
maximum of 2 0 -fold transcriptional activation (relative to the luciferase activity in 
the absence of E2) is observed with the PV1 8E2 and PV2 8E2 constructs. PV1 6E2 
and PV2 6E2, which both have the TATA proximal E2 site (BS1) mutated, have a 2- 
to 3-fold elevated response over the PV 6E2 construct (Fig. 3.1.3). This is in 
agreement with previous studies showing that BS1 is responsible for mediating 
down-regulation of transcription by elevated levels of E2.
To determine if the epithelial specific response of the full length LCR is retained by 
the promoter region, the ability of increasing concentrations of HPV-16 E2 to 
activate transcription from the PV 6E2 construct was assayed in both PalK and PalF 
cells. In keratinocytes transcription is upregulated a maximum of 5-fold at a 1:1 ratio 
of E2 expression vector to reporter plasmid, while over a range of increasing E2 
concentrations transcription is not activated more than 2-fold in fibroblasts (Fig. 
3.1.4a). To determine the effect of the TATA box proximal E2 binding site mutations 
on epithelial specific transcriptional regulation, the transcriptional response to HPV- 
16 E2 of the PV1 6E2 and PV2 6E2 constructs were assayed in both PalK and PalF 
cells. Low levels of E2 are sufficient to upregulate transcription from the PV1 and 
PV2 promoters in PalK cells. A  1:1 ratio of E2 expression vector to reporter plasmid 
activates transcription 12-fold from the PV1 promoter (Fig. 3.1.4b) and 10-fold from
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the PV2 promoter (Fig. 3.1.4c). Over a range of E2 concentrations the PV1 (Fig. 
3.1.4b) and PV2 (Fig. 3.1.4c) promoters are not upregulated more than 2-fold in PalF 
cells. However, previous studies have shown that E2 activates transcription in 
fibroblasts when the BPV-4 LCR is cloned upstream of a heterologous promoter 
(Jackson and Campo, 1991; Morgan et al., 1998). Western blot analysis was 
therefore carried out to determine whether E2 fails to activate transcription from the 
BPV-4 promoter constructs in PalF cells because of a lack of expression. PalK and 
PalF cells were transiently transfected with increasing amounts of pCMV HPV-16 
E2 expression vector. Equal amounts of whole cell extract were separated by 10% 
SDS-PAGE and transferred onto a nitrocellulose membrane. The level of E2 
expression was monitored by probing the membranes with a monoclonal antibody 
directed against an epitope in the amino terminal region of HPV-16 E2. Fig. 3.1.5 
shows that failure of E2 to function in fibroblasts is not due to lack of expression as 
E2 is being expressed at similar levels as a doublet of approximately 42 kDa in both 
PalK and PalF cells.
These results demonstrate that the BPV-4 promoter mimics the response of the full 
length LCR to transcriptional up-regulation by E2, that is, the response is much 
enhanced in PalK cells when compared with PalF. The results confirm that the 
TATA box proximal E2 DNA binding sites BS1 and BS2 mediate down-regulation 
of transcription by E2. Mutation of these sites to prevent E2 binding does not affect 
the epithelial specific response of the BPV-4 promoter to E2. The results also show 
that the epithelial specific enhancer element of the BPV-4 LCR is not required for the 
enhanced activity of E2 in PalK cells.
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3.1.3. The BPV-4 promoter shows an enhanced epithelial response to 
transcriptional activators
It has been proposed that the epithelial specific transcriptional regulation of the BPV- 
4 LCR by E2 might be mediated by the E2 transactivation domain (Morgan et al., 
1998). To test this hypothesis the ability of a VP16-E2 chimaera, the VP16 
transactivation domain fused to the BPV-1 E2 DNA binding domain, and of wild 
type BPV-1 E2 to activate transcription from the PV2 6E2 construct was assayed. 
VP16 is a strong acidic transactivator from the Herpes Simplex Virus (HSV). The 
PV2 6E2 construct was used in these experiments as the PV2 promoter contains the 
TATA box proximal E2 DNA binding site mutations eliminating down-regulation of 
transcription at elevated levels of E2 as a complicating factor. Fig. 3.1.6a. shows that 
BPV-1 E2 activates transcription 18-fold in PalK cells but no more than 2-fold in 
PalF cells. This may not represent an accurate value of the background activity in 
PalF cells due to the sensitivity of the BioOrbit luminometer used in this experiment 
(see Fig. 3.1.13 measured using a Tropix TR717 luminometer). However, this result 
demonstrates that the preferential activation in epithelial cells is retained with BPV-1 
E2. VP16-E2 also activates transcription from PV2 6E2 better in PalK cells than in 
PalF (Fig. 3.1.6b). At low levels VP16-E2 activates transcription 180-fold in 
fibroblasts and 900-fold in keratinocytes. At high levels of VP16-E2 transcription is 
down-regulated in both cell types. This may be due to squelching where excess 
VP16-E2 proteins not bound to DNA sequester factors required for transcriptional 
activation. The PV2 promoter has a 8 - to 9-fold enhanced epithelial response to 
activation by BPV-1 E2 and a 5-fold enhanced response to activation by VP16-E2 in 
epithelial cells, demonstrating that the E2 transactivation domain is not solely
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responsible for the enhanced function of E2 on the BPV-4 promoter in epithelial 
cells.
Two components of the cellular basal transcription initiation complex, TBP and 
TFIIB, have been shown to interact directly with the carboxy terminal DNA binding 
domain of E2 (Rank and Lambert, 1995). However, the functional significance of 
these interactions are not known. To analyse the contribution of the DNA binding 
domain of E2 to cell type specific transcriptional activation four copies of the LexA  
site from the colEl promoter were cloned upstream of the PV2 promoter which 
contains both TATA box proximal E2 binding sites mutated (Fig. 3.1.7a). 
Concatamers of LexA binding sites were generated in the same manner as the E2 
DNA binding sites. The ability of a chimaeric molecule which has the VP16 
transactivation domain fused to the bacterial LexA DNA binding domain to activate 
transcription from this construct was assayed in PalK and PalF cells. At low to 
intermediate levels VP16-LexA activates transcription to a similar degree in both cell 
types. However, the BPV-4 promoter shows a 5-fold enhanced epithelial response to 
activation by high levels of VP16-LexA. A  1:1 ratio of expression vector to reporter 
plasmid upregulates transcription approximately 2 0 0 -fold in fibroblasts and 1 0 0 0 - 
fold in keratinocytes (Fig. 3.1.7b). This difference is similar to that observed with 
VP16-E2. These results suggest that the C-terminal region of E2 is not involved in 
mediating epithelial specific transcriptional regulation of the LCR promoter but 
functions to localise active E2 dimers to the target promoter.
To address the possibility that E2 binding to its target sequences was being blocked 
by cellular factors in fibroblasts and that the enhanced epithelial response to
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transcriptional activators was a specific property of the BPV-4 promoter an E2 
responsive tk promoter construct was generated (Fig. 3.1.8a). The HSV tk promoter 
from nucleotide 75-199 was PCR amplified as a Bglll-Hindlll fragment. This tk 
promoter fragment containing the tk TATA box, the initiator element and a binding 
site for the Spl transcription factor was cloned into pGL3 6E2. pGL3 6E2 contains 
six E2 DNA binding sites inserted into the Bglll site of the pGL3 luciferase vector. 
The tk promoter has similar background transcriptional activity in both PalK and 
PalF cells in the absence of E2 (data not shown) and is approximately the same 
length as the PV promoter so that the E2 molecules are operating from a similar 
distance. The ability of VP16-E2 to upregulate transcription from the tk 6E2 
construct was assayed in PalK and PalF cells. It is clear that the VP16-E2 chimaera is 
being expressed, binding to its target sites and activating transcription in both PalK 
and PalF cells (Fig. 3.1.8b). At low levels VP16-E2 activates transcription from the 
tk promoter preferentially in PalF cells. At intermediate levels VP16-E2 activates 
transcription to a similar degree in both cell types while at high levels of VP16-E2 
transcriptional activity is down-regulated probably due to a squelching mechanism. 
To further investigate the contribution of the E2 transactivation domain to epithelial 
specificity the ability of HPV-16 E2 to upregulate transcription from the tk 6E2 
construct was assayed in PalK and PalF cells. E2 upregulates transcription from the 
tk promoter in a cell type independent manner (Fig. 3.1.9). A  maximum of 
approximately 90-fold activation is observed with a 0.1:1 ratio of expression vector 
to reporter plasmid in both cell types. These results demonstrate that the tk promoter 
does not show an epithelial preference to activation by either VP16-E2 or HPV-16
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Taken together, these results show that a level of epithelial specificity resides in the 
BPV-4 promoter. The BPV-4 promoter has an enhanced epithelial response to 
activation, not only by HPV-16 and BPV-1 E2, but also by VP16-E2 and VP16- 
LexA. The enhanced epithelial response is a promoter specific effect as the tk 
promoter shows no such epithelial preference to activation by VP16-E2 and E2 itself. 
The E2 transactivation domain does not contribute towards an enhanced epithelial 
response of the tk promoter although it still remains a possibility that the E2 
transactivation domain contributes towards epithelial specific transcriptional 
regulation of the BPV-4 promoter.
3.1.4. The ability of TBP overexpression to enhance E2 mediated 
transcriptional activation depends on promoter structure
Activators are believed to function, at least in part, through contacting components of 
the cellular transcription machinery and affecting the formation and/or stability of the 
preinitiation complex. The interaction between TBP and the TATA box, the first step 
in preinitiation complex assembly, is often a rate limiting step for transcription 
initiation (Chatterjee and Struhl, 1995). Many transcriptional activators, including 
VP16 and E la  bind TBP in vitro (Boyer and Berk, 1993; Ingles et al., 1991). 
Mutations that decrease binding to TBP decrease transcriptional activation, 
demonstrating functional significance. The C-terminal E2 DNA binding domain has 
also been shown to interact with TBP (Rank and Lambert, 1995). However, the 
ability of activators to stimulate TBP binding in vivo is a tightly controlled, 
cooperative process involving multiple transcription factors (Li et al., 1999). Also, 
the arrangement of recognition elements in a core promoter can determine the 
differential response to upstream activators (Das et al., 1995). To determine whether
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TBP overexpression can enhance E2 mediated transactivation of the BPV-4 promoter 
increasing concentrations of TBP were cotransfected with a 0.01:1 ratio of E2 
expression vector to PV2 6E2 reporter construct. This ratio is sub-optimal for E2 
mediated activation of the BPV-4 LCR. Fig. 3.1.10a shows that TBP overexpression 
enhances E2 mediated transcriptional activation of the BPV-4 promoter in a dose 
dependent manner in both PalK and PalF cells. Low levels of E2 (0.01 p,g) upregulate 
transcription from the PV2 promoter 6 -fold in PalK and 4-fold in PalF cells. It should 
be noted that from this point luciferase activity was monitored on a Tropix TR717 
luminometer. This is more sensitive than the previous BioOrbit model accounting for 
the higher level of E2 activation in PalF cells. High ratios of TBP to E2 (1:0.01) 
increase E2 activity approximately 20-fold in PalK and 12-fold in PalF cells. 
However, TBP overexpression preferentially upregulates basal BPV-4 promoter 
activity in keratinocytes (Fig. 3.1.10b). High levels of TBP upregulate transcription 
from the PV2 6E2 construct 17-fold in PalK and 4-fold in PalF cells. This result 
suggests that TBP is recruited more efficiently to the BPV-4 promoter in the absence 
of E2 in PalK cells than in PalF. The tk promoter has a different response to TBP 
overexpression (Fig. 3.1.11). Low levels of E2 (O.Olpg) upregulate transcription 
preferentially in fibroblasts. A  0.01:1 ratio E2 expression vector to tk 6E2 reporter 
construct activates transcription 10-fold in PalK and 50-fold in PalF cells. TBP 
overexpression potentiates E2 mediated activation of the tk promoter in a dose 
dependent manner in PalK cells. Cotransfection of 0.01:1 ratio of E2 to TBP 
enhances E2 activity approximately 6 -fold in keratinocytes. Low levels of TBP 
increase the ability of E2 to activate transcription from the tk promoter in PalF cells 
while high levels of TBP downregulate E2 mediated transcription (Fig. 3.1.11a). 
However, TBP overexpression has a moderate effect on basal tk promoter activity
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(Fig. 3.1.11b). High levels of TBP upregulate basal tk promoter activity 5.5-fold in 
PalK and 3-fold in PalF cells. Taken together, these results suggest that core 
promoter elements play an important role in determining the effect of TBP 
overexpression on basal and activated promoter activity.
3.1.5. Identification of the promoter region responsible for the 
enhanced epithelial response of the BPV-4 promoter to upstream 
activators
The enhanced epithelial response of the BPV-4 promoter may be determined by DNA  
bound proximal promoter factors that are either cell type specific, differentially 
expressed, alternatively spliced, or modified in a cell type dependent manner. Also, 
as shown for the Pit-l/GHF-1 gene, which contains a 15 bp minimal TATA 
containing pituitary specific promoter (McCormick et al., 1991), the TATA box and 
surrounding sequences can dictate cell type specific transcriptional regulation. To 
identify the BPV-4 promoter region responsible for the differential response of this 
promoter in keratinocytes and fibroblasts, two chimaeric promoters with six E2 
DNA binding sites inserted upstream were generated by ‘splicing by overlap 
extension’ PCR. The region of the heterologous tk promoter containing the tk TATA 
box and initiator was exchanged with the corresponding region in the BPV-4 
promoter to generate the lcr/tk hybrid promoter (Fig. 3.1.12a). The PV2 promoter 
from nucleotide 184-279 and the tk promoter from nucleotide 120-199 were PCR 
amplified. The internal primers used were designed so that the primary PCR products 
contained 20 bp overlapping complementary ends. A  second PCR reaction using 
primers annealing at the non-overlapping ends was performed to generate the lcr/tk 
hybrid promoter as a Bglll/Hindlll fragment. This fragment was then cloned into
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pGL3 6E2. The tk/lcr hybrid, generated in the same manner, contains the BPV-4 
TATA box and surrounding sequence (nucleotides 279-310) fused to the upstream tk 
promoter region from nucleotide 75-119 containing the Spl site (Fig. 3.1.12b).
The ability of E2 and VP16-E2 to upregulate transcription from these constructs was 
assayed in PalK and PalF cells. Fig. 3.1.13a shows the enhanced epithelial response 
of the BPV-4 promoter to upstream activators. E2 upregulates transcription a 
maximum of 7-fold in PalF and 60-fold in PalK cells, while VP16-E2 transactivates 
the PV2 promoter a maximum of 700-fold in PalF and 2500-fold in PalK cells. Fold 
activation is higher than that observed previously due to luciferase activity now being 
assayed on a Tropix TR717 luminometer. The lcr/tk hybrid promoter retains the 
enhanced epithelial response of the BPV-4 promoter to activation by E2 and VP16- 
E2 (Fig. 3.1.13b). E2 activates transcription a maximum of 2.5-fold in PalF and 11- 
fold in PalK cells. VP16-E2 upregulates transcription a maximum of 130-fold in 
fibroblasts and 300-fold in keratinocytes. The overall level of response of the lcr/tk 
6E2 construct is reduced when compared with the PV2 promoter suggesting that the 
BPV-4 TATA box is more responsive than that of the tk promoter. The tk/lcr 
chimaeric promoter shows no such epithelial preference (Fig. 3.1.14a). E2 
transactivates the tk/lcr hybrid promoter a maximum of 320-fold in PalK and 250- 
fold in PalF cells. VP16-E2 upregulates transcription from the tk/lcr promoter 
preferentially in fibroblasts. A  maximum of 850-fold activation in PalK and 2600- 
fold activation in PalF cells is observed. Fig. 3.1.14b shows the cell type independent 
response of the tk promoter to activation by E2 and the preferential response to 
activation by VP16-E2 in fibroblasts. E2 upregulates transcription a maximum of 90- 
fold in both cell types whereas VP16-E2 activates transcription a maximum of 1000-
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fold in PalK and 2500-fold in PalF cells. These results suggest that it is the upstream 
BPV-4 LCR promoter region and not the core TATA box and adjacent sequence that 
dictates the enhanced epithelial response of the BPV-4 promoter to upstream 
activators.
3.1.6. Identification of the DNA elements responsible for the differential 
response of the BPV-4 promoter to upstream activators in fibroblasts 
and keratinocytes
The chimaeric promoter constructs have identified the upstream BPV-4 promoter 
region as an important determinant of cell type specific transcription. A  series of 5 ’ 
deletions of the PV2 promoter were therefore generated to identify the specific LCR 
promoter elements that either co-operate or antagonise with E2 to regulate 
transcription preferentially in keratinocytes (Fig. 3.1.15). Promoter deletions were 
PCR amplified as Bglll-Hindlll fragments and cloned into pGL3 6E2. The ability of 
HPV-16 E2 to upregulate transcription from the E2 responsive promoter deletion 
constructs was assayed in PalK and PalF cells. It should be noted that in each 
construct the E2 DNA binding sites are an extra 6 bp upstream from the TATA box 
due to the Bglll restriction enzyme site used for cloning. Deletion analysis of the 
papillomavirus promoter identifies two novel repressor elements that are, at least in 
part, responsible for mediating the differential response of the BPV-4 promoter to 
upstream activators in fibroblasts and keratinocytes (presented graphically in Fig. 
3.1.16 and numerically in Table 3.1.1.). Deletion of the region from 19bp to 3bp 
TATA results in a 3.5-fold increase in transcriptional activation by E2 in PalK and a 
7-fold increase in PalF cells. This region defines Promoter Repressor Element-1 
(PRE-1). The PRE-1 element spans the TATA box proximal E2 binding sites in the
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BPV-4 LCR that have been mutated to prevent E2 binding. Although this is not the 
wild type BPV-4 sequence, these mutations do not affect the epithelial specific 
response of the BPV-4 promoter to E2 (Fig. 3.1.4.). Deletion from 80bp to 6 6 bp 
TATA (Promoter Repressor Element-2 (PRE-2)) results in a 3-fold increase in 
transactivation in PalK and a 6.5-fold increase in PalF cells. Deletion of either of 
these regions does not have a significant effect on basal promoter activity (data not 
shown).
A  core tk promoter must contain at least two elements to be able to respond to E2 
and these elements, the TATA box, the initiator element, or a binding site for an 
upstream promoter factor are interchangeable (Ham et al., 1991a). In contrast to a 
minimal tk TATA box containing promoter E2 efficiently activates a minimal BPV-4 
TATA promoter that contains neither an initiator element nor a binding site for an 
upstream factor. E2 upregulates transcription approximately 560-fold in keratinocytes 
and 280-fold in fibroblasts from the 3bp TATA construct (Fig. 3.1.16 and Table 
3.1.1.). This minimal promoter contains only 32 bp of BPV-4 promoter sequence. 
This result suggests that the general transcription machinery assembled at the BPV-4 
and tk TATA boxes contain distinct coactivator complexes. Also, the minimal BPV- 
4 TATA promoter has an elevated epithelial response to E2 suggesting that the BPV- 
4 TATA box and surrounding sequence may play an important role in determining 
cell type specific transcription or that the E2 protein contributes to activating 
transcription from the BPV-4 promoter preferentially in keratinocytes.
To address these possibilities the ability of increasing concentrations of VP16-E2 and 
HPV-16 E2 to activate transcription from the 3bpTATA construct was assayed (Fig.
Chapter 3-Results 90
3.1.17). At low to high levels VP16-E2 activates transcription preferentially in 
fibroblasts. A  maximum of approximately 3500-fold in PalF and 1500-fold 
activation in PalK cells is observed at a 1:1 ratio of expression vector to reporter 
plasmid (Fig. 3.1.17a). The 5-fold enhanced epithelial response of the PV2 promoter 
to activation by VP16-E2 shown in Fig. 3.1.6b is lost with the minimal BPV-4 
TATA containing construct demonstrating that the BPV-4 TATA box is not involved 
in dictating the enhanced epithelial response of the BPV-4 promoter to activation by 
VP16-E2. This is in agreement with the results obtained with the chimaeric promoter 
constructs (Fig. 3.1.13. and Fig. 3.1.14.). Low to intermediate levels of E2 activate 
transcription from the 3bp TATA construct to a similar degree in both PalK and PalF 
cells. At these levels of E2 the activation of the PV2 promoter is 8 - to 9-fold 
enhanced in epithelial cells (Fig. 3.1.6a) confirming the involvement of PRE-1 and 
PRE-2 in mediating the cell type selective response of the BPV-4 promoter to 
upstream activators. However, at high levels of E2 ( lp g ) transcription is 
downregulated from the 3bp TATA construct in fibroblasts while in keratinocytes 
activation remains elevated. A  maximum of approximately 300-fold in fibroblasts 
and 450-fold activation in keratinocytes is observed (Fig. 3.1.17b). A s E2 is 
expressed at similar levels in both PalK and PalF cells (Fig. 3.1.5) these results 
suggest that certain cell type specific co-activators may interact with the E2 
transactivation domain in epithelial cells but not in fibroblasts enabling E2 to retain 
the ability to activate transcription at elevated levels in PalK cells.
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3.1.7. PRE-1 and PRE-2 can repress the basal activity of a strong 
heterologous promoter
Two functional types of repressor elements exist. Negative regulatory elements 
(NRE) that are promoter specific and silencer elements that are able to repress 
heterologous promoter activity out of context of the native promoter. To further 
characterise the functional properties of BPV-4 promoter repressor elements, PRE-1 
and PRE-2, oligomers corresponding to these sequences were multimerised upstream 
of the SV40 promoter in the pGL3 luciferase vector in both a positive and negative 
orientation (Fig. 3.1.18). These potential repressor binding sites were generated in the 
same manner as shown for the E2 sites. The ability of these elements to direct 
repression of SV40 promoter activity was assayed in both PalK and PalF cells. Fig. 
3.1.19 shows that over a range of concentrations one copy and four copies o f PRE-1 
strongly represses the SV40 promoter by about 50-80% in both cell types. As the 
extent of repression does not depend on the number of copies of PRE-1, this 
suggests that the cellular factor interacting with PRE-1 acts independently to repress 
transcription. In fibroblasts repression is orientation independent. However, in 
keratinocytes repression is alleviated at high levels of reporter construct when PRE-1 
is cloned in the reverse orientation. Although this result is reproducible there is no 
obvious explanation for the loss of repression under these conditions. Over a range of 
concentrations four copies of PRE-2 represses SV40 promoter activity approximately 
40-80% in PalK and 60-80% in PalF cells (Fig. 3.1.20). Orientation of PRE-2 had no 
effect on the extent of repression in both cell types. These results demonstrate that 
PRE-1 and PRE-2 can repress the basal activity of a strong heterologous constitutive 
promoter.
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3.1.8. PRE-2 binds a single protein complex in both PalK and PalF cells
Extensive database searches revealed that PRE-1 and PRE-2 do not contain any 
known transcription factor binding sites. The PRE-2 motif is conserved in position 
and sequence in the related mucosal epitheliotropic papillomaviruses, BPV-3 and 
BPV - 6  (Fig. 3.1.18). Also, a YY-1 independent silencer in roughly the same position 
as PRE-2 in the HPV-16 LCR has recently been identified (O'Connor et al., 1998). 
As functional analysis has identified PRE-2 as a transcriptional silencer band shift 
assays were performed to determine whether PRE-2 could bind a nuclear protein. A  
double stranded synthetic oligonucleotide containing the 20 base pair PRE-2 motif 
detected a single protein complex with both PalK and PalF nuclear extracts (Fig. 
3.1.21). Binding to PRE-2 was confirmed to be specific as it was competed by 100- 
fold excess non-radioactive self oligonucleotide but not by the unrelated AP-1 
oligonucleotide. No reproducible specific complex binding to PRE-1 could be 
detected by EMSA analysis. This may reflect the sensitivity and conditions used in 
the band shift assay.
3.1.9. Functional characterisation of the PRE-2 binding complex
In vitro footprinting shows that PRE-2 contains a DNA binding site for a potential 
transcription factor (Jackson and Campo, 1991). To identify the exact nucleotides 
necessary for in vitro binding two double stranded oligonucleotides each containing a 
single PRE-2 motif with a 3 base pair substitution in the footprint were generated 
(Fig. 3.1.22a.). The mutant PRE-2 oligonucleotides were tested for competition using 
the band shift assay. Fig. 3.1.22b demonstrates that binding of the detected protein 
complex is not competed by either of the two mutant sequences identifying these
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mutated residues to be important for sequence specific binding in both PalK and 
PalF cells.
To determine the functional consequences of loss of binding four copies of PRE-2 
m tl were inserted upstream of the SV40 promoter in the pGL3PRO reporter vector 
generating PR 04X m tl. Again, this was performed as described for the 
multimerisation of E2 sites. The ability of this construct to relieve PRE-2 mediated 
repression of SV40 promoter activity was assayed in both PalK and PalF cells. Fig. 
3.1.23 shows that loss of factor binding correlates with loss of transcriptional 
repression. Over a range of concentrations the activity of the PR 04xm tl construct is 
similar to that of the SV40 promoter alone in both PalF and PalK cells. To determine 
the effect of loss of binding on cell type specific transcriptional regulation of the 
BPV-4 promoter, PRE-2 m tl was introduced into the 80bp TATA promoter construct 
by PCR amplification using a 5 ’ primer containing the mutation. Six E2 sites were 
inserted upstream of this mutated promoter fragment generating 80bpmtl. The ability 
of E2 to upregulate transcription from 80bpmtl was assayed in both PalK and PalF 
cells (Fig. 3.1.24). The 80bpmtl construct has a two-fold increase in transcriptional 
activation by E2 in PalF cells and a 0.5-fold increase in PalK relative to the 
80bpTATA promoter deletion. This result confirms that the PRE-2 binding protein 
represses the transcriptional response of the BPV-4 promoter to E2 and suggests that 
PRE-2 is one component involved in mediating the cell type selective response of 
the BPV-4 promoter to activation by E2 in PalF and PalK cells.
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3.1.10. PRE-2 specifically binds a 50 kDa cellular protein
UV cross-linking was performed to determine the molecular weight of the active 
DNA binding form of the detected protein complex. A  single radiolabelled 
bromodeoxyuridine (BrdU) substituted PRE-2 motif was used to probe PalK and 
PalF nuclear extracts in a band shift assay. No difference in binding was observed 
when the wild type and BrdU substituted PRE motifs were used as probes in band 
shift assays. After electrophoresis, the gel was UV irradiated (304 nm) to cross-link 
the protein to the DNA. The retarded complexes were visualised using a phosphor 
imager, the bands of interest excised and the protein complexes resolved by 10% 
SDS-PAGE. A  non-labelled BrdU PRE-2 motif and the unrelated AP-1 
oligonucleotide were used to assess the specificity of binding. Fig. 3.1.25 shows that 
BrdU PRE-2 binds a major species of approximately 50 kDa in both PalK and PalF 
nuclear extracts. Binding of this factor was confirmed to be specific as it was 
competed by excess non-labelled BrdU PRE-2 but was not competed by AP-1 in both 
cell types. A  minor species was also detected just above the 50 kDa band. This 
suggests that the PRE-2 binding protein may be post translationally modified or that 
a heterodimeric protein complex interacts with the DNA.
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Fig. 3.1.1. (a) Organisation of the BPV-4 LCR. The LCR can be divided roughly 
into two regions, the promoter region and an epithelial specific enhancer. The LCR 
contains four binding sites for the viral transcription factor, E2 (BS1-BS4). BS1 and 
BS2 are separated from each other and the TATA box by 3 bp. BS3 is 77 bp 
upstream from BS2 and BS4 is a further 409 bp upstream, (b) E2 responsive 
promoter constructs. The BPV-4 promoter region from nucleotide 184 to 310 was 
PCR amplified as a Bglll-Hindlll fragment. This region contains the TATA box, E2 
BS1 and BS2 but no initiator element. Mutations were introduced into the TATA 
proximal E2 sites preventing E2 binding to generate PV1 and PV2. A  series of 
concatamers of E2 binding sites were inserted into the Bglll site immediately 
upstream in the position of E2BS3.
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E2 responsive promoter constructs
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Fig. 3.1.2. In vitro translated HPV-16 E2 specifically binds the - 
ACCGAAAACGGT- sequence used in cloning. Radiolabelled synthetic E2 BS 
was incubated with either in vitro translated HPV-16 E2 or control luciferase protein 
in a band shift assay. 100-fold excess unlabelled E2 BS and AP-1 oligonucleotides 
were used as indicated to assess the specificity of binding. Retarded complexes were 
separated on a 6% polyacrylamide gel and visualised by autoradiography.
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Transcriptional activation of the BPV-4 
promoter by HPV-16 E2 in PalK cells
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Fig. 3.1.3. E2 upregulates transcription from the BPV-4 promoter in additive 
manner. 1 pg reporter plasmid was cotransfected with 0.1 pg pCMV HPV-16 E2 
expression vector into PalK cells. This ratio has previously been shown to be optimal 
for maximal activation of the LCR promoter by E2. Results are expressed as fold 
transactivation relative to the luciferase activity of each reporter in the absence of E2 
(normalised to 1). Each transfection was repeated at least three times in duplicate.
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Epithelial specific transcriptional regulation of 
the BPV-4 promoter by HPV-16 E2
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Epithelial specific transcriptional regulation of 
the BPV-4 promoter by HPV-16 E2
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Fig. 3.1.4. Epithelial specific transcriptional regulation of the BPV-4 promoter 
by HPV-16 E2. 1 p,g of either (a) PV 6E2 or (b) PV1 6E2 or (c) PV2 6E2 reporter 
construct was cotransfected with increasing amounts of pCMV HPV-16 E2 
expression vector into both PalK and PalF cells. pCMV was used to make the total 
amount of DNA transfected equal in all cases. A  control vector with the SV40 
enhancer and promoter driving expression of the luciferase gene (pGL3 CONT) gave 
similar activity in both cell types.
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l e v e l s
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Fig. 3.1.5. HPV-16 E2 is expressed at similar levels as a doublet of 
approximately 42 kDa in both PalK and PalF cells. PalK and PalF cells were 
transfected with increasing amounts of pCMV HPV-16 E2 expression vector. 50 mg 
whole cell extracts were separated by 10% SDS-PAGE, transferred to nitrocellullose 
and probed with a TVG261 monocloned antibody directed against amino acids 2 to 
17 in the amino terminus of HPV-16 E2.
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Fig. 3.1.6. The PV2 promoter shows an enhanced epithelial response to 
transcriptional activators. PalK and PalF cells were cotransfected with 1 pg PV2 
6E2, which has both the TATA box proximal E2 BS1 and BS2 mutated, and the 
indicated amounts of pCG BPV-1 E2 and pCG VP16 E2 expression vectors. pCG 
was used to make the total amount of DNA used 2 pg in each case. Results are 
expressed as fold transactivation over the luciferase activity in the absence of 
expression vector.
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Transcriptional activation of the PV2 promoter 
by BPV-1 E2 and VP16-E2
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Fig. 3.1.7. (a) PV2 4LexA reporter construct. Four copies of the LexA site from 
the colEl promoter were cloned into the Bglll site immediately upstream of the PV2 
promoter, (b) The PV2 promoter shows an enhanced epithelial response to 
activation by VP16-LexA. PalK and PalF cells were cotransfected with 1 pg PV2 
4LexA reporter construct and the indicated amounts of pCGVP16-LexA expression 
vector. The total amount of DNA transfected was made equal in each case. Results 
are expressed as fold transactivation over the luciferase activity in the absence of 
VP16-LexA expression vector (set at 1).
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Functional analysis of the E2 C-terminus
A
PV2 4LexA
TCG ACT GCTGTAT AT AAAACCAGT GGTTAT AT GT AC AGTA
B
1200 r
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PalF800 -
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200 -
0 10.10.001 0.01
V P16-L exA  expression vector (^ig)
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Fig. 3.1.8. (a) E2 responsive tk promoter construct. The tk promoter from 
nucleotide 75 to 199 containing the TATA box, initiator element and a GC rich box 
was PCR cloned as a Bglll-Hindlll fragment. Six E2 binding sites were inserted into 
the Bglll site immediately upstream to generate tk 6E2. (b) The tk promoter does 
not show an epithelial preference to activation by VP16-E2. PalK and PalF cells 
were cotransfected with 1 pg tk 6E2 reporter plasmid and the indicated amounts of 
pCGVP16-E2 expression vector. PCG was added to make the total amount of DNA  
transfected 2 pg in each case. Results are expressed as fold transactivation over the 
luciferase activity in the absence of VP16-E2.
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Cell type independent activation of the tk 6E2 
construct by VP16-E2
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Activation of the tk promoter by HPV-16 E2
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Fig. 3.1.9. HPV-16 E2 activates transcription from the tk promoter in a cell type 
independent manner. PalK and PalF cells were cotransfected with tk 6E2 and the 
indicated amounts of pCMV HPV-16 E2 expression vector. 1 pg reporter construct 
was used in each assay and the total amount of DNA transfected was made equal by 
the addition of pCMV. Results are expressed as fold transactivation over the 
luciferase activity in the absence of E2.
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Effect of TBP overexpression on PV2 promoter 
activity
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Fig. 3.1.10. TBP overexpression upregulates basal and E2 activated PV2 
promoter activity preferentially in PalK cells. PalK and PalF cells were co­
transfected with 1 pg of PV2 6E2 reporter construct and the indicated amounts of 
hTBP expression vector in the (a) presence or (b) absence of 0.01 pg of pCMV 
HPV-16 E2. A  0.01:1 ratio of E2 expression plasmid to reporter construct is sub- 
optimal for E2 mediated activation of the BPV-4 LCR. The total amount of DNA  
transfected was made equal in all cases. Results are expressed as fold activation 
relative to the luciferase activity of the PV2 6E2 reporter construct alone (set at 1).
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TBP potentiation of activated and basal tk 
promoter activity
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Fig. 3.1.11. The tk promoter has a different response to TBP overexpression.
PalK and PalF cells were co-transfected with 1 pg of tk 6E2 reporter construct and 
the indicated amounts of hTBP expression vector in the (a) presence or (b) absence 
of 0.01 pg of pCMV HPV-16 E2. The total amount of DNA transfected was made 
equal in all cases. Results are expressed as fold activation relative to the luciferase 
activity of the PV2 6E2 reporter construct alone (set at 1).
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Chimaeric promoter constructs
lcr/tk 6E2
E2 E2 E2 E2 E2 E2
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84 279.
TATTAAG Inr
B tk/lcr 6E2
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75
Spl
CZD tk 
BPV-4
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TATATAA
Fig. 3.1.12. E2 responsive chimaeric promoter constructs were generated by splicing 
by overlap extension PCR (a) The lcr/tk hybrid promoter contains the BPV-4 
upstream promoter region from nucleotide 184-279 fused to the tk promoter region 
from nucleotide 120-199. This region of the tk promoter contains the TATA box and 
initiator element, (b) The tk/lcr hybrid promoter contains the tk upstream promoter 
region from nucleotide 75-119 containing the Spl site fused to the BPV-4 TATA box 
and surrounding sequence (nucleotides 279-310).
Fig. 3.1.13. The lcr/tk hybrid promoter retains the enhanced epithelial response 
of the BPV-4 promoter to upstream activators. PalK and PalF cells were co­
transfected with the indicated amounts of pCMV HPV-16 E2 and pCG VP 16 E2 
expression vectors and either lp g  of (a) PV2 6E2 or (b) lcr/tk 6E2 reporter 
constructs. The total amount of DNA transfected was made equal in each case. 
Results are expressed as fold transactivation relative to the luciferase activity in the 
absence of expression vector.
Fo
ld 
tra
ns
ac
tiv
at
ion
 
Fo
ld 
tr
an
sa
ct
iv
at
io
n
113
Activation the lcr/tk hybrid promoter by HPV-16
E2 and VP16-E2
PV2 prom oter
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Fig. 3.1.14. The tk/lcr hybrid promoter shows no epithelial preference to 
activation by HPV-16 E2 and VP16-E2. PalK and PalF cells were co-transfected 
with the indicated amounts of pCMV HPV-16 E2 and pCG VP16 E2 expression 
vectors and lp g  of either (a) tk/lcr 6E2 or (b) tk 6E2 reporter constructs. Empty 
expression vector was used to make the total amount of DNA transfected 2 pg in 
each case. Results are expressed as fold transactivation relative to the luciferase 
activity in the absence of expression vector (set at 1).
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Transcriptional response of the tk/lcr hybrid 
promoter to upstream activators
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Fig. 3.1.15. (a) Sequence of the BPV-4 promoter from nucleotide 184 to 310. The
TATA box and potential binding sites for transcription factors identified by 
footprinting studies are shown in bold. The TATA box proximal E2 binding sites are 
shown underlined. Mutations have been introduced into these sites preventing E2 
binding as these have been shown to mediate down-regulation of transcription at 
high levels of E2. Promoter deletions are indicated by arrows, (b) E2 responsive 
promoter deletion constructs. A  series of 5 ’ deletions of the BPV-4 promoter were 
PCR amplified as Bglll-Hindlll fragments. These fragments were cloned into 
pGL36E2 which contains six E2 DNA binding sites inserted into the Bglll site of 
pGL3.
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Characterisation of the BPV-4 promoter 
deletion mutants
184 80bpi5’ G GTCGAAACTCTCACGCTAGGTAAGTGTTGT
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Transcriptional activation of the BPV-4 
promoter deletions by HPV-16 E2
700 
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PV2 80bp 66bp 41bp 19bp 3bp
6E2 TATA TATA TATA TATA TATA
Promoter deletion construct
Fig. 3.1.16. Deletion analysis of the BPV-4 promoter identifies two repressor 
elements. PalK and PalF cells were cotransfected w ithl pg of the indicated reporter 
plasmid and 0.1 pg of pCMV HPV-16 E2 expression vector. This ratio has 
previously been shown to be optimal for maximal activation of the LCR promoter by 
E2. Results are expressed as fold activation relative to the luciferase activity of each 
reporter in the absence of E2.
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Transcriptional activation of the BPV-4 
promoter deletions by HPV-16 E2
Promoter deletion PalF PalK
Fold TA se Fold TA se
PV2 6E2 5.06 0.97 36.06 2.97
80bp TATA 3.54 0.82 23.88 1.44
66bp TATA 23.09 4.92 68.83 9.06
41 bp TATA 20.86 3.30 122.40 24.15
19bp TATA 40.52 6.85 157.68 12.77
3bp TATA 286.22 12.01 566.55 50.27
Table 3.1.1. Numerical representation of the results shown in Fig. 3.1.16.
Transcriptional activation of the minimal BPV-4 
TATA containing promoter
A
No E2 0.001 0.01 0.1 1
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Fig. 3.1.17. PalK and PalF cells were cotransfected with 1 pg of the 3bpTATA 
construct, which contains neither an initiator element nor a binding site for an 
upstream factor, and the indicated amounts of either (a) pCG VP16 E2 or (b) pCMV 
HPV-16 E2 expression vectors. PCMV or pCG was used to make the total amount 
of DNA transfected equal in all cases. Results are expressed as fold transactivation 
over the luciferase activity in the absence of activator.
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Repressor constructs
PRE-l sites
SV40
PR El CAATCGTAAAGAATCGAATGCA
PREl(-) TGCATTCGATTCTTTACGATTG
PRE-2 sites
SV40
PRE2
BPV-3
BPV-6
GCTAGGTAAGT. GTTGTACCT
AGGTAAGT. GTTGT
^AGTAAGTCA TTAT
80bp TATA 66bp
PRE-2(-) AGGTACAACACTTACCTAGC
Fig. 3.1.18. PRE SV40 constructs. The PRE-l and PRE-2 elements were 
multimerised and inserted into the BglH site, upstream of the SV40 promoter in the 
pGL3 luciferase vector, in both a positive and negative orientation. The position and 
sequence of PRE-2 is conserved between the mucosal epitheliotropic 
papillomaviruses BPV-4, BPV-3 and BPV-6.
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PRE-1 mediated repression of SV40 promoter 
activity
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Fig. 3.1.19. PRE-l strongly represses SV40 promoter activity in a cell type 
independent manner. PalK and PalF cells were transfected with the indicated 
amounts of pGL3PRO, PROIXPREI, PR04XPRE1 and PR04XPRE1(-). Results 
are expressed relative to the lucifierase activity of pGL3PRO (set arbitrarily at 100%) 
which contains only the SV40 promoter.
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PRE-2 mediated repression of SV40 promoter 
activity
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Fig. 3.1.20. PRE-2 strongly represses SV40 promoter activity in an orientation 
independent manner. PalK and PalF cells were transfected with the indicated 
amounts of pGL3PR0, PR04XPRE2 and PR04XPRE2(-). Results are expressed 
relative to the luciferase activity of the SV40 promoter alone (set at 100%).
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E M S A  a n a l y s i s  t o  d e t e c t  n u c le a r  p r o t e in s  
in t e r a c t in g  w it h  P R E -2
PalF PalK
100x PRE-2 -  + -  -  + -
lOOx A P I  + ------- +
Fig. 3.1.21. PRE-2 binds a specific protein complex in both PalK and PalF cells.
A single radiolabelled PRE-2 motif was used to probe PalK and PalF nuclear extracts 
in a band shift assay. 100-fold excess unlabelled PRE-2 and AP-1 oligonucleotides 
were used as indicated to assess the specificity of binding. Retarded complexes were 
resolved on a 6% polyacrylamide gel and visualised by autoradiography.
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Fig. 3.1.22. (a) Sequence of PRE-2 mutants. Footprinting studies demonstrate 
PRE-2 contains a potential binding site for a transcription factor (shown underlined). 
Two double stranded oligonucleotides, each containing a single PRE-2 motif with a 
three base pair substitution in this footprint, were generated and tested for 
competition in the band shift assay, (b) PRE-2mtl and PRE-2mt2 do not compete 
for binding to the detected protein complex. A single radiolabelled PRE-2 motif 
was used in a band shift assay to probe PalK and PalF nuclear extracts. Cold 
competitors were added as indicated at either 100-fold (+) or 500-fold (++) molar 
excess as shown. Binding reactions were electrophoresed on a 6% polyacrylamide 
gel, the gel was dried and visualised by autoradiography.
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G e n e r a t io n  o f  P R E -2  n o n - b in d in g  m u t a n t s
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Functional consequences of loss of binding on 
PRE-2 mediated repression
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Fig. 3.1.23. Loss of complex binding to PRE-2 correlates with loss of 
transcriptional repression. Four copies of m tl were inserted into the Bglll site, 
upstream of the SV40 promoter in the pGL3PRO luciferase vector, generating 
PR 04X m tl. PalK and PalF cells were transfected with the indicated amounts of 
pGL3PRO, PR04XPRE-2 and PR 04X m tl. Results are expressed relative to the 
luciferase activity of pGL3PRO (set arbitrarily at 100%) which contains only the 
SV40 promoter.
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Transcriptional response of the 80bpmt1 
deletion construct to HPV-16 E2
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Fig. 3.1.24. The PRE-2 binding protein represses the transcriptional response to 
HPV-16 E2. PRE-2 m tl was introduced into the 80bp TATA promoter construct 
generating 80bpmtl. 1 pg 80bpTATA and 80bpmtl reporter constructs were 
cotransfected into PalK and PalF cells with 0.1 pg pCMV HPV-16 E2 expression 
vector. A  0.1:1 ratio of E2 to reporter has previously been shown to be optimal for 
maximal activation of the BPV-4 LCR by E2. Results are expressed as fold 
transactivation relative to the luciferase activity of each reporter in the absence of E2.
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Fig. 3.1.25. M olecular weight determination of the PRE-2 binding factor. PalK 
and PalF nuclear extracts were probed with a radiolabelled BrdU substituted PRE-2 
motif in a band shift assay. After polyacrylamide gel electrophoresis and UV 
exposure the PRE-2 crosslinked protein complexes were excised and separated on a 
10% SDS gel. Competition band shift reactions with either 100-fold non-labelled 
BrdU or AP-1 were performed as indicated to assess the specificity of binding.
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3.2. Analysis of the interactions between the HPV-16 E2 
transactivation domain and cellular proteins
The product of the papillomavirus E2 ORF is required for viral transcriptional 
regulation and DNA replication and is therefore essential for the viral life cycle (for a 
review see (Desaintes and Demeret, 1996)). The E2 protein can be divided into three 
functional domains: an amino terminal transactivation domain, a central flexible 
hinge region and a carboxy terminal dimerisation and DNA binding domain (see 
(Ham et al., 1991b) for a review). The structure and function of the amino and 
carboxy terminal domains is relatively conserved among human and animal 
papillomavirus, while the hinge region is of indeterminant function and is highly 
variable in sequence and length. The E2 protein binds to the 12bp palindromic DNA  
sequence -ACCGNNNNCGGT- as a dimer. All papillomavirus LCRs contain DNA  
binding sites for E2. The E2 carboxy terminus localises active E2 dimers at the target 
promoter while the E2 transactivation domain is essential for transcription and 
replication of the viral genome. Mutational analysis of the BPV-1 and HPV-16 E2 
amino terminus has demonstrated that the ability of E2 to regulate transcription and 
replication can be separated, indicating that the proteins with which E2 interacts to 
carry out these two functions are different (Brokaw et al., 1996; Ferguson and 
Botchan, 1996; Grossel et al., 1996; Sakai et al., 1996)].
E2 can also disrupt cellular growth control in certain mammalian cell lines and in 
yeast. Overexpression of different papillomavirus E2 proteins can induce a growth 
arrest in both the G1 and G2/M phases of the cell cycle, and can induce apoptosis 
through both p53 dependent and independent mechanisms (see (Massimi et al., 1999) 
and references therein). The exact mechanism of how E2 functions to disrupt cellular
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growth control remains unclear and seems to differ between E2 proteins. For 
example, induction of apoptosis by BPV-1 E2 seems to be p53 independent 
(Desaintes et al., 1999) whereas HPV-16 E2 can induce apoptosis in certain HPV 
transformed and non-HPV transformed cell lines through p53 dependent mechanisms 
(Webster et al., 2000). Mutations that block the DNA binding activity of HPV-16 E2 
do not impair the ability of HPV-16 E2 to induce apoptosis, while removal of both 
amino terminal domains of the E2 dimer completely blocks HPV-16 E2-induced cell 
death (Webster et al., 2000).
3.2.1. Interaction of proteins with the HPV-16 E2 transactivation domain
To identify proteins that interact with the HPV-16 E2 transactivation domain, the 
cDNA encoding amino acid 2 to 229 was PCR cloned as a BamHI-EcoRI fragment 
into the pGEX-2TK expression vector immediately upstream of the glutathione-S- 
transferase (GST) and protein kinase A  recognition site (RRASV) (Fig. 3.2.1a). To 
assess the potential significance of any interaction in transcriptional activation a 
mutant E2 fusion protein, which has amino acid 73 mutated from an isoleucine to an 
alanine, was generated by ‘splicing by overlap extension’ PCR (Fig. 3.2.1a). This 
mutant E2 protein retains the ability to support viral DNA replication but fails to 
activate transcription (Sakai et al., 1996). Internal primers containing the att to get 
mutation were designed for the primary PCR reaction. Two PCR products containing 
20 bp overlapping ends were generated and used as template for a further round of 
PCR. The second PCR reaction using primers annealing at the non-overlapping ends 
was used to amplify the I73A mutant transactivation domain as a BamHI-EcoRI 
fragment. This was again inserted into pGEX-2TK.
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The GST-E2 and GST-I73A proteins were bacterially expressed, purified with 
glutathione beads (Fig. 3.2.1b) and in vitro  P labelled using the catalytic subunit of 
protein kinase A  (Fig. 3.2.1c). Both GST-E2 and GST-I73A were expressed to 
similar levels in E. coli and appeared to be identically labelled in vitro. Equal 
amounts of the P labelled probes were then incubated with immobilized, renatured 
PalK, PalF and HeLa whole cell extracts in a Far Western blot assay to detect 
proteins that directly interact with the E2 transactivation domain. Fig. 3.2.2 shows 
that the E2 transactivation domain can directly interact with at least 12 cellular 
proteins in PalK cells and at least 8 in PalF cells. There are obvious differences in the 
pattern of cellular proteins with which E2 interacts in these two cell types. Although 
the functional significance of these interactions are unknown they may represent 
proteins involved in mediating some of the epithelial specific functions of E2. At 
least 8 cellular proteins interact with the wild type E2 transactivation domain in HeLa 
cells (an HPV-18 immortalised keratinocyte cell line). There are no obvious 
differences between the factors interacting with the I73A mutant transactivation 
domain, which is defective for transcriptional activation, compared to wild type E2. 
This result suggests that there are additional factors, necessary for transcriptional 
activation by E2, that interact with the wild type amino terminus but not with the 
173A  mutant that cannot be detected using this assay. Radiolabelled GST alone does 
not interact with any cellular factors when used as a probe under the same conditions 
(data not shown).
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3.2.2. Expression cloning to identify proteins interacting with the HPV- 
16 E2 amino terminus
To isolate cDNAs encoding cellular proteins that interact directly with the E2 amino 
terminus, an oligo-dT primed, XTriplex HeLa cDNA expression library was screened 
with bacterially expressed, 32P labelled GST-E2. XTriplex expresses each cDNA in 
all three open reading frames increasing the likelihood that a recombinant vector 
containing the target cDNA will be detected by expression screening. The XTriplex 
multiple cloning site is located within an embedded plasmid, which is flanked by 
loxP sites at the X junctions. This plasmid (pTriplEx) can be released automatically 
by cre-recombinase-mediated recombination at the loxP sites when transduced into 
bacteria expressing cre-recombinase. 2xlOb independent clones were initially 
screened (the first round of screening was carried out by W. Boner and I. Morgan). 
This number is representative of about one third of the cDNA population present in 
the library. Seven positive clones were obtained after the primary screen. The 
proteins produced in positive plaques were purified by subsequent rounds of 
screening. Amplification of positive plaques was observed with each successive 
round. After the tertiary screen the plasmid clone was excised from the positive 
phage by transduction into E.coli BM25.8 cells. Colonies were directly PCR screened 
to determine the size of the insert. The sequence of the positive cDNAs were 
compared with those available in databases using basic logic search alignment 
(BLAST).
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Clone Homology Comments
1 L31 ribosomal protein complete 
open reading frame
Human ribosomal protein mRNA with 
increased expression in colorectal 
tumours
2 Triplex cloning vector False positive
3 Two inserts of different sizes 
obtained- plaques not purified
4 Unknown cDNA Identical to clone 5
5 Unknown cDNA Identical to clone 4
6 Two inserts of different sizes 
obtained- plaques not purified
7 Partial human immunoglobulin 
superfamily 4 gene (ISFG4) 
sequence
ISFG4 spans the tumour suppressor 
gene locus llq 23 .2
Table 3.2.1. Sequence analysis of cDNAs interacting with the HPV-16 E2 
transactivation domain
The sequence analysis of cDNAs interacting with the E2 transactivation domain is 
shown in Table 3.2.1. Although, no proteins previously shown to interact with the E2 
transactivation domain, such as Spl (Li et al., 1991), TFIIB (Yao et al., 1998) and 
AMF-1 (Breiding et al., 1997) have been identified, verification that the screen has 
been successful comes from clones 4 and 5 which represent the same cDNA  
independently isolated. BLAST searches reveal that this cDNA contains no extensive 
homologies to any known genes. PCR screening shows that clones 3 and 6 contain 
inserts of different sizes (data not shown) and require subsequent screening steps to 
purify the positive plaque. Clone 2 represents the LTriplex cloning vector and is a 
false positive. This is probably due to misalignment of the nitrocellulose filter and
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the agar plate whilst picking a positive plaque in the tertiary screen. Clone 7 contains 
the partial sequence of the immunoglobulin superfamily 4 gene (ISFG4). ISFG4 is 
transcribed into a 1.6 or 4.4 kb RNA encoding a 442 amino acid protein (Gomyo et 
al., 1999). IGSF4 spans the tumour suppressor gene locus llq 23 .2 . Deletion of this 
region has been associated with cancer of the lung and breast and with neuroblastoma 
(Gomyo et al., 1999). Clone 1 encodes the human L31 ribosomal protein (accession 
number NM_000993), a component of the 60S large ribosomal subunit. The L31 
ribosomal protein cDNA and complete open reading frame is shown in figure 3.2.3. 
The signal peptide responsible for nucleolar localisation, RLSRKR, is shown 
underlined (Quaye et al., 1996).
3.2.3. L31 ribosomal protein and EIF3 (E2 interacting factor 3) bind the 
HPV-16 E2 transactivation domain in vitro
L31 was identified from a normal colon cDNA library on the basis of overexpression 
in familial adenomatous polyposis (Chester et al., 1989). L31 is also expressed at 
abnormally high levels in various haematopoietic malignant tumour cells and 
differentiation of the K562 erythroleukaemia cell line is associated with a coordinate 
decrease in expression of L31 mRNA (Lin et al., 1994; Shimbara et al., 1993). EIF3 
was isolated using a yeast two hybrid screen to identify cellular proteins that interact 
with the E2 amino terminus (Boner and Morgan, unpublished). An E2 mutant 
transactivation domain which has amino acid 39 mutated from a glutamic acid to an 
alanine (E39A) was used in this screen. The E39A mutant protein fails to activate 
transcription in yeast but still activates transcription in mammalian cells. This 
mutation abolishes the interaction between E2 and E l, the viral replication factor,
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inhibiting the ability of E2 to enhance viral DNA replication (Sakai et al., 1996). 
EIF3 encodes a truncated version of the p27BBP protein (accession number Y11435), 
which has been shown to bind the cytoplasmic domain of integrin P4 (Biffo et al.,
1997). p27BBP is induced in mast cells by allergic reaction (Cho et al., 1998) and has 
also been identified as the putative eukaryotic translation initiation factor (eIF6 ) 
based on its in vitro ability to inhibit the association between the 40S and 60S 
ribosomal subunits (Si et al., 1997). p27BBP is present in both in the nucleolus and 
associated with the nuclear matrix in all cells analysed, and is also in the cytoplasm 
enriched at the basal membrane of integrin p4 expressing cells (Sanvito et al., 1999).
GST pull down assays were performed to determine whether L31 and EIF3 directly 
interact with the wild type E2 transactivation domain in vitro. The L31 and EIF3 
cDNAs were cloned into the pGADT7 expression plasmid. L31 was PCR amplified 
as a EcoRI-XhoI fragment from pTriplEx-L31 whereas EIF3 was PCR amplified as a 
Xmal-Xhol fragment from pGADGH-EIF3. These fragments were inserted into 
pGADT7. The restriction sites chosen ensured that each protein would be expressed 
in frame under control of the T7 promoter. Bacterially expressed GST-E2, the HPV- 
16 E2 amino terminus from amino acids 2-229 fused to GST, was immobilised on 
glutathione beads and incubated with 35S labelled in vitro translated L31 and EIF3. 
Fig. 3.2.4 shows that L31 interacts with GST-E2 in vitro. Approximately 5% input 
L31 bound to GST-E2. The binding observed between L31 and GST alone was 
strongly reduced when compared to L31 and GST-E2. In vitro translated 35S labelled 
EIF3 interacts with both GST-E2 and GST at low salt concentration (Fig. 3.2.5a.). 
EIF3 was isolated using the GAL4 DNA binding domain-E2 E39A mutant amino 
terminus fusion protein as a bait in a yeast two hybrid screen. EIF3 does not interact
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with the GAL4 DNA binding domain alone (Boner and Morgan, unpublished). To 
confirm that EIF3 specifically interacts with the wild type E2 transactivation domain 
in vitro GST pull down assays were performed with increasing salt concentrations. 
Binding of GST-E2 to EIF3 was detected at high salt concentrations (800 mM NaCl) 
demonstrating a high affinity interaction while the binding of GST to EIF3 decreased 
as the salt concentration increased.
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Fig. 3.2.1. (a) Schematic representation of the GST-E2 fusion proteins. The wild 
type E2 and I73A mutant transactivation domain from amino acid 2 to 229 were PCR 
amplified as BamHI-EcoRI fragments and inserted into the pGEX-2TK expression 
vector. The expressed chimaeric proteins contain GST and a recognition site for the 
catalytic subunit of protein kinase A  fused to either the wild type or mutant E2 amino 
terminal domain, (b) Coomassie blue staining of GST fusion proteins. GST-E2 
and GST-I73A were expressed in bacteria. Equal amounts of cell lysates were 
purified with glutathione beads and separated by 10% SDS-PAGE. Proteins were 
visualised by Coomassie blue staining, (c) In vitro 32P labelled probes. The fusion 
proteins, expressed in bacteria, were radiolabelled on glutathione beads using the 
catalytic subunit of protein kinase A. Labelled proteins were eluted from the beads, 
equal volumes were separated by 10% SDS-PAGE and visualised by 
autoradiography.
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Characterisation of GST-E2 fusion proteins
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Far Western blot analysis of interactions 
between GST-E2, GST-I73A and cellular
proteins
GST E2 AD GST I73A AD
PalK PalF HeLa
m m
i
«§
A
A
PalK PalF HeLa
I
V
Fig. 3.2.2. Direct protein-protein interactions between P labelled GST-E2, 
GST-I73A and cellular proteins. 60 pg PalK, PalF and HeLa whole cell extracts 
were separated by 10% SDS-PAGE, transferred to nitrocellulose and 
denatured/renatured in 6M to 0.187M guanidine hydrochloride. Membranes were 
probed with 200 000 cpm/ml of either 32P labelled (a) GST-E2 or (b) GST-173 A and 
visualised by autoradiography.
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L31 ribosomal protein sequence analysis
1 ccgcagaatg gctcccgcaa agaagggtgg cgagaagaaa aagggccgtt 
51 ctgccatcaa cgaagtggta acccgagaat acaccatcaa cattcacaag 
101 cgcatccatg gagtgggctt caagaagcgt gcacctcggg cactcaaaga 
151 gattcggaaa tttgccatga aggagatggg aactccagat gtgcgcattg 
201 acaccaggct caacaaagct gtctgggcca aaggaataag gaatgtgcca 
251 taccgaatcc gtgtgcggct gtccagaaaa cgtaatgagg atgaagattc 
301 accaaataag ctatatactt tggttaccta tgtacctgtt accactttca 
351 aaaatctaca gacagtcaat gtggatgaga actaa
B
1 MAPAKKGGEK KKGRSAINEV VTREYTINIH KRIHGVGFKK RAPRALKEIR 
51 KFAMKEMGTP DVRIDTRLNK AVWAKGIRNV PYRIRVRLSR KRNEDEDSPN 
101 KLYTLVTYVP VTTFKNLQTV NVDEN
Fig. 3.2.3. (a) L31 complete cDNA. Start and stop codons are shown in bold, (b) 
L31 protein sequence. Amino acids are shown using the single letter code. The 
peptide sequence responsible for nucleolar localisation is underlined.
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In vitro binding of L31 and GST-E2
220 —  
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Fig. 3.2.4. E2 transactivation domain specifically interacts with L31 in vitro. 3 S
labelled in vitro translated L31 was incubated with bacterially expressed GST or 
GST-E2 immobilised on glutathione beads. 15% of the input L31 is also shown. 
Bound proteins were separated by 10% SDS-PAGE and visualised by 
autoradiography.
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In vitro binding of EIF3 and GST-E2
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Fig. 3.2.5. E2 transactivation domain specifically binds EIF3 at high salt 
concentrations. GST and GST-E2 immobilised on glutathione beads were incubated
t r
with S labelled in vitro translated EIF3 in the indicated salt concentrations. 15% 
input EIF3 is also shown. Bound proteins were separated by 10% SDS-PAGE and 
visualised by autoradiography.
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Chapter 4 -  Discussion
4.1. Cell type specific transcriptional regulation of the BPV-4 
LCR
4.1.1. Transcriptional characterisation of the BPV-4 promoter
The rate of transcription initiation by RNA polymerase II (pol II) is controlled by cis 
acting DNA elements that are bound by specific transcription factors. The basal level 
of transcription of a gene and precise site at which transcription starts is determined 
by the general transcription factors that assemble at the core promoter to form the 
pre-initiation complex (for a review see (Roeder, 1996)). Recognition elements in the 
core promoter include the TATA box, located 25 to 30 bp upstream of the start site, 
and the initiator (Inr) element which spans the start site. The rate of transcription 
initiation is regulated by proximal and distal DNA elements that are bound by 
activator or repressor proteins. In general, this involves the promotion or inhibition of 
rate limiting steps in pre-initiation complex formation or function through 
interactions with one or more of the general transcription factors. Furthermore, 
eukaryotic DNA does not exist as naked DNA in vivo but is packaged into 
chromatin. Nucleosomes, which organise the structure of chromosomal DNA, 
negatively regulating gene expression. Activation of transcription by RNA pol II 
therefore requires the modification of chromatin structure to allow access of 
transcription factors to the DNA.
The genomes of double stranded DNA viruses, such as papillomaviruses, are also 
organised in the form of nucleosomes both in the viral capsids and in the nuclei of
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infected cells (Stunkel and Bernard, 1999). The papillomavirus E2 protein, of which 
there is no human homologue, functions as the major papillomavirus encoded 
transcription factor and regulates viral gene expression through contacting 
components of the cellular transcription machinery. To study the mechanisms of E2 
mediated transcriptional regulation of mucosal epitheliotropic papillomaviruses a 
series of increasing numbers of concatamers of E2 DNA binding sites were inserted 
upstream of the BPV-4 promoter (Fig. 3.1.1.). In PalK cells, the natural target cell 
type for transformation by BPV-4, HPV-16 E2 up-regulates transcription from the 
BPV-4 promoter in an additive manner increasing as the number of E2 DNA binding 
sites increases (Fig. 3.1.3.). Such an additive effect of pairs of E2 DNA binding sites 
has been observed previously (Gauthier et al., 1991; Ham et al., 1991a; Thierry et al., 
1990). However, many transcriptional activators have been shown to function 
synergistically. Synergism is thought to be mediated by an activation domain 
contacting multiple components of the general transcription machinery. E2 has also 
been shown to synergistically activate transcription when E2 sites are inserted 
upstream from heterologous promoters (Hawley-Nelson et al., 1988). One E2 DNA  
binding site activates transcription weakly whereas two or more form a strong E2 
inducible enhancer. Multiple E2 sites inserted upstream from the yeast CYC1 
promoter has demonstrated that E2 mediated synergistic activation of transcription is 
accompanied by a modification of chromatin structure around the promoter (Lefebvre 
et al., 1997). Synergy does not result from cooperative DNA binding as E2 interacts 
with both a single and multiple copies of the strong E2 site used in this study with the 
same affinity in vivo . E2 does not upregulate transcription from the BPV-4 promoter 
in a synergistic manner when multiple E2 sites are inserted upstream raising the
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possibility that the chromatin organisation of the BPV-4 promoter may be assembled 
into a transcriptionally active conformation in the absence of E2 in PalK cells.
Mutation of the TATA box proximal E2 DNA binding sites in the BPV-4 promoter 
results in an elevated response to transcriptional upregulation by E2 (Fig. 3.1.3.). 
This is in agreement with previous studies on the BPV-4 and HPV LCRs showing 
that the E2 interaction with BS1 and BS2 mediates down regulation of transcription 
by elevated levels of E2 (Jackson and Campo, 1995; Morgan et al., 1998; 
Romanczuk et al., 1990; Steger and Corbach, 1997). The LCR of all genital HPVs 
contain a conserved SP1 site separated from E2 BS2 by 1 bp. Binding of Spl to this 
element is displaced by increasing amounts of E2 (Demeret et al., 1994; Tan et al., 
1992). A 3 bp insertion between the adjacent Spl and E2 BS2 sites allows both Spl 
and E2 to simultaneously bind the DNA resulting in the loss of E2 BS2 mediated 
repression (Dong et al., 1994a). However, there is no Spl site in the BPV-4 proximal 
promoter. As E2 can interact with TBP and E2 BS1 is separated from the TATA box 
by 3 bp it has been suggested that the interaction of E2 with BS1 displaces TBP from 
the TATA box resulting in a down-regulation of transcription initiation (Dostatni et 
al., 1991; Tan et al., 1994). Band shift assays suggest that E2 and purified human 
TBP cannot bind E2 BS1 and the TATA box simultaneously but when the distance 
between the E2 sites and TATA box is increased these two factors interact 
cooperatively with the DNA. In addition to steric hindrance of TBP binding E2 has 
also been suggested to function as an active repressor under certain conditions by 
preventing the assembly of a functional pre-initiation complex (Dostatni et al., 1991). 
In vitro experiments using an E2 dependent cell free transcription system 
reconstituted with purified factors demonstrates that HPV-11 E2 represses
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transcription by directly targeting components of the basal transcription machinery 
after TBP has bound the DNA (Hou et al., 2000). Repression can be alleviated by 
pre-incubation of a minimal TFIID-TFIIB-RNA pol H-TFIIF pre-initiation complex 
but not by pre-incubation with TBP or TFIID alone.
E2 upregulates transcription efficiently from the BPV-4 LCR in PalK cells but does 
so only poorly in PalF (Morgan et al., 1998). This epithelial specific response to E2 is 
retained by the BPV-4 promoter region as over a range of increasing HPV-16 E2 
concentrations the PV 6E2 construct is not transactivated more than two-fold in 
fibroblasts (Fig. 3.1.4a.). Mutation of the TATA box proximal E2 sites to prevent E2 
binding does not affect the epithelial specific response of the BPV-4 promoter to E2 
(Fig. 3.1.4 b,c.). However, the competition between E2 and cellular factors may 
represent an important control point in the regulation of viral gene expression during 
the papillomavirus life cycle. Differential effects on transcription would be observed 
depending on the concentration of E2 in the cell. Cellular nuclear factors have been 
demonstrated to produce DNAse I footprints over E2 BS2 and BS3 in the BPV-4 
LCR. Although the factor interacting with E2 BS2 remains to be characterised, the 
cellular factor PEBP2 binds E2 BS3 and upregulates BPV-4 LCR promoter activity 
(Jackson and Campo, 1995). The PEBP2 transcription factor family, which includes 
the human AML1 gene, are heterodimers composed of two groups of subunits, a  and 
|3. The a  subunit is expressed in a cell type specific manner while the p subunit 
appears to be ubiquitous (Ogawa et al., 1993). The PEBP2 family appears to be 
involved in developmental regulation and differentiation, suggesting that PEBP2 may 
be one of the cellular factors that couple the BPV-4 life cycle to keratinocyte
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differentiation. Unknown positively acting cellular factors have also been shown to 
bind E2 BS1 and BS3 within the HPV-16 LCR (Lewis et al., 1999).
Failure of E2 to function in fibroblasts is not due to lack of expression, as western 
blot analysis shows that E2 is being expressed, under control of the cytomeglovirus 
promoter, at similar levels as a doublet of approximately 42 kDa in both PalK and 
PalF cells (Fig. 3.1.5). This suggests that HPV-16 E2 is post-translationally modified, 
for example, by phosphorylation or glycosylation, when expressed in PalK and PalF 
cells. BPV-1 E2 is phosphorylated at two major sites, ser 298 and 301, located in the 
hinge region (McBride et al., 1989a). Phosphorylation at these sites has been 
implicated in long term episomal maintenance of BPV-1 viral genomes (Lehman et 
al., 1997). Also, BPV-1 E2 proteins with a serine to alanine mutation at position 301 
have an increased half life compared with wild type E2. It is suggested that 
phosphorylation at this position regulates E2 protein levels by targeting E2 for 
ubiquitin mediated degradation by the proteosome (Bastien and McBride, 2000). 
HPV-16 E2, which is a smaller protein than full length BPV-1 E2 due to a shorter 
hinge, is phosphorylated when expressed from recombinant baculoviruses in insect 
cells (Sanders et al., 1995). It therefore remains possible that post-translational 
modification of E2 may facilitate the interaction between E2 and cellular proteins in 
a cell type dependent manner resulting in an increased transcriptional activation in 
epithelial cells.
Chimaeric E2 molecules were used to assess the contribution of the E2 functional 
domains to epithelial specificity. It has been suggested that the E2 transactivation 
domain interacts with a specific cellular protein(s) to restrict activation of the BPV-4
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LCR to epithelial cells as a VP16-E2 chimaera upregulates transcription from the 
BPV-4 LCR in a cell type independent manner (Morgan et al., 1998). However, the 
BPV-4 promoter shows an enhanced epithelial response to activation, not only by 
HPV-16 E2 (Fig. 3.1.4.) and BPV-1 E2 (Fig. 3.1.6a.), but also by VP16-E2 (Fig. 
3.1.6b.) and VP16-LexA (Fig. 3.1.7b.). The difference in response of the BPV-4 LCR 
and BPV-4 promoter to activation by VP16-E2 can be explained by the observation 
that the BPV-4 promoter constructs have similar background transcriptional activity 
in PalK and PalF cells in the absence of E2. The full length LCR is approximately 
40-fold more active in keratinocytes than fibroblasts in the absence of E2 due to the 
presence of the epithelial specific enhancer making the interpretation of changes in 
fold activation more complex. The enhanced epithelial response of the BPV-4 LCR 
to E2 is therefore more of a property of the BPV-4 promoter region which responds 
better to transcriptional activators in epithelial cells. This enhanced activation in 
epithelial cells is a promoter specific effect as the tk promoter shows no such 
epithelial preference to activation by VP16-E2 (Fig. 3.1.8b.) and HPV-16 E2 (Fig. 
3.1.9.).
Like many other transcriptional activators E2 interacts with TBP (Rank and Lambert, 
1995). However, the ability of activators to stimulate TBP recruitment to the 
promoter, the first step in the assembly of the pre-initiation complex, is a tightly 
controlled cooperative process involving multiple transcription factors (Li et al., 
1999). TBP overexpression upregulates basal activity and potentiates E2 mediated 
activation of the PV2 promoter preferentially in PalK cells when compared with PalF 
(Fig. 3.1.10.). It is therefore possible that TBP is recruited more efficiently to the 
BPV-4 promoter in the absence of E2 in keratinocytes than in fibroblasts. These
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results also suggest that E2 and TBP either cooperate with positively acting BPV-4 
promoter factors to activate transcription preferentially in keratinocytes or that 
negatively acting factors, such as Drl which directly associates with TBP (for a 
review see (Maldonado et al., 1999)), block the transcriptional response to E2 in 
fibroblasts. As the basal and activated PV2 promoter activity are both upregulated by 
TBP overexpression these results are consistent with the hypothesis that the E2 
transactivation domain functions by affecting a step in the assembly of the pre­
initiation complex after TBP has bound the DNA (Steger et al., 1995). In agreement 
with previous studies demonstrating that cooperativity between E2 and TBP depends 
on core promoter structure (Ham et al., 1994), the tk promoter shows a different 
response than the PV2 promoter to TBP overexpression (Fig. 3.1.11.). 
Overexpression of TBP increases E2 mediated activation of the tk promoter in PalK 
cells while in PalF low amounts of TBP increase the ability of E2 to activate 
transcription while at high levels E2 mediated transcription is downregulated. TBP 
overexpression has a moderate effect on basal tk promoter activity in both cell types. 
The tk promoter, which is activated by E2 to similar levels in both PalK and PalF 
cells, does not show any significant cell type preference to TBP overexpression. 
Therefore, it could be suggested that the ability of a promoter to respond to TBP 
overexpression may reflect the differential response to upstream activators.
4.1.2. Possible mechanisms of cell type specific gene expression
The 127 bp BPV-4 promoter region contains the TATA box and presumably as yet 
unidentified upstream promoter elements but does not have the putative initiator 
element identified in the BPV-4 LCR. The enhanced epithelial response of the BPV-
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4 promoter may be determined by DNA bound positively acting proximal promoter 
factors that are either cell type specific, differentially expressed, or modified in a cell 
type dependent manner. Proximal promoter factors conferring cell type specificity 
have been described previously, for example, hepatic nuclear factor 1 (HNF-1), a 
liver specific transcription factor, regulates liver specific expression of the albumen 
promoter. Also, epithelial specific functions of transcription factors interacting with 
HPV promoter regions, such as NF1-C/NF1-X and Spl/Sp3, also exist (Apt et al., 
1994; Apt et al., 1996). Cell type specific gene expression can also be determined by 
cell type specific components of the basal transcription machinery assembled at the 
TATA box or by cell type specific adaptor proteins mediating the interaction between 
the basal machinery and upstream factors. An involvement of the core TATA box 
region in cell type specific transcription has been described for melanocyte specific 
expression of the human tyrosinase promoter (Bentley et al., 1994) and brain specific 
transcription of the mouse myelin basic protein promoter (Tamura et al., 1990). Also, 
a TBP associated factor highly expressed in B lymphocytes, TAFn105, has been 
identified (Dikstein et al., 1996). In addition to positively acting factors, sequence 
specific transcriptional repressors may play a role in restricting the expression of 
genes to specific cell types. For example, MyoD and E12 are basic helix loop helix 
proteins that recognise similar E-box motifs in the regulatory regions of target genes. 
MyoD is a muscle-specific transcriptional activator while E12 is a B-cell activator. 
The immunoglobulin heavy (IgH) chain enhancer, which contains the same E-boxes 
as the myogenic muscle creatine kinase (MCK) enhancer, is activated by E l 2 but not 
by MyoD. The IgH enhancer is able to discriminate between MyoD and E l2 through 
a cis acting negative element flanking one of the E-boxes that specifically targets 
MyoD. This suggests that MyoD only activates myogenic genes, not only because its
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expression is restricted to muscle, but also because non-muscle enhancers that 
contain E-boxes also contain negative elements that prevent MyoD activity 
(Weintraub et al., 1994).
4.1.3. The upstream BPV-4 promoter region is an important determinant 
of cell type specific transcription
E2 responsive chimaeric promoters, made by exchanging regions of the heterologous 
tk promoter with the corresponding regions in the BPV-4 promoter, suggest that the 
upstream BPV-4 promoter region determines the cell type selective response of this 
promoter to upstream activators. The lcr/tk hybrid, the upstream BPV-4 promoter 
sequence from nucleotide 184-279 fused to the core tk TATA box containing region, 
retains the enhanced epithelial response of the BPV-4 promoter to activation by E2 
and VP16-E2 (Fig. 3.1.13). The tk/lcr hybrid, the upstream tk promoter sequence 
containing the Spl element fused to the core BPV-4 TATA region from nucleotide 
279-310, shows no epithelial preference to activation by E2 and VP16-E2 (Fig. 
3.1.14). Deletion analysis of the BPV-4 promoter confirms a role for the upstream 
promoter region in mediating epithelial specificity. The results identify two repressor 
elements that are, at least in part, responsible for the differential response of the 
BPV-4 promoter to upstream activators in fibroblasts and keratinocytes (Fig. 3.1.16 
and Table 3.1.1). Database searches reveal that these elements show no homology to 
any of the published transcription factor binding sites. The PRE-1 region spans the 
TATA box proximal E2 binding sites that have been mutated to prevent E2 binding. 
These mutations do not affect the epithelial specific response of the BPV-4 promoter 
to E2 (Fig. 3.1.4). The PRE-2 element is conserved in position and sequence in the 
related mucosal epitheliotropic papillomaviruses, BPV-3 and BPV-6, suggesting
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functional significance (Fig. 3.1.18). A  silencer element in roughly the same position 
as PRE-2 in the HPV-16 LCR has been identified (O'Connor et al., 1998). This 
element, which binds the transcriptional repressor CCAAT displacement protein 
(CDP/Cut), represses the transcriptional activity of the HPV-16 enhancer. 
Subsequently, it has been shown that six other genital HPV types contain binding 
sites for CDP/Cut (O'Connor et al., 2000). Also, CDP/Cut is highly expressed in 
basal epithelial cells but not in differentiated primary keratinocytes suggesting that it 
is involved in coupling HPV gene expression to epithelial cell differentiation (Ai et 
al., 1999).
4.1.4. Analysis of the BPV-4 TATA region
Several lines of evidence suggest that the BPV-4 and tk TATA regions are 
functionally distinct. The overall levels of response of the lcr/tk hybrid are reduced 
compared with the PV2 promoter (Fig. 3.1.13.) while the levels of activation of the 
tk/lcr hybrid are higher than that of the tk promoter (Fig. 3.1.14.). This suggests that 
the BPV-4 TATA region is stronger than that of the tk promoter. Consistent with 
this, an in vitro transcription study using promoters containing different TATA 
sequences in the context of the adenovirus major late promoter has demonstrated that 
the TATATAA sequence, which corresponds to the BPV-4 TATA box, represents a 
strong TATA sequence. TBP binds this sequence with high affinity forming a stable 
TBP-TATA complex with a relatively slow rate of dissociation. It was suggested that 
the corresponding high rate of transcription initiation from the TATATAA 
containing promoter was due to the conformation of the TBP-TATA complex 
favouring recruitment of the general transcription factors. The interaction of TBP
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with a weak TATA sequence such as TATTAAA, which differs only from the tk 
TATA sequence by the 3 ’ A, forms a complex with a significantly faster rate of 
dissociation. Transcription from the TATTAAA containing promoter was less 
efficient and it was suggested that the TBP-TATA complex adopted a different 
conformation as measured by footprinting studies and DNA bend (Hoopes et al.,
1998).
Also, a minimal BPV-4 TATA promoter containing neither an initiator element nor a 
binding site for an upstream factor is sufficient to support activated transcription by 
E2 (Fig. 3.1.16. and Table 3.1.1). In contrast, E2 requires the co-operation of at least 
one additional DNA binding proximal promoter factor, such as Spl, for the 
activation of a minimal tk TATA box promoter (Ham et al., 1991a; Ushikai et al., 
1994). This suggests that the general transcription machinery assembled at the BPV-4 
and tk TATA boxes contain distinct coactivator complexes. Quanitative differences 
between the factors interacting with the HPV-16 and SV40 TATA elements and 
surrounding sequences have also been observed (Smits et al., 1993). The HPV-16 
enhancer-promoter is virtually inactive in normal human diploid fibroblasts, but 
active in human fibroblasts with a deletion in the short arm of one chromosome 11 
(del-11 cells). Del-11 cells are susceptible to transformation by HPV-16. Mutation of 
the HPV-16 TATAAAA box to the SV40 TATTTAT sequence reduces the activity 
of the HPV-16 enhancer-promoter in del-11 cells. DNA-protein complexes formed 
with an HPV-16 promoter fragment are quantitatively different in del-11 cells and 
diploid fibroblasts. This difference disappears upon mutation of the HPV-16 TATA 
to the SV40 TATA sequence indicating specificity of the HPV-16 TATA box
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sequence. This raises the possibility that mucosal epitheliotropic papillomavirus 
promoter regions may be recognised by a distinct subset of TFIID complexes.
Deletion analysis of the BPV-4 promoter also demonstrates that the 8- to 9-fold 
enhanced epithelial response of the BPV-4 promoter to activation by E2 has been 
reduced to two-fold with a minimal BPV-4 TATA containing promoter. This 
suggests that the BPV-4 TATA box and surrounding sequence and/or the E2 protein 
may also play an important role in determining cell type specific transcription. This is 
in contrast to the results of the tk/lcr hybrid promoter which is activated in a cell type 
independent manner by E2. However, the high level of activation of this promoter 
due to the functional co-operation of E2 and Spl may mask any cell type specificity. 
Increasing concentrations of VP16-E2, which upregulate transcription from the 
minimal BPV-4 TATA containing promoter preferentially in fibroblasts, suggests 
that the BPV-4 TATA region does not contribute towards cell type specific 
transcription. This result also confirms an important role for the promoter repressor 
elements in mediating the differential response of the BPV-4 promoter to upstream 
activators in fibroblasts and keratinocytes. However, low levels of E2 activate 
transcription from the minimal BPV-4 TATA containing promoter to similar levels 
in both cell types while at high levels transcription is downregulated in fibroblasts 
but remains elevated in keratinocytes. As E2 is expressed to similar levels in both 
PalK and PalF cells this suggests that certain cell type specific coactivators 
assembled at the BPV-4 TATA region specifically interact with the E2 
transactivation domain enabling E2 to activate transcription at elevated levels in 
keratinocytes.
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The involvement of differential interactions between factors bound to specific 
upstream elements and components of the basal machinery in mediating cell type 
specific transcription has been described previously. A  muscle specific enhancer was 
shown to function with the core promoter elements of the myoglobin gene but when 
the TATA box sequence was changed to that of the SV40 promoter responsiveness to 
the muscle specific enhancer was abolished (Wefald et al., 1990). Also, the B cell 
enriched TFIID subunit, TAFnl05, is involved in Oct dependent B cell specific 
transcriptional activation. The B cell specific cofactor, OCA B, has been shown to 
form a molecular bridge between both the ubiquitous Oct-1 and the B cell specific 
Oct-2 proteins and TAFnl05 (Wolstein et al., 2000).
4.1.5. Characterisation of the papillomavirus promoter repressor 
elements
The papillomavirus repressor elements, PRE-1 and PRE-2, function as autonomous 
cis acting elements to repress the basal activity of the SV40 promoter in a cell type 
independent manner (Fig. 3.1.19 and Fig. 3.1.20.). Band shift assays demonstrate that 
PRE-2 binds a specific protein complex in both PalK and PalF cells (Fig. 3.1.21.). 
However, no reproducible specific complex binding to PRE-1 could be detected by 
EMSA analysis. This may be due to the sensitivity and conditions used in the band 
shift assay. In vitro footprinting of the BPV-4 LCR using an immortalised fibroblast 
nuclear extract has shown previously that the PRE-2 region contains a DNA binding 
site for a potential transcription factor (Jackson and Campo, 1991). Base pair 
substitutions in this footprint confirm that these nucleotides are necessary for 
sequence specific binding of a nuclear protein in PalK and PalF cells (Fig. 3.1.22). 
PRE-2 mutants that do not compete for binding in band shift assays do not repress
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transcription when multimerised upstream of the SV40 promoter (Fig. 3.1.23). Non­
binding mutations introduced into the BPV-4 promoter result in a differential 
increase in response to transcriptional activation by E2 in fibroblasts and 
keratinocytes (Fig. 3.1.24). UV crosslinking using a BrdU substituted PRE-2 motif 
demonstrates that the PRE-2 binding form of the protein complex has a molecular 
weight of approximately 50 kDa in both PalK and PalF cells (Fig. 3.1.25). Of the 
transcriptional repressors known to bind papillomavirus promoters, such as YY1 
(Bauknecht et al., 1992), C/EBPp (Bauknecht and Shi, 1998), Sp3 (Apt et al., 1996) 
and CDP/Cut (O'Connor et al., 2000), none of them are this size. Taken together, 
these results suggest that the PRE-2 binding protein is a novel transcriptional 
repressor and regulator of mucosal epitheliotropic papillomavirus transcription. The 
results also suggest that the context of the repressor elements within the BPV-4 
promoter is important for mediating cell type selectivity. A  model could therefore be 
proposed in which the interplay between upstream bound activators, repressor 
proteins interacting with the PRE elements, and the basal transcription machinery 
assembled at the BPV-4 TATA region, determines the differential response of the 
BPV-4 promoter in fibroblasts and keratinocytes.
4.1.6. Mechanisms of transcriptional repression
In general, transcriptional repressors can work either passively to antagonise activator 
function or actively to target components of the general transcription machinery in 
such a way as to decrease the frequency of transcriptional initiation (for a review see 
(Ogbourne and Antalis, 1998)). Negative regulatory elements that direct a passive 
repression mechanism are position dependent within the context of the native 
promoter. Passive repressors generally function by displacing the binding of a
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positively acting factor, either by interference of overlapping or neighbouring 
activator binding sites, such as E2 mediated repression of the HPV-16 promoter by 
displacing Spl from a proximal promoter element (Tan et al., 1992), or by direct 
competition for the same binding site, for example, the Spl/Sp3 antagonism (Apt et 
al., 1996). In certain cases passive repressors have also been shown to function by 
masking the transactivation domain of a positively acting factor or by titrating out 
limiting cofactors necessary for activator function. For example, the MDM2 
oncoprotein can inhibit the ability of p53 to stimulate transcription by binding p53 
and disrupting interactions with the basal transcription machinery (Oliner et al., 
1993). Also, the glucocorticoid receptor has been shown to inhibit AP-1 
transcriptional activity through competition for limiting amounts of p300/CBP in 
within the cell (Kamei et al., 1996). Active repressors have been shown to function, 
with or without the recruitment of a corepressor, to inhibit different steps during pre­
initiation complex assembly (for a review see (Maldonado et al., 1999)). Examples 
include the ability of pRb to repress E2F mediated transcriptional activation by 
targeting the recruitment of TFIIA and TFIID to the promoter (Ross et al., 1999), and 
the repression of transcription by the unliganded thyroid hormone receptor a  by 
directly binding TBP (Fondell et al., 1996).
The protein interacting with the PRE-2 element does not simply displace the binding 
of a positively acting factor as PRE-2 can repress the basal activity of the SV40 
promoter out of context of the BPV-4 LCR. The extent of repression does not depend 
on the cell type or on the orientation of the PRE-2 element. This suggests that the 
PRE-2 binding factor directs an active repression mechanism through interacting 
with a component of the general transcription machinery. However, it is also possible
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that the PRE-2 binding protein functions through distinct promoter specific 
mechanisms. In contrast to the SV40 promoter, deletion of the PRE-2 region of the 
BPV-4 LCR has no significant effect on basal promoter activity. This suggests that 
the PRE-2 binding protein is repressing activator dependent transcription, perhaps by 
disrupting the interaction between the E2 transactivation domain and the basal 
transcription machinery assembled at the BPV-4 TATA region.
The chromatin organisation of the HPV-16 and -1 8  genomes also suggest important 
regulatory roles of nucleosomes during the viral life cycle (Stunkel and Bernard, 
1999; Stunkel et al., 2000). Two nucleosomes are precisely positioned on the HPV- 
16 LCR: one overlaps the centre of the epithelial specific enhancer, while a second 
nucleosome overlaps the proximal promoter region. The HPV-18 LCR shows 
specific assembly of a nucleosome over the replication origin and the proximal 
promoter, positioned approximately 90 bp upstream of the homologous region of the 
HPV-16 LCR. There is accumulating evidence suggesting a link between 
papillomavirus transcription and chromatin modification. E2 has been shown to 
interact with the transcriptional coactivator p300/CBP (Lee et al., 2000). p300 has 
intrinsic histone acetyltransferase (HAT) activity and has been implicated in 
chromatin remodelling (Bannister and Kouzarides, 1996). Acetylase activity 
stimulates transcription by weakening the interaction between the highly positively 
charged tails of histones H3 and H4 and the phosphate backbone of DNA within the 
nucleosomes. Conversely, a number of transcriptional repressors have been shown to 
recruit histone deacetylase activity as part of multi-protein complexes. Deacetylation 
of histone tails promotes nucleosome assembly thereby inhibiting the ability of 
transcription factors to gain access to the DNA. Using an epithelial raft culture
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system, Trichostatin A  (TSA), a specific inhibitor of histone deacetylase activity, has 
been shown to upregulate the HPV-11 LCR promoter predominantly in the basal 
layers of the epithelium (Zhao et al., 1999). This effect was promoter specific but 
showed no cell type specificity. This suggests that histone deacetylases contribute 
towards maintaining the relatively low level of HPV gene expression in the lower 
layers of the epithelium. Also, the differentiation specific factor, CDP/Cut, binds to a 
silencer element just upstream of the promoter proximal positioned nucleosome in 
the HPV-16 LCR and represses transcription by a histone mediated mechanism 
(O'Connor et al., 2000). It therefore seems possible that PRE-2 may function by 
recruiting histone deacetylases to repress transcription.
The importance of cellular repressors of papillomavirus transcription has also been 
highlighted by a of number studies. It has been proposed that a class of cellular genes 
called cellular interference factors (CIF) exist in normal cells (zur Hausen, 1989). 
The inactivation of these genes, which negatively regulate viral gene expression, is 
necessary to release the papillomavirus transforming genes from cellular repression 
in vivo, contributing to the development of carcinoma. Consistent with this, studies 
have shown that HPV positive primary tumours or metastases contain episomal 
HPV-16 DNA with a prevalence of mutated or deleted YY1 transcription factor 
binding sites (Dong et al., 1994b; May et al., 1994). Negative regulators of 
papillomavirus transcription may therefore play an important role, not only in 
limiting expression of viral proteins to the host cell type, but also in regulating the 
appropiate levels of viral gene expression during the differentiation dependent viral 
life cycle.
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4.1.7. Future Work
To further understand the function of the PRE-2 binding factor (PBF-2) in 
transcriptional regulation it will be necessary to first isolate a cDNA clone. UV  
crosslinking has demonstrated that the PRE-2 element interacts with a major protein 
species of approximately 50 kDa. However, due to the presence of a minor species 
just above the 50 kDa band it is not clear whether the active DNA binding form of 
the protein is a monomer or higher order structure or requires a post-translational 
modification to bind its target site. South Western blot analysis would initially be 
performed to determine the subunit composition and the method of purification of 
PBF-2. A  successful South Western blot would allow the direct screening of an 
expression library using radiolabelled PRE-2 to isolate the cDNA clone encoding 
PBF-2. The cDNA clone may be incomplete as only sufficient information to 
generate a complete DNA binding domain is needed for a positive screen. A  full 
length clone would be isolated either using EST database searches or further 
screening steps using the initial clone as a hybridisation probe. Alternatively, affinity 
chromatography using a biotinylated PRE-2 element immobilised onto a streptavidin 
column would be used to purify PBF-2 to homogeneity. Increasing salt 
concentrations would be used to elute the protein and the different fractions would 
be monitored for sequence specific DNA binding using the band shift assay. The 
partial DNA sequence would be determined and used to identify a full length cDNA  
clone by screening an expression library with the appropiate oligonucleotides.
Once the full length clone has been isolated it would be inserted into the appropiate 
vectors for further biochemical and functional analysis. Initially, band shift assays 
and UV crosslinking using in vitro translated PBF-2 and radiolabelled PRE-2 would
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be carried out to determine that the DNA binding specificity of the isolated clone 
mimics that of the detected cellular protein. Overexpression studies, using a suitable 
mammalian cell line that either lacks or has low endogenous levels of PBF-2, would 
also be performed to demonstrate that PBF-2 functions as a transcriptional repressor. 
These studies would aim to show both repression of basal SV40 promoter activity 
and repression of the transcriptional response of the BPV-4 promoter to E2. The 
minimal domain required for transcriptional repression would also be mapped by 
constructing PBF-2 deletion mutants.
Eventually, the isolation of factors interacting with the PBF-2 repression domain 
would allow the mechanism of repression to be elucidated, whether this is through a 
direct interaction with the basal machinery, or via a co-repressor, or by recruitment of 
histone deacetylase activity. Initially, overexpression studies in the presence of TSA  
would be used to determine whether PBF-2 represses transcription from the SV40 
and BPV-4 promoters by a histone mediated mechanism. As TSA is toxic and may 
have non-specific effects on transcription co-transfection of HDAC expression 
vectors in the functional assays would be used to assess specificity. In vitro and in 
vivo assays using GST-PBF-2 fusion proteins and tagged PBF-2 constructs would 
then be performed to try and detect a specific interaction with a HDAC. Interactions 
between PBF-2 and components of the basal transcription machinery would first be 
tested using GST-PBF-2 proteins and in vitro translated general factors in a pull 
down assay. Mutations in the PBF-2 repression domain that abolish binding would be 
identified and tested in the functional assays to determine the effect on repression. 
Ideally, PRE-2 mediated repression of basal promoter activity would also be 
reconstituted using a cell free in vitro transcription system. By staging pre-initiation
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complex assembly in vitro the targets of the PBF-2 repression domain could be 
identified and a detailed biochemical analysis could be performed.
These experiments would extend on the functional and biochemical analysis of the 
PRE-2 silencer element identified in the BPV-4 promoter. They would lead to the 
identification and characterisation of an apparently novel transcriptional repressor 
and regulator of mucosal epitheliotropic papillomavirus transcription.
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4 .2 . In teraction  o f  ce llu la r  p r o te in s  w ith  th e  E2 a m in o  
te r m in u s
4.2.1. Detection and identification of E2 interacting proteins
The papillomavirus E2 protein is the major regulator of viral transcription and is 
essential for viral DNA replication (for a review see (Desaintes and Demeret, 
1996)). When overexpressed E2 can disrupt cellular growth control in certain HPV 
transformed and non-HPV transformed cell lines (see (Massimi et al., 1999) and 
references therein). A  chimaeric E2 protein in which the N-terminal E2 
transactivation domain is fused to the GAL4 or LexA DNA binding domain 
efficiently activates transcription in yeast and mammalian cells (Breiding et al., 1996; 
Winokur and McBride, 1996). This indicates that the E2 N-terminus is able to 
function independently of the C-terminal DNA binding and dimerisation domain to 
activate transcription. By analogy to other acidic transactivators the E2 
transactivation domain is believed to function, at least in part, through contacting 
components of the cellular transcription machinery and affecting the formation 
and/or stability of the pre-initiation complex. E2 has previously been shown to 
interact with the cellular transcription factors TBP (Rank and Lambert, 1995), TFIIB 
(Yao et al., 1998), Sp l (Li et al., 1991), p300 and AMF-1 (Breiding et al., 1997). 
However, as E2 can function in a core promoter specific manner it is likely that there 
are additional, as yet unidentified, E2 interacting cellular factors. For example, E2 
efficiently activates a minimal BPV-4 TATA promoter containing neither an initiator 
element nor a binding site for an upstream factor (Fig. 3.1.16.) but is unable to 
activate a minimal tk TATA box promoter (Ham et al., 1991a). Also, E2 mutant 
proteins exist that activate transcription in mammalian cells but fail to do so in yeast
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(Breiding et al., 1996), suggesting the presence of additional mammalian specific 
transcriptional regulatory pathways. In order to gain a greater understanding of how 
E2 regulates transcription the additional cellular proteins with which it interacts must 
therefore be identified.
Far Western blot analysis using a GST-E2 fusion protein to probe PalK, PalF and 
HeLa whole cell extracts demonstrates that the E2 amino terminus interacts with at 
least 12 cellular proteins in PalK and at least 8 in PalF cells (Fig. 3.2.2.). There are 
obvious differences in the pattern of interacting proteins in PalK and PalF cells. 
Although the functional significance of these interactions are unknown and the 
proteins remain to be characterised they may represent proteins involved in mediating 
some of the epithelial specific functions of E2. Consistent with this, Fig. 3.1.17. 
suggests that certain cell type specific transcriptional co-activators may interact with 
the E2 transactivation domain in keratinocytes and not in fibroblasts enabling E2 to 
activate transcription at elevated levels in epithelial cells. There are no obvious 
differences between the factors interacting with wild type E2 and a mutant 
transactivation domain which has amino acid 73 mutated from an isoleucine to an 
alanine. This mutant protein retains the ability to support viral DNA replication but 
fails to activate transcription (Ferguson and Botchan, 1996; Sakai et al., 1996). The 
crystal structure of the E2 amino terminus showed that amino acid 73 is exposed to 
the solvent indicating that it might be involved in intermolecular interactions (Antson 
et al., 2000). Taken together, these results suggest that there are additional cellular 
factors, necessary for transcriptional activation by E2, that interact with the wild type 
transactivation domain but not with the I73A mutant, that cannot be detected using 
this assay. The detection of direct protein-protein interactions in HeLa cells by Far
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Western blotting demonstrates that the cDNAs encoding E2 interacting proteins can 
be isolated by expression screening of a HeLa cDNA library using radiolabelled 
GST-E2. In contrast, a traditional yeast two hybrid screen cannot be used to identify 
E2 interacting proteins as the wild type E2 transactivation domain activates 
transcription in yeast.
Seven independent cDNAs encoding polypeptides interacting with the E2 amino 
terminus were isolated by expression screening (Table 3.2.1.). However, no proteins 
previously shown to interact with E2 were identified. This probably reflects 
differences in the assays used to detect these interactions. Clone 2 represents a false 
positive probably due to misalignment of the nitrocellulose filter and agar plate 
whilst picking a positive plaque in the tertiary screen. Clones 3 and 6 were not 
sufficiently purified after three rounds of screening and clone 7 contains the partial 
sequence of the ISFG-4 gene. These four clones were not chosen for further analysis. 
Clones 4 and 5 represent the same cDNA independently isolated. This cDNA was 
approximately 1.5 kb in length and showed no extensive homologies to any known 
genes. Analysis of the predicted amino acid sequence showed multiple stop codons in 
all three open reading frames (data not shown). This suggests that the potential E2 
interacting polypeptide has a low molecular weight. Attempts to in vitro transcribe 
and translate a 35S labelled polypeptide from this cDNA in all three open reading 
frames were unsuccessful. However, failure to detect a product may be due to a lack 
of 35S incorporation because of a low level of methionine residues in the encoded 
small polypeptide.
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Clone 1 encodes the full length human L31 ribosomal protein. GST pull down assays 
demonstrate that in vitro translated L31 specifically interacts with the E2 amino 
terminus (Fig. 3.2.4). Immunofluorescence has demonstrated that L31 is targeted to 
the nucleolus, the site of ribosomal RNA synthesis and ribosome assembly (Quaye et 
al., 1996). Due to the high level of conservation with the yeast L34 protein L31 is 
believed to play an important role in ribosome biosynthesis (Nobori et al., 1989). 
After processing and targeting of the ribosomal subunits to the cytoplasm the L31 
protein is believed to form a component of the mature 60S large ribosomal subunit. It 
is also suggested that L31 might be able to interact with nucleic acid due an 
unusually high content of basic amino acids compared with other ribosomal proteins.
Ribosomal proteins are potential mediators of growth regulation as rapidly 
proliferating cells with a high protein synthesising activity have a high ribosome 
content. Indeed, L31 is expressed at abnormally high levels in colorectal tumours and 
various haematopoietic malignant tumour cells (Chester et al., 1989; Shimbara et al., 
1993). Also, the in vitro terminal differentiation of several immature leukaemia cell 
lines is associated with a decrease in expression of L31 mRNA (Lin et al., 1994). It is 
therefore possible that the interaction of E2 with L31 may be involved in E2 
mediated disruption of cellular growth control. It is also possible that L31 may 
function downstream of transcription initiation to alter the levels of viral gene 
expression.
Papillomaviruses exploit several post-transcriptional levels of regulation during the 
viral life cycle such as the differentiation specific alternative splicing of BPV-1 late 
mRNAs (Barksdale and Baker, 1993). Functional interactions between E2 and RNA
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binding proteins have been demonstrated previously. BPV-1 E2 can bind the product 
of the survival motor neuron (SMN) gene (Strasswimmer et al., 1999). SMN is the 
determining gene for spinal muscular atrophy, an inherited neuromuscular disease. 
The SMN protein functions in the distribution and regeneration of the pre-mRNA 
splicing machinery and in snRNA biosynthesis. When tethered to a DNA binding 
domain SMN does not activate transcription. It is therefore suggested that the 
interaction between E2 and SMN stimulates viral gene expression through an RNA 
transport or processing step. Also, the arginine/serine rich hinge of HPV-5 E2 has 
been shown to interact with a set of cellular splicing factors including 4 SR proteins 
which are involved in the modulation of splice site choice and 2 snRNP associated 
proteins (Lai et al., 1999). snRNPs are required for RNA processing. Functional 
assays have demonstrated that the HPV-5 E2 hinge can facilitate the splicing of a 
primary transcript transactivated by E2 itself in a distant dependent manner. This 
work suggested that HPV-5 E2 can mechanistically couple transcription and pre- 
mRNA splicing. It also seems possible that E2 may be able to control the nuclear 
export of processed RNA or even translation of the protein.
The interaction between E2 and EIF3 was also characterised. EIF3 was isolated using 
a yeast two hybrid screen with a mutant E2 amino terminus that activates 
transcription in mammalian cells but fails to do so in yeast (Boner and Morgan, 
unpublished). Fig. 3.2.5. shows that EIF3 specifically interacts with the wild type E2 
transactivation domain at high salt concentrations in vitro. EIF3 has many interesting 
characteristics that suggest it might be a physiologically relevant target for E2. EIF3 
encodes a truncated version of p27BBP, a protein highly expressed in epithelial cells, 
which was initially isolated based on its ability to bind the cytoplasmic domain of
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integrin P4 (Biffo et al., 1997). In cells expressing integrin P4, p27BBP is present both 
in the cytoplasm enriched at the basal membrane and in the nucleus, present in the 
nucleolus and associated with the nuclear matrix (Sanvito et al., 1999). Integrins are 
involved in the control of cell growth, apoptosis and differentiation through the 
recruitment of several signal transduction and adaptor molecules. Recently, the JAB- 
1 (jun activation domain binding protein 1 ) co-activator for c-jun transcription has 
been shown to interact with the P2 subunit of the integrin LFA-1. JAB-1 is found in 
two pools in the cell: one cytoplasmic pool and one in the nucleus. Binding of ligand 
to LFA-1 increases the JAB-1 nuclear pool resulting in enhanced DNA binding 
activity of c-jun containing AP-1 complexes and an increase in transcription from an 
AP-1 dependent promoter (Bianchi et al., 2000). By analogy, EIF3 may represent a 
co-factor for E2 mediated transcriptional activation.
However, it is also proposed that P4 independent functions of p27BBP also exist as 
p27BBP is present in the nucleolus and associated with the nuclear matrix in the 
absence of p4 (Sanvito et al., 1999). Also, a yeast homolgue of p27BBP, 80% 
identical to the human protein, has been identified (Sanvito et al., 1999). Yeast have 
no p4 integrin. It therefore seems likely that p27BBP performs different roles in each 
subcellular compartment. Indeed, p27BBP has also been identified as eIF6 , a putative 
translation initiation factor based on its in vitro ability to inhibit the association 
between the 40S and 60S ribosomal subunit (Si et al., 1997) and has subsequently 
been shown to function in ribosome biosynthesis (Sanvito et al., 1999). Interestingly, 
both L31 and EIF3 are present in the nucleolus and are implicated in ribosome 
biogenesis. It could be suggested that E2 might target the processing of the 60S large 
ribosomal subunit to suppress cellular proliferation. Indeed, the yeast homologue of
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p27BBP is essential for cell viability as deletion o f the p27BBP yeast gene is lethal 
(Sanvito et al., 1999). In addition, reduction of p27BBP protein levels in yeast leads to 
a huge decrease in the levels of free 60S ribosomal subunit and growth arrest in the 
G1 phase of the cell cycle. This lethal effect can be rescued by expression of human 
p27BBP. Furthermore, in the gut epithelium p27BBP expression levels are high in 
rapidly cycling cells and low in villous cells committed to apoptotic cell death 
(Sanvito et al., 2000).
It should also be noted that a pool of EIF3 exists associated with the nuclear matrix 
(Sanvito et al., 1999). It is therefore possible that EIF3 may tether E2 to the nuclear 
matrix. Nuclear matrix attachment regions (MAR) are DNA segments with a high 
affinity for the nuclear matrix and may play a role regulating transcription by 
bringing cis-responsive DNA elements close to matrix bound transcriptional 
complexes. Two MARs in the HPV-16 genome are positioned close to the epithelial 
specific enhancer and the E6 promoter and origin of replication (Tan et al., 1998). 
These MARs are involved in the regulation of HPV-16 transcription (Stunkel et al., 
2000). In transient transfections, the MARs repress HPV-16 transcription but after 
integration of the viral DNA into cellular chromosomes the MARs function as 
enhancers (Stunkel et al., 2000). Sequence analysis suggests that these MARs are 
conserved among genital papillomaviruses suggesting that the nuclear matrix, and 
perhaps EIF3, might regulate an important process of the HPV life cycle.
The results in this chapter therefore demonstrate the detection of direct protein- 
protein interactions between the wild type E2 transactivation domain and cellular 
proteins by Far Western blotting. The isolation of cDNAs encoding proteins
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interacting with the region of E2 involved in regulating transcription, replication and 
growth control by expression cloning is described. Also, the results demonstrate an in 
vitro interaction between E2 and two previously unidentified E2 interacting factors, 
the L31 ribosomal protein and EIF3, a truncated version of a protein previously 
shown to bind the cytoplasmic domain of integrin p4.
4.2.2. Future work
The functional characterisation of the interaction between E2 and the cellular factors, 
L31 and EIF3, would initially be the main focus of the continuation of this work. 
Overexpression studies would be performed to look specifically at the involvement 
of these factors in E2 mediated transcriptional regulation. Initially, the full length 
EIF3 clone would be isolated. Attempts to obtain the 5 ’ portion of the EIF3 cDNA  
missing from the yeast 2 hybrid clone by PCR amplification of a HeLa cDNA library 
have been unsuccessful. A  full length clone would therefore be isolated by screening 
a HeLa cDNA library using a radiolabelled 5 ’ EIF3 oligonucleotide fragment as a 
probe. The full length L31 and EIF3 clones would then be inserted into mammalian 
expression vectors. L31 and EIF3 would be co-expressed with E2 in HeLa cells to 
determine whether these factors can enhance the ability of E2 to activate transcription 
from both the BPV-4 and tk promoters. Antisense L31 and EIF3 expression vectors 
would also be constructed for further functional analysis. If L31 and EIF3 are 
necessary for E2 mediated transcriptional regulation, then expression of antisense 
RNA should inhibit transcription by blocking synthesis of endogeneous L31 and 
EIF3. Western blot analysis would also be carried out to determine if the antisense 
expression vectors affect the level of E2 protein. Eventually, a mutant of E2 that fails
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to interact with L31 or EIF3 in vitro would be tested for transcriptional activity. Also, 
mutants of L31 and EIF3 that fail to interact with E2 in a GST pull down assay 
would be overexpressed to try and squelch E2 mediated transactivation. These 
experiments would determine whether L31 or EIF3 are involved in E2 mediated 
transcriptional regulation. However, the contribution of these factors to E2 mediated 
regulation of viral DNA replication and cellular growth control would also have to be 
examined.
It would also be important to demonstrate an interaction between E2 and L31 and 
EIF3 in vivo . E2 and HA tagged L31 and EIF3 proteins would be co-expressed in 
mammalian cells. Immunoprecipitation of L31 and EIF3 using an HA antibody 
along with an antibody that specifically recognises E2 would determine whether E2 
and these factors associate in transfected cells. Immunofluorescent staining and 
confocal microscopy would be used to examine the subcellular localisation of E2 and 
L31 and EIF3. It has previously been shown that E2 has a diffuse nuclear staining. 
However, when co-expressed with the papillomavirus L2 protein E2 is recruited to 
POD domains (Day et al., 1998). Immunofluorescent staining of cells transfected 
with HA tagged L31 and EIF3 proteins and E2 would be performed to detect if E2 
co-localises with these factors in vivo. The effect of E2 expression on the sub-cellular 
localisation of L31 and EIF3 would also be examined. It would also be essential to 
develop antibodies against L31 and EIF3 to look at the endogeneous proteins. These 
antibodies would also be used for in immunoprecipitation experiments. The results of 
the in vivo analysis would provide further evidence to whether the E2 and L31 and 
EIF3 interaction is biologically significant.
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